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Abstract
In past few years, genome-wide RNAi screens have identified many novel genes involved in
diseases for many viruses such as Human Immunodeficiency Virus-1 (HIV-1), Hepatitis C virus
(HCV), West Nile Virus (WNV) and Influenza virus (IV)[1–8]. However, due to difference
in experimental conditions, usage of different viral strains and inherent biological noise, these
screens have shown low number of common or overlapping hits for a virus[9]. Moreover, this
overlap gets poorer for similar studies on viruses of different families. Although these overlaps
are significant, their lower size restricts a comprehensive insight from a comparative analysis.
Thus, a direct comparison of gene hit-lists of RNAi screens may not always give meaningful
results. To address this problem we propose an integrative bioinformatics pipeline that allows
for network based meta-analysis of viral HT-RNAi screens. Initially, human protein interac-
tion network (PIN) generated by collating data from various public repositories, is subjected
to unsupervised clustering to determine functional modules. Those modules that are signifi-
cantly enriched in host dependency factors (HDFs) and/or host restriction factors (HRFs) are
then filtered based on network topology and semantic similarity measures. Modules passing
all these criteria are then interpreted for their biological significance from enrichment analyses.
With our approach we could predict Tankyrase-1 as a potential novel hit within the functional
subnetworks, within the human PIN for Hepatitis C virus (HCV). and Human Immunodefi-
ciency Virus-1 (HIV-1), based on HDFs and HRFs identified in the corresponding genome-wide
RNAi screens of these viruses. Thus, our approach allows for a network based meta-analysis
of genome-wide screens to develop plausible hypotheses for novel regulatory mechanisms in
virus-host interactions based on RNAi screens.
Zusamenfassung
Durch genom-weite RNAi-Screenings konnten in den letzten Jahren viele Gene neu identifiziert
werden, die an Infektionen beteiligt sind, die durch Viren wie das Humane Immundefizienz-
Virus (HIV-I), das Hepatitis C Virus (HCV), das West-Nil-Virus (WNV) und das Influenza-Virus
(IV) hervorgerufen werden [1–8]. Aufgrund unterschiedlicher experimenteller Bedingungen,
der Verwendung verschiedener Erregerstämme und Rauschens in den Daten haben verschiedene
Untersuchungen zu einem Virus jedoch nur wenige gemeinsame Gene hervorgebracht [9]. Die
Anzahl gemeinsamer Treffer sinkt sogar noch weiter, wenn Studien zu Viren unterschiedlicher
Gattungen betrachtet werden. Zwar sind die überlappungen signifikant, doch erlaubt die kleine
Anzahl gemeinsamer Treffer keine tieferen Einblicke, und ein direkter Vergleich der detek-
tieren Gene verschiedener RNAi-Screenings liefert womöglich keine belastbaren Ergebnisse.
Zur Lösung dieses Problems stellen wir einen integrativen Bioinformatik-Ansatz zur netzwerk-
basierten Meta-Analyse viraler HT-RNAi-Screenings vor. Zunächst werden öffentlich verfüg-
bare Daten zusammengeführt und durch unüberwachte Clustering-Verfahren Protein-Interaktions
netzwerke (PIN) generiert. Cluster, die signifikant erhöhte host dependeny factors(HDF) und/oder
host restriction factors(HRF) aufweisen, werden anschließend auf Grundlage von Netzwerk-
Topologie und semantischen ähnlichkeitsmaßen gefiltert. Nach dieser Filterung werden die
verbleibenden Cluster auf ihre biologische Signifikanz untersucht. Mit diesem Verfahren kon-
nten wir Tankyrase-1 als potentiellen neuen Treffer in funktionellen Unternetzwerk, innerhalb
der humanen PIN fuer Hepatitis C und HIV, basierend auf HDFs and HRFs in genom-weiten
RNAi-Screenings dieser Viren detektiert werden. Unser Verfahren erlaubt daher mittels netzwerk-
basierter Meta-Analyse von genom-weiten Screenings die Entwicklung neuer Hypothesen zu
regulativen Mechanismen von Virus-Wirt Interaktionen.
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Chapter 1
Introduction
In the past decade, the advent of high throughput technology and its application in biology
has redefined our understanding of cellular and molecular biology. The completion of the hu-
man genome project in 2003[10, 11] opened the floodgates of data, after which the need to
decipher biology computationally, became obligatory[12, 13]. To tackle the vast amount of
sequence data, numerous algorithms were developed that made extraction of meaningful infor-
mation possible[14].
The parallel discoveries in experimental molecular biology, particularly, that of RNA interfer-
ence (RNAi) allowed researchers to probe molecular systems in an altogether different man-
ner. Instead of determining functions of individual genes through cross-overs and biochemical
techniques, this otherwise "reverse" approach to determine the cell’s phenotype after "shutting
off,knocking down" the expression of particular gene, gained momentum. Scientists could then
envision this process to scale up in order to probe multiple genes in a single experiment in order
to determine cellular fate, roughly mimicking a stress response or a disease state of a cell. This
would prove to be a paradigm shift in the way we understood the cell itself; from complex cel-
lular processes to molecular aspects of disease. This chapter introduces the concept of RNAi, its
application to understand human diseases and experimental/bioinformatics approaches to tackle
problems of this technology.
1.1 RNA Interference
RNA Interference can be defined as a biomolecular process triggered by double stranded RNA
(dsRNA) molecules and controlled by the RNA-induced silencing complex (RISC) which re-
duces the RNA targets of dsRNA in a sequence specific manner. This phenomenon was first
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observed in C.elegans[15, 16]. For this fundamental discovery, both, Craig Mello and Andrew
Fire received the Nobel prize for Medicine in 2006.
The process is triggered by the introduction of dsRNA in the cell. The dsRNA is recog-
nized by RNase III family member(e.g. Dicer in Drosophila) and then cleaved into siRNAs
of 21-23 nucleotides[15, 16]. These siRNAs then form the RNA-induced silencing complex
(RISC) which degrades any mRNA homologous with the incorporated siRNA from the previous
step[17]. Specifically, the target mRNA is cleaved in the centre complimentary to the siRNA
thus resulting into rapid degradation of the target mRNA and subsequently, reduced protein
expression[18].
Over time RNAi has proven to be one of the powerful techniques to interrogate gene function in
cellular systems, tissues and organisms such as Caenorhabditis elegans,Drosophila melanogaster
and plant species like Arabidopsis thaliana. This process was up-scaled for high-throughput
analyses, wherein thousands of genes could be analysed by loss-of-function. Till date there
have been numerous examples highlighting the advantages of this technique in different cellular
systems applied to probe different questions.
1.2 Genome-wide RNAi screens
Applying RNAi to determine gene function pushed researchers to scale up this technology in
order to probe thousands of genes. The rationale behind this approach was to have an unbiased
view of how genes interact with each other in a network to modulate stress response, transmit
signals from receptors to effector molecules and how these networks alter during a pathogen
attack.
1.2.1 Application to viral diseases
Viruses are obligate intracellular parasites which are also causative agents of many human
diseases. These diseases now account for more than 3 million deaths per year worldwide
(http://www.cdc.gov). With their small sized genomes, they rely heavily on the host system
they attack in order to replicate. Thus, such host factors required in the viral life cycle become
indispensable targets for antivirals[19, 20]. However, identifying host factors that are druggable
yet non-lethal to the host is a difficult task. With the advances in RNAi screening technolo-
gies and design of siRNA libraries for majority of genes in the human genome, researchers
could now probe genes in a high-throughput manner to determine their role in viral diseases. It
was easy to set up genome-wide screens in the Drosophila cells as Drosophila melanogaster
genome was completed earlier than the human genome[21] which allowed for synthesising
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dsRNA libraries[22, 23]. Subsequently, the first genome wide screen performed on viruses
was on Drosophila C virus[24]. This screen had a very simple setup; cells were incubated with a
single RNAi specific to each gene in a 384 well setup and incubated for 3 days with DCV. A day
later, the cells were processed for immunoflourescence against the capsid antigen and subjected
to automated microscopic imaging. The experiment yielded 210 dsRNA species that reduced
the ¯relative number of infected cells by > 40% and were identified by visual inspection. dsR-
NAs targeting these genes were re-synthesised and re-tested for their ability to decrease DCV
infection. This "Validation screening" further identified 112 Host Dependency Factors (HDFs);
66 of them being ribosomal proteins specifically required for translation of DCV polyprotein.
In contrast, these genes were not required by vesicular stomatitis virus whose genome, unlike
DCV, doesn’t contain a ribosomal entry site (IRES) mediating RNA translation in the absence of
a 5’ cap. Thus, the authors concluded that the 66 genes discovered in the 2nd step, are essential
for DCV IRES mediated genome translation.
This approach has now been successfully applied to multiple viruses including Human Immun-
odeficiency Virus (HIV-1) , Hepatitis C virus (HCV), Dengue virus (DV), Influenza virus (IV)
and West Nile Virus (WV) multiple screens to identify host factors for HIV, HCV, Influenza
virus and West Nile virus [1–8, 25–30]. A common factor of all these screens has been that all
these screens were able to detect novel host factors that reduced viral replication upon silencing,
thus called Host Dependency Factors and those that increased viral replication upon silencing,
thus called Host Restriction Factors. Discovery of these novel genes have allowed for designing
novel drugs for these viral diseases.
1.2.2 Current Issues with the technology
As with any technology, RNAi is not without its own limitations. One of the major issues with
RNAi, has been the "Off-target" effect. It refers to the non-specific gene silencing by siRNAs
which often leads to false-positives. Recent studies have enabled scientists to understand the
causes of these effects and eventually, devise strategies to overcome these effects[31]. Off-target
effects can be of two types, namely:
[1] Sequence dependent effects: As the name suggests, these effects arise due to se-
quence homology of the siRNA with multiple targets, including unintended ones. Specif-
ically, siRNAs regulate the expression of certain genes in a sequence-dependent manner
by acting like a microRNA. This occurs when the exogenously introduced siRNA induces
microRNA-like effects by interacting with its target sequences through its seed region; the
5’ region of guide strand of an siRNA or miRNA sequence, extending from nucleotides
2-7 (hexamer) or 2-8 (heptamer)[32–35].
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Sequence independent effects: Introduction of exogenous siRNA or short hairpin RNAs
(shRNAs) may affect cellular physiology in various ways. For instance, exogenous ex-
pression of shRNA can interfere with endogenous processing of microRNAs, as the branches
of siRNA and microRNA pathway converge at the Dicer cleavage stage in the RNAi path-
way. This has been shown to have fatal consequences in mice, possibly due to saturation
of the pathway that is used to export miRNA precursors from the nucleus[36]. A second
manifestation of exogenous siRNA introduction can be that these siRNAs can displace
endogenous microRNAs, which leads to alteration of normal patterns of gene expression.
A bioinformatics analysis of published transcriptional profiling experiments revealed that
the predicted targets of endogenous microRNAs show higher expression after transfec-
tion of a siRNA directed towards silencing of a specific gene[37]. A third type of cellular
change involves activation of the non-specific immune response to the introduced double-
stranded RNA (dsRNA) or from the transfect viruses used to express shRNAs[38, 39].
Either type of these effects influence the final outcome of a RNAi screen, which tends to
misinterpretation of results. In general, it leads to higher false-positives. For instance, in a
screen to identify novel regulators of the HIF-α transcription pathway, the top scoring hits
were obtained through microRNA-like seed-match effects instead of specific knockdown
of their targets[40]. This was also true in the case of a large scale screen to determine mod-
ulators of the TGF-β signaling pathway, where at least 1% of the sequences targeting the
6000 genes of the library showed measurable off-target effects occurring via microRNA-
like regulation, on the upstream pathway components TGF-β receptors 1 and 2 (TGFBR1
and TGFBR2)[41]. The second type, false-negatives, pose another problem. Most of the
time, they are missed due to low coverage of the RNAi library. Booker et al. performed
a meta-analysis to determine false-negative rates in Drosophila screens, where they de-
termined that this rate is at least 8% [42]. These rates are influences by RNAi reagents,
namely, siRNA pools which are different than the endogenous Drosophila cellular dsR-
NAs.
For both scenarios, there are certain common remedial measures. For instance, using
multiple siRNAs for the same gene cancels these error rates to some extent and effec-
tively reducing the occurrences of false-positives and false-negatives. However, there is
always a chance of the inherent error rates of these multiple siRNAs to add up instead
of cancelling each other which may have the exact opposite effect. Thus, this measure
comes with a certain trade-off of its own. Another approach is to complement the results
of a RNAi screen with transcriptome data, where expression levels of strong hits can be
checked in a particular cell-line or tissue [42]. This can, to some extent reduce the number
of false-positives and false-negatives. However, for significant reduction and recovery of
true-positives, additional measures and strategies have to be devised. We discuss these in
the following subsection with emphasis on bioinformatics approaches.
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1.3 Bioinformatics Approaches for analysis of genome-wide RNAi
screens
Parallel to the developments in HT-RNAi technology, statistical and bioinformatics approaches
have also been developed to overcome the shortcomings of this technology. A major focus of
these algorithms has been to improve reliability of the hits and to allow for in-depth of the biol-
ogy of host-virus interactions, with RNAi hits being the starting point. Based on the the method-
ology used, we broadly categorise these studies in 2 classes; "Machine Learning Approaches"
and "Network-based approaches".
1.3.1 Machine-learning approaches
The increase in the number of genome-wide screens to determine novel host factors for viruses
has helped strengthening confidence of theoretical approaches, as the novel host factors serve as
high-confidence positive sets in machine-learning methods to predict novel host factors.
An example of such approach is the SinkSource algorithm by Murali et.al who developed a semi-
supervised machine learning approach to predict novel HIV-1 HDFs using previously identified
ones[1–3, 43]. HDFs identified in these 3 HIV screens were utilised in a classification algorithm
that would learn from these hits and predict novel HDFs. Specifically, the host PPI network was
modelled as a liquid flow network. Each node (protein) in the network acts as a reservoir and
the edge (interaction) connecting them is a pipe. The weight of an edge is directly proportional
to the amount of fluid that can flow through the pipe per unit time. When the liquid attains equi-
librium (amount of liquid flowing in and out remains constant) the height of the node denotes
its confidence of being a HDF. Known HDFs from the screens were assigned a node value of
1 while non-HDFs were assigned a node value of 0. The authors note that their algorithm is
similar to Nabieva et al. which was formulated for functional prediction of genes, except that
SinkSource accepts negative values in the form of non-lethal, non-HDFs[44]. Thus, the non-
lethal, non-HDFs formed the negative set while the HDFs identified in the 3 screens and their
intersections formed the 4 positive sets, which were then used for two-fold cross validation.
Two-fold cross validation involved splitting of each of the positive and negative sets in halves
and each half was used for prediction of genes from the other half. Ultimately, SinkSource
predicted new 1394 HDFs in addition to 908 form the above 3 screens, with an accuracy >
80% based on the above mentioned two-fold cross validation. Combining these HDFs to form a
protein network, dense subgraphs were detected using MCODE[45]. Enriched GO terms from
these subgraphs included;spliceosome, kinetochore and mitochondrion, whereas GTPase medi-
ated signal transduction, DNA replication initiation and MHC protein complex, all relevant to
HIV-1 replication.
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A major advantage of machine learning methods lies in the analysis of hi-dimensional image-
based screens. For e.g. Walter et al. developed an automated classification to classify phe-
notypes in a genome wide screen by time-lapse imaging. They utilised 190 features from hi-
content images to classify nuclei from these images into different stages of mitosis (interphase,
prometaphase, metaphase and anaphase)[46]. They further introduced Event Order Maps, a vi-
sualisation tool for visualising phenotypic dynamics from time lapse RNAi screens, which could
then specifically determine tendencies of causes and consequences of phenotypic classes.
Another important application of supervised classification is to recover false negatives from
genome wide RNAi screens which is extremely difficult or impossible from experimental meth-
ods. Wang et al. developed a network-based phenotype scoring method that considers network
topology and RNAi screening results to identify putative false positives and false negatives
within a RNAi screen[47]. Using 24 genome-wide screens they observed that RNAi hits are
tightly connected to each other in a protein interaction network when compared to random hits.
Thus, they considered network centralities such as direct neighbour, shortest path, diffusion ker-
nel and association analysis-based transformation along with gene similarities and developed a
set of scoring functions called Network RNAi Phenotype (NePhe)[48]. Applying the guilt by-
association principle, Wang et al., hypothesised that FNs should be scored higher by a scoring
function over false positives (FPs), as they are linked by a greater number of true hits. Thus,
an ideal gene classifier would always rank FNs with a higher rank compared to a non-hit. They
applied this scoring function to Wnt and the Hedgehog signaling pathways and the NePhe scor-
ing system could identify all regulators of these pathways which were even missed by follow-up
Drosophila knockdown screens.
1.3.2 Network-based approaches
This section describes how using network data enhances and complements RNAi screens. This
subsection is further subdivided into 3 subsections which describe usage of network data and
network topology, applied for analysing RNAi screens.
1.3.2.1 Using heterogeneous data
The increased throughput in biology has not only developed the amount of data but also its
types. These include genome-wide association studies, gene expression, protein protein in-
teraction, gene regulatory interactions, transcription factor binding site data and so on. They
individually answer specific questions but their combination further helps in improved under-
standing of biological systems. For instance, Zhu et al. combined multiple data types which
included genotypic, expression, transcription factor binding site (TFBS), and protein-protein in-
teraction (PPI) to reconstruct causal gene networks for yeast [49]. From these networks, Zhu
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et al. could identify that this reconstructed network identified knockdown signatures better than
networks constructed using the respective, singular dataset. Reiss et al. reiterate the advantages
of such data combination wherein their algorithm, cMonkey derives biclusters from subsets of
experimental conditions using gene expression data and multiple gene association networks[50].
cMonkey identified additional motifs in the bacteriorhodopsin regulon.
1.3.2.2 Using PPI data
In the past decade, there has been a constant rise in the identification of protein interactions
across all species and the repositories housing them. Among these, repositories with virus-
host protein interactions are an important subset. Virusmint, VirHostNet and the HIV-1 Human
Protein Interaction Database (HHPID) at National Institute of Allergy and Infectious Diseases
(NIAID) are few examples[51–53]. Of late, many approaches have come forth to analyse and
interpret the genome-wide RNAi screens using protein interaction networks and host-virus in-
teraction networks.
Another instance of an integrated network analysis is from Macpherson et al. who used host-
virus protein interaction data from HIV-1 HHPID at NIAID[53, 54]. They identified individual
enriched clusters from the host-virus interaction network using bi-clustering. For obtaining a
hierarchical view of function, these clusters were organised in a functional cladogram where
the distance between 2 clusters was determined by the number of overlaps between the clus-
ters; clusters with more overlapping genes were closer to each other than clusters with fewer
overlaps. GO enrichment analysis of these clusters indicated that 37 host subsystems were po-
tentially important for HIV-1 infection. Moreover, hits from the 3 HIV screens were enriched in
10 of these subsystems and included proteasome core complex, regulation of apoptosis, mRNA
transport, endosome, RNA polymerase activity, peptidase activity, regulation of transcription,
ubiquitin camp-dependent protein kinase complex, and v-akt. The HIV-1 HHPID resource de-
fines how a single viral protein interacts with a single host protein. Although important, it takes
further computations to determine how viral proteins interact with host proteins. To that end,
Macpherson et al. described how viral proteins interact with host subsystems over individual
proteins. This aids the identification of novel hits and mechanisms in a theoretical framework.
The ultimate goal of viral RNAi screens has been to discover novel drug targets. Using drug-
target information in conjunction with protein interaction networks allows to predict or hypothe-
sise drug mechanism and adapt the therapeutic in case there are chances of side-effects. A recent
study by de Chassey et al. used the Drugbank database (http://www.drugbank.ca, pro-
tein interaction networks and 6 Influenza(IFV) virus screens[7, 8, 27, 28, 55–58] to predict drug
targets for Influenza virus. A total of 925 host factors were identified, which the authors termed
as Essential Host Factors (EHFs). Network analysis using the PPI dataset from VirHostNet
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revealed that 17 EHFs are directly targeted by a viral protein[52]. Interestingly, the neighbour-
hood of these directly targeted proteins was equally informative; which included 204 proteins
targeted by at least one viral protein. Secondly, drug molecules interacting with EHFs were
further retrieved from the DrugBank database. From these retrieved molecules, it was found
that 100 EHFs could be targeted by 298 molecules comprising of 204 FDA-approved drugs and
94 experimental drugs. For further confidence, these 100 EHFs were further filtered for the
following three criteria, such that a molecule satisfies at least one of these:
2• EHF was directly targeted by a viral protein.
• EHF was connected to at least another EHF.
• EHF was connected to a non-EHF targeted by the virus.
This filtering yielded 33 EHFs, 32 of which could be targeted by 49 FDA approved molecules
with an exception of HSP90AA1 which also satisfied the first 2 criteria mentioned above.
HSP90AA1 can be targeted by 1 FDA-approved molecule and 5 experimental drugs. Amongst
these experimental drugs, Geldanamycin has been proved to reduce IFV replication by 2 logs in
cell culture[59]. Lastly, the authors suggest that a combination of drugs including Geldanamycin
and Ribafutin(used as 1st line of treatment against tuberculosis) may represent a novel strategy
to identify novel drugs to combat IFV infection.
These studies show that how usage of network data enhance the findings of a RNAi screen.
Moreover, it also helps researchers to realise the ultimate goal of such RNAi screens which is
to determine novel drug targets and suggest alternative therapeutic measures in addition to the
known ones.
1.3.2.3 Using network topology
Integrating network data with RNAi screens and then interpreting screen hits seems a "direct"
approach towards analysing a screen. There has been a complementary or "reverse" approach as
well where researchers have studied network properties of hits targeted by pathogens (including
viruses) and how usage of such properties has helped in interpreting virus-host interactions.
To this end, the most comprehensive study about network topological properties of pathogen
targeted proteins has been published by Dyer et al[60]. The authors studied topological features
of host factors involved in the life cycle of 190 different pathogens partitioned into 54 groups
(35 viral, 17 bacterial, and two protozoan) pooled from 7 public databases[61–67]. The primary
finding from this study has been that pathogens preferentially target Bottleneck or Hub proteins
which indicates targeting central proteins in a network is a common property that is shared by
many pathogens. Another important finding from this study has been that viral targeted host
proteins also play a major role in different cancers, some of which are induced by viral infection
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itself (For e.g., Herpesvirus and Papillomavirus). A similar study, specific to HIV, by van Dijk et
al analysed the HIV-1-Human protein interaction data and reconfirmed that viral proteins attack
Bottlenecks or Hub proteins. Furthermore, they also identified distinct network structures, oth-
erwise known as Network Motifs, which allowed for dynamics interpretation of interactions. For
instance, the 2-node feedback loop found in the HIV-host activation/inhibition network, shows
the inhibitory nature of HIV proteins towards HRFs.
There have also been experimental approaches to study the virus-host interactome of HCV,
DENV and HTLV-1/2[68–70]. A recent study also studied a comprehensive set of genes form-
ing the interactome of 70 viral modulators of the innate immune response from 30 different
viruses[71]. The primary conclusions from these experimental approaches reinstate a key fea-
ture of viral proteins; they target many host proteins that are central to the networks, target
proteins that are key components of many cellular pathways as compared to an average human
protein. Summing up, it is clear that a virus targets a protein that has the following properties:
1. Higher Betweenness and Degree or more central proteins
2. Smaller mean path lengths compared to whole networks
3. Proteins that are closely bound
The results of these studies can then be used to develop a classifier, that can utilise network
topology to theoretically predict potential HDFs for a virus. Moreover, other network topolo-
gies can be probed to determine if they contribute towards a protein being a viral HDF/HRF. For
e.g. Node PageRank centrality has been utilised to predict novel HIV hits using published data
by Jaeger et al.[72]. They used node PageRank to identify 21 surface membrane proteins critical
for HIV-1 infection of which 11 are novel predictions, 3 are confirmed hits (chemokine receptor
CCR1, chemokine binding protein 2 and duffy antigen chemokine receptor). The remaining 7
proteins have been confirmed in other studies. These receptors are involved in different phases
of HIV infection and thus influence progression of AIDS.
From both experimental and computational studies of network topology, it is clear that viral
HDFs/HRFs possess distinct topological features from other proteins in the network. It would
be worthwhile to study other network centralities to see if they too influence a protein being a
viral HDF/HRF. We thus utilised as many as 7 network centralities and 2 semantic similarity
measures to define subnetworks enriched with viral HDF/HRF. The details of their implementa-
tion and interpretation is described at length in the following chapters.
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Chapter 2
Materials and Methods
This chapter gives a detailed description of the methodology developed in this thesis. Since the
methodology involved usage of several scoring functions and enrichment tools, a short descrip-
tion of each of these is provided.
2.1 Defining the problem!
Genome-wide RNAi screens have provided ample opportunities to investigate host-virus inter-
actions and to identify novel host factors, their mechanisms in a high-throughput manner. This
is evident from the many genome-wide screens for viruses such as HIV, Influenza virus, HCV,
WNV. These results have opened possibilities of comparing them and understand similarities-
differences in viral infection. Other data sources such as gene expression, protein interaction
networks, and small molecule or drug screens can also be utilised in tandem to add depth to
such analyses. Thus, the availability of heterogeneous data on one hand and genome-wide RNAi
screens on the other have opened up many avenues for a systems approach of analysing RNAi
screens. However, incorporating this data and utilising it for a comprehensive systems analysis
of RNAi screens, is a challenging task.
Based on this data, we posed 2 key questions;
1 Are there functional regions in the HPIN that are broadly targeted by many viruses and/or
specific to only some viruses?
2 Using network topological properties of such regions, can we predict novel hit proteins or
host-virus mechanisms?
We approached this problem in the following manner:
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1. To identify functional regions within the HPIN, we initially constructed a HPIN using
collated interactions from public repositories.
2. Functional modules were identified using a clustering algorithm, in this case, ClusterOne[73].
3. These modules were filtered in 2 steps:
a. Modules significantly enriched with Hits from a RNAi screen(s). These Hit-enriched
modules were further filtered based on network topology in the next step.
b. Topological filtering of modules, wherein Hit-enriched modules from the previous
step were filtered based on network topology.
4. These doubly filtered modules were then functionally characterised based on pathway and
GO enrichment.
5. Novel host factors were predicted using gene-expression data, virus-host interaction data
and known human protein complexes.
2.1.1 Datasets
The following subsections describe the different types of datasets used for this study.
2.1.1.1 Protein Interaction Networks
To build a comprehensive set of host protein interactions, we downloaded human protein inter-
actions from multiple public resources. Protein interactions were pooled from 10 different pub-
lic repositories that included computationally predicted interactions. These were downloaded
from iRefIndex v9.0[74] that provided unique indices to protein interactions from public repos-
itories; DIP[63], IntAct[61], MINT[62], BioGRID[75], BIND[67], CORUM[76], MPact[77],
HPRD[64], MPPI[65], OPHID[78], summarised in table 2.1. We also included predicted inter-
actions(that constitute 50% of the interactions of the final dataset) from STRING[79] in order
to have enhanced coverage of the network. STRING assigns a score to each protein interac-
tion pair based on the sources from which the interaction is referenced[79]. For interactions
from STRING, we employed a filter by including interactions that had a combined score of
0.75 and above. This resulted in an interaction network from 15383 proteins and 337413 in-
teractions. Hereafter, this network is referred as integrated human protein-protein interaction
network Hu.PPI.
2.1.1.2 RNAi screen Hits
In general, Hits are defined as genes that are at least 2SDs ≥ plate mean, identified in the pub-
lished studies[1–6, 30]. These were either called Host Dependency Factors (HDFs) or Host
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FIGURE 2.1: The figure summarises the work flow executed in this analysis. 1) In step 1,
we build the Human Protein Interaction Network(HPIN) by collating interactions from public
databases (See Datasets). 2) In this step, we apply ClusterONE on HPIN to identify functional
modules.3) RNAi hits are then mapped to these modules and their enrichment in each of these
modules is determined using Fisher’s exact test. Modules statistically significant at 5%, are
then subjected to topological filtering in the next step. 4) This step further filters the enriched
modules from the previous step, using mean network centralities and semantic similarity scores
(See Filtering subnetworks).5) Subnetworks obtained from these 2 filtering steps are then func-
tionally analysed using, Reactome and GO enrichment.
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Source Version (date)
BIND 2005-05-25
BIND Translation Version 1.0 (2010-12-15)
BioGRID Version 3.1.81 (2011-10-
01)
CORUM 02/12/09
DIP 10/10/10
HPRD Release 9 (2010-04-13)
IntAct 2011-09-29
MINT 21/12/10
MPACT 10/01/08
MPPI 2004-06-01 (from
archive)
OPHID 2006-07-07
TABLE 2.1: IrefIndex ver 9.0 and versions of the included databases. We also used STRING
v9.0 to build the final host protein interaction network (HPIN).
Restriction Factors (HRFs). These hits were further grouped in 2 classes; Virus-specific Hits
and Combined Hits. Virus-specific hits included hits from multiple screens for a virus (of the
same species). For example, HIV hits comprised HDFs and HRFs from the 3 HIV-1 genome-
wide RNAi screens[1–3]. HCV hits were pooled accordingly. Since there was only one screen
for WNV, it was directly used as it was published. On the other hand, Combined Hits in-
cluded hits from all screens, including inter-species(between hit-sets of virus species) or intra-
species(within hit-sets virus species) overlapping hits. The pipeline was run on each of these
hit-sets separately. All these screens used the Dharmacon siGENOME library consisting of
17745 proteins.
2.1.1.3 Tissue-specific Expression Data
Human tissue expression data was downloaded from http://www.proteinatlas.org/
version 10.0 - 2012.09.12, Ensembl version: 67.37. The flatfile consisted of Ensembl gene
identifier ("Gene"), tissue name ("Tissue"), annotated cell type ("Cell type"), expression value
("Level"), the type of annotation (annotated protein expression (APE), based on more than one
antibody, or staining, based on one antibody only) ("Expression type"), and the reliability or
validation of the expression value ("Reliability"). Genes were filtered for moderate to high
expression levels based on the expression value labels - "Medium/Moderate" or "High/Strong".
The same filter was applied to the Reliability field of this dataset, wherein genes with high
support were selected (Reliability values were "High" or "Supportive"). Using these filters we
short-listed moderate-high expressed genes in macrophages (HIV) and liver (HCV) from this
set.
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FIGURE 2.2: Boxplot displaying mean betweenness of subnetworks for all cluster sizes for
all the HCV subnetworks. These values were further utilised to filter these subnetworks for
topological enrichment, detailed in the Parameters section.
2.1.2 Clustering Hu.PPI Network
We used a clustering algorithm that allows for detection of overlapping protein complexes by
neighbourhood expansion, called ClusterONE[73]. The usage of an algorithm that detects over-
lapping complexes was to identify multifunction proteins that play different roles in different
complexes for the same virus as well as in different viruses. Such multifunction proteins can
also help interpret the role of the protein complex, of which they are a part of, in multiple per-
spectives. One of the required input parameters to the algorithm was minimum cluster size.
ClusterONE generates clusters of at least the size specified in the size parameter, so different
clusters of sizes ranging from 25 to 100 were obtained. For values of cluster size 100 and above,
the cluster size and the number of the generated clusters remained constant as shown in Fig 2.2.
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2.1.2.1 ClusterONE algorithm
The algorithm is based on the concept of cohesiveness score and then uses a greedy growth
process to find groups that could potentially be protein complexes. Cohesiveness measures the
likelihood of a group of proteins to form a complex. It is defined as follows. Consider win(V)
as the total weight of the edges contained between the group or proteins V , and let wbound(V)
denote the total weight of the edges that connect the group to the rest of the network. The
cohesiveness of V is given by,
f (V ) =
win(V)
win(V)+ wbound(V )+ p|V| (2.1)
p|V| is a penalty term that is used to model the uncertainty in the data based on the assumption
that there exist yet undiscovered protein interactions. By allowing values of p ≥ 0, offsets the
boundary weight wbound(V )byp|V |, that implies every protein in V has p additional boundary
connections that could not be identified owing to limitations of experimental procedures. Thus,
the authors suggest that, different values of p can be used for different biological assumptions.
For instance, a well-studied protein can have lower p value as it is highly unlikely that it has
undiscovered interactions. For sake of simplicity, we chose not to alter this penalty term and
used the default value as set by the algorithm. The ClusterONE algorithm works in 5 major
steps:
while v⊂V 6= φ do
Step1 : let V0 = {v0}, t = 0;
Step2 : Calculate cohesiveness for Vt using (2).
Step3 : and let Vt+1 = Vt ;
For every external vertex v on at least one boundary edge, cohesiveness of V ′ = Vt∪ vt. If
f (V ′) > f (Vt+1), let Vt+1 = V ′ ;
Step4 : For every internal vertex v on at least one boundary edge, cohesiveness of
V” = Vt∪ vt. If f (V”) > f (Vt+1), let Vt+1 = V” ;
Step5 : if Vt 6= Vt+1, increase t and return to Step 2.;
Else Vt a locally optimal cohesive group.
end
Algorithm 1: ClusterOne algorithm
An illustration for this greedy cohesive process of group detection is illustrated in figure 2.3.
This graph consists of 12 nodes, marked from node0 to node11. Assuming p = 0, the cohesive-
ness of the shaded set is 7/14. In steps 3 and 4, the algorithm can add either of the following
nodes; node5, node6, node7 and node8. The best choice is to add node 7 as it increases the
internal count by 4 as it converts these boundary edges to internal ones. Thus, the cohesiveness
of the group would be 11/14 while for node8 it would be 10/14, for node6 will be 9/14 and for
node5 it will be 8/14.
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FIGURE 2.3: Illustration of greedy cohesive group detection in ClusterOne. Shaded area is in-
dicated by a shaded area. Thick blue edges are completely internal, dashed edges are boundary
edges and forward slash edges are completely external.
1. In the first step, the algorithm grows groups of proteins with high cohesiveness from se-
lected seed proteins. First, a protein with highest degree is selected as the 1st seed and
a greedy search procedure grows a cohesive group from this protein. When this growth
process ends, the algorithm selects the next seed from the unassigned proteins and repeats
the process. This process continuous till there are no proteins left to consider.
2. In this step, locally optimal cohesive groups are merged. The extent of overlaps between
each group pair is computed and those groups that have the overlaps beyond a certain
threshold(ω > 0.8), are merged.
ω((A,B) =
|A∩B|2
|A||B| (2.2)
ClusterONE performs these overlaps pair-wise; overlap scores for each group pair is cal-
culated and an overlap graph is constructed where each vertex represents a cohesive group.
Two groups are connected to each other are merged into protein complex candidates. If
a group has no further connections to any other groups, it is then labelled as a protein
complex candidate and no additional merging is performed.
3. In this final step, the predicted groups are pruned for size and density. Specifically, those
groups smaller than 3 and a density δ below a certain threshold are discarded, where δ is
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defined as,
δ =
Σwin(V)
n(n−1)
2
(2.3)
where n is the number of proteins.
2.1.3 Determine RNAi hits enrichment for all clusters
For every cluster generated, a p-value was calculated using the Fisher’s exact test to determine
significant enrichment of hits in a cluster[80]. This was repeated for all hit-sets mentioned above
which resulted in 4 sets of clusters, namely: HIV, HCV, WNV and Combined. The Combined
hit-set consisted of hits pooled for all viruses from all screens. For all subsequent references in
the analysis, a subnetwork will refer to a visual representation of an enriched cluster. Each of
these enriched cluster sets were analysed for network topology in the next step.
We demonstrate hit enrichment in a subnetwork with the following illustration. This is a con-
tingency table used for the Fisher’s exact test, to compute p-values. For the HCV hit-set, we
obtained one of the subnetwork of size 40, of which 38 proteins are from the library of genes
that were screened (in this case the library being Dharmacon siGENOME library which was
common for all the 7 screens). Thus, the contingency table of this subnetwork will be:
Sr.No Hits Non-
Hits
TOTAL
In-
cluster
4 34 38
Not-in-
cluster
0 2 2
TOTAL 4 36 40
TABLE 2.2: An example of RNAi hit enrichment in subnetwork
2.2 Parameters
2.2.1 Network Centralities
In order to understand how a network functions, it is worthwhile to study its structural properties
and how these impacts its function. Intuitively, the manner in which individual components of
the network interact provides a basis for quantifying such structural properties. Formally, these
measures that allow to quantify and characterise network topology are referred to as, Network
Centralities. This term was elaborated by Freeman in his seminal paper titled, "Centrality
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FIGURE 2.4: A sample protein interaction network (PIN), represented as an undirected, un-
weighted graph. The nodes represent proteins and the edges represent interactions between
them.
in social networks conceptual clarification"[81]. Over the years, researchers developed a set of
such centralities that characterise different aspects of a network. For e.g. Betweenness centrality
gives the extent to which the shortest paths pass through a particular node. The higher number
of paths passing through such a node, the higher is its "Betweenness". In protein networks, this
automatically translates to proteins that function as Bottlenecks which are more likely to be
essential proteins and play an important role in gene expression[82, 83].
Before we describe these network centralities, we introduce some basic concepts of graph theory
as defined in the literature, along with their mathematical representation[84].
1. Undirected graph: A graph G can be defined as a pair (V,E) where V is a set of vertices
representing nodes and E is a set of edges representing the connections between the nodes.
A single connection between nodes i and j is defined as E = {(i, j)|i, j ∈ V}, in which case i
and j are neighbours. If the edges connecting the vertices have no direction and numerical
weights assigned to them, then such a graph is called an undirected, unweighted graph.
Protein interaction networks are more often represented as these graphs.
2. Directed graph: A directed graph is defined as an ordered triple G = (V,E, f ), where
f is a function that maps each element in E to an ordered pair of vertices in V . Such
directed pairs of edges are called directed edges, arcs or arrows[85]. In protein interaction
networks, a directed connection usually represents sequential interaction of the elements
and the flow of information in the network. For e.g. signaling networks that consists
of signaling cascades where binding of a receptor triggers a certain pathway which is
followed by their action on final effector molecules, the direction of an edge represents the
flow of such a signal.
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3. Adjacency Matrix: For a graph G = (V,E), the adjacency matrix is represented by |V |x|V |=
nxn matrix A = (ai j) such that ai j = 1 if (i, j) ∈ V or ai j = 0 or otherwise
A =

a11 . . . a1n
...
. . .
...
an1 . . . ann
 ,n = |V |
For the sample PIN listed above 2.4, the matrix will be,
ASampleNetwork =

0 0 0 1 1 0 0 0 0 0
0 0 1 0 1 0 0 0 0 1
0 1 0 1 0 0 0 0 0 1
1 0 1 0 0 1 0 0 0 0
1 1 0 0 0 0 0 0 0 1
0 0 0 1 0 0 1 1 0 0
0 0 0 0 0 1 0 0 1 0
0 0 0 0 0 1 0 0 1 0
0 0 0 0 0 0 1 1 0 0
0 1 1 0 1 0 0 0 0 0

,n = 10
In case of undirected graphs, the matrix is symmetric because ai j = a ji. This isn’t true in
the case of directed graphs, as the upper and lower triangle parts of the matrix reveal the
direction of edges.
4. Walk, Path and Trail - A walk is a pass through a specific sequence of nodes (v1,v2, . . . ,vN)
and (v1,v2),(v2,v3), . . . ,(vN−1,vN) ⊆ E. A simple path is a walk with no repeated nodes
while a trail is a path where no edge is repeated.
5. Shortest Path - For a pair of nodes i, j ∈V , the distance δ (i, j) from i to j is the length of
the shortest path from i to j in G. If no such path exists, then δ (i, j) = inf. Shortest path
problem refers to the process to determine a path between two nodes in a graph such that
the sum of the weights of its constituent edges is minimised.
We utilised 7 network centralities and 2 semantic similarity measures to filter subnetworks.
With reference to the sample network in Fig. 2.4, we describe few basic graph theory ter-
minologies and definitions of these measures as follows:
1. Degree centrality - As defined by Freeman, degree of a node denotes the number
of edges incident to a node or emanating from it [81]. For an undirected graph G,
G = (V,E) where V is the set of vertices/nodes and E is the set of edges, the degree
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of a vertex v is denoted by, deg(v). By this definition, the nodes node1, node2, node3,
node4, node5 and node9 of the sample network, have the highest degree, which is
3. Intuitively, higher degree also reflects a node’s importance in a network, in this
case, indicates the multifunction aspect of a protein. Such proteins are also referred
to as Hubs and indeed, are essential for normal cellular function purely due to their
abundant interaction partners[86].
2. Closeness centrality - indicates the extent to which a node is "closer" to other nodes
in the network. It also determines the ability of a node to quickly communicate with
other nodes with respect to flow of information. Mathematically, it is defined as the
inverse of the shortest path between a pair of nodes. For an undirected graph G =
(V,E), closeness centrality of a node i Ccloseness(i) is defined as,
Ccloseness(i) =
1
∑|V|j∈V dist(i, j)
(2.4)
where dist(i, j) denotes the distance or the shortest path p between the nodes i and j.
Mazurie et al. showed that, in a metabolic reaction network, a more central node has a
faster rate of transfer of metabolites than the less central ones[87]. Specifically, nodes
with higher closeness aid in faster transfer of metabolites in a metabolite reaction net-
work. They also showed that as distance between metabolic pathways increased, it led
to a consequent decrease in the closeness centrality of metabolites in these pathways
in context of bacterial evolution. In the context of signaling networks, a special class
of PINs, it indicates how a particular signal can transfer within a network.
Using the formula above, closeness centrality of the proteins in the sample network
are as follows:
Centrality node1 node2 node3 node4 node5 node6 node7 node8 node9 node10
CLS 0.0435 0.0526 0.0625 0.0435 0.0555 0.0417 0.05 0.033 0.0435 0.0417
BWN 0.5 10.0 21.0 2.0 18.5 3.5 5.0 0.5 0.5 3.5
PGR 0.106 0.107 0.112 0.108 0.121 0.087 0.077 0.089 0.106 0.087
CC 0.67 0.33 0.0 0.33 0.0 0.0 0.0 0.0 0.67 0.0
TABLE 2.3: Centralities for all nodes in the sample network. The 3-letter abbreviations in the
first column denote centralities; CLS-Closeness, BWN-Betweenness, PGR-PageRank central-
ity and CC-Clustering coefficient.
From the table 2.3, it is clear that "node3" is closer to all other nodes in the network
and thus, can quickly convey a signal from one protein to another.
3. Betweenness centrality - Betweenness of a node indicates the number of shortest
paths passing through that node, for any two nodes in a network[88–90]. Such nodes
thus act as bridging nodes between closely connected regions or communities within
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a network. Removal of such nodes can disconnect these communities and break the
network. These are also referred to as Bottlenecks. For unique nodes, i, j,w ∈V (G),
σi j be the total number of shortest paths between i and j while σi j(w) be the number
of shortest paths between i and j passing through w. Furthermore, for w ∈ V (G), let
V(i) denote the set of ordered pairs, (i,j) in V(G)×V(G) such that i,j,w are distinct.
Then, the Betweenness centrality of w is given by,
CBetweenness(w) = ∑
(i, j)∈V (w)
σi j(w)
σi j
(2.5)
In PINs, proteins with high betweenness(Bottlenecks), alike those with high de-
gree(Hubs) are favoured by many pathogens.
Betweenness centrality values for the proteins in the sample network are mentioned
in 2.3. It is clear from this table that node3 and node5 are the nodes with high be-
tweenness.
4. Mean path length - As mentioned above, the shortest path between a node pair (i,j) in
a graph G is given by, δ (i, j). Thus, the mean or average path length of a graph G is
defined as the average of δ (i, j) taken over all distinct pairs of nodes, i, j ∈ V(G) given
that they are at least connected by one path. Specifically, the average path length of
a network is the mean number of edges between nodes, which must span the shortest
path between a node pair. It is given by,
δ =
2
N(N−1)
N
∑
i=1
N
∑
j=1
δmin(i, j) (2.6)
where δmin(i, j) is the minimum distance between nodes i,j and N is the total number
of nodes in a network. Some of the popular algorithms to determine shortest paths in
a network, are the Dijkstra’s greedy algorithm[91] and Floyd’s algorithm[92].
For the sample PIN listed above 2.4, the shortest path matrix will be represented as,
Thus, using the above formula, the average path length of the sample network is 2.44.
5. PageRank/Eigenvector centrality - It uses the principle that, the importance of a
node is determined by how important its neighbours are. Thus, a node connected to
more important neighbours is ranked higher than a node with lower number of such
neighbours. Mathematically, it is the largest eigenvalue of an adjacency matrix. Such
an implementation was suggested by Bonacich, who deemed that it can be a good
centrality measure[93]. For a graph G(V,E), consisting of vertices V and edges E, let
A be the adjacency matrix for this graph; ai j = 1 if i and j are connected and ai j = 0
otherwise. The matrix A is symmetrical and thus, its eigenvalues are real, its eigen-
vectors orthogonal. The largest eigenvalue of A is then represented by λmax, given
by, λCeiv = ACeiv, where Ceiv is the eigenvector of λmax. Thus, for a undirected graph
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node1 node2 node3 node4 node5 node6 node7 node8 node9 node10
node1 0 1 2 1 3 4 2 5 1 4
node2 1 0 1 2 2 3 2 4 1 3
node3 2 1 0 2 1 2 1 3 2 2
node4 1 2 2 0 3 4 1 5 1 4
node5 3 2 1 3 0 1 2 2 3 1
node6 4 3 2 4 1 0 3 1 4 2
node7 2 2 1 1 2 3 0 4 2 3
node8 5 4 3 5 2 1 4 0 5 1
node9 1 1 2 1 3 4 2 5 0 4
node10 4 3 2 4 1 2 3 1 4 0
TABLE 2.4: Shortest paths matrix for all against all nodes. The diagonal elements of this
matrix are 0 while the upper and lower diagonal elements consists of pairwise distances.
G with its adjacency matrix A with V (G) = {v1, . . . ,vn} and ρ(A) = maxλ∈σ(A) |λ |,
then the eigenvector centrality Ceiv(Vi) of the node vi is given by the ith coordinate xi
of a normalised eigenvector that satisfies the condition Ax = ρ(A)x. This algorithm
has been implemented to efficiently ranking of web pages, notably by Google. Using
this measure, Jaeger et al. identified novel surface membrane receptors of HIV from
a PIN[72].
From table 2.3, node5 has the highest eigenvalue or PageRank value of 0.121 indicat-
ing that it is the most important node in the network.
6. Clustering coefficient - It’s a measure to indicate the connectedness of a vertex to its
neighbours, for the graph in consideration[94]. For an undirected graph G, if i is a
vertex with degree deg(i)=k and the number of edges between the k neighbours of i in
G are e, then the Local clustering coefficient is given by,
C(i) =
2e
k(k−1) (2.7)
In other words, Ci measures the ratio of the number of edges between the neighbours
of i to the total possible edges, which are k(k− 1)/2 and ranges within 0 ≤ Ci ≤ 1.
The mean clustering coefficient of the whole network is then given by,
Cmean =
1
N
N
∑
i=1
Ei
ki(ki−1) (2.8)
where, N = |V | is equal to the number of vertices. The closer the value of Cmean is to
1, the greater is its tendency to form a cluster. Table 2.3, shows the local clustering
coefficient values for nodes in the sample network. Using the equation for Cmean, the
mean clustering coefficient of the sample network is 0.273.
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2.2.2 Semantic similarity indices
1. Dice Similarity Coefficient - For an undirected graph, G, such that G = (V,E) where
V is a set of vertices and E is a set of edges; then for a vertex pair, u,v, the Dice
Similarity coefficient for the vertex pair is given by,
Diceu,v =
2C
|Degu|+ |Degv| (2.9)
Here, C denotes common neighbours of u and v whereas Degu and Degv denotes
degrees of nodes u and v. We iterate this formula over a whole subnetwork and then
obtain the mean Dice similarity coefficient.
2. Wang similarity coefficient - A GO term A can formally be represented as a set of
directed acyclic graph, DAGA = (A,TA,EA), where TA is the set of GO terms in DAGA
including A and all its ancestor terms in the GO graph and EA is the set of edges
connecting the GO terms in DAGA. For a quantitative comparison of GO terms, Wang
defined that the semantic value of GO term A is the aggregate contribution of all terms
in DAGA. In other words, the contribution of term t to the semantics of GO term A is
referred to as the semantic value or the S-value of GO term t related to A. So, for any
of term t in DAGA = (A,TA,EA), its S-value related to term A, SA(t) is defined as:{
SA(A) = 1
SA(t) = max{we×SA(t ′)|t ′ ∈ childreno f (t)}i f t 6= A
(2.10)
where we is the semantic contribution factor for edge e ∈ EA linking term t with its
child term t’. In this function, contribution of term A towards itself is assigned a value
of 1. After computing all S-values for all terms in DAGA, the semantic value of GO
term A, SV(A), is calculated as:
SV (A) = ∑
t∈TA
SA(t) (2.11)
Thus for any given GO terms, A and B, the Wang similarity between A and B,
simWang(A,B), is given by,
simWang(A,B) =
∑t∈TA∩TB SA(t)+ SB(t)
SV (A)+ SV (B)
(2.12)
wherein SA(t) is the semantic or S-value (SV) of GO term t related to term A and
SB(t) is the S-value of GO term t related to term B. Wang’s method determines the
semantic similarity of two GO terms based on both the locations of these terms in
the GO graph and their relations with the ancestor terms. For a group or protein like
the ones in our subnetworks, we utilised the mean of the Wang similarity coefficient,
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FIGURE 2.5: GOSemSim sample calculation
calculated pairwise for each GO term pair for a protein m with another protein n.
Thus, the above equation can then be represented as,
simWang.avg(g1,g2) =
∑mi=1∑
n
j=1 sim(go1i,go2 j)
m×n (2.13)
where g1 and g2 are a gene pair and go1i and go2j are their corresponding GO terms,
such that GO1 = {go11,go12, . . . ,go1m} and GO2 = {go21,go22, . . . ,go2n}. For our
subnetwork, we consider a protein pair and all its associated GO terms, for all on-
tologies. We then perform a ontology-wise calculation of the Wang similarity score
for each combination of GO terms for this pair. This is iterated for all possible pairs
within a subnetwork. Finally, we calculate the mean of Wang similarity for each GO
ontology and assign it to the subnetwork. Thus, each subnetwork has 3 values that are
the mean Wang similarity scores for the three GO ontologies. The following exam-
ple shows a sample calculation of semantic similarity scores using the mgoSim and
goSim functions of the GOSemSim package.
2.2.3 Filtering subnetworks
Cluster size is one of the important parameters in any graph based clustering algo-
rithm (in our case, subnetwork size generated from these clusters). The 2 main/re-
quired inputs to ClusterOne [73] are: the network to be subjected for clustering and
the minimum size of predicted complex. There are 11 other input parameters which
are as follows:
1. –input-format - indicates the input format of the file. This can be either an
edge list or simple interaction file (sif)
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2. –output-format - indicates the output format of the file (plain, csv or genepro)
3. –min-density - used to set the minimum density of the complexes to be pre-
dicted.
4. –debug - initiates the debugging mode in the algorithm
5. –fluff - used to fluff the clusters as a post processing step. This parameter
should be used in a case specific manner. The main purpose is to check if the
external boundary nodes of each cluster connect to more than two third of the
internal nodes; if such is the case, these external boundary nodes are added to
the cluster. It must be applied before the size and density filters.
6. –haircut - This parameter is used to apply a haircut transformation as a post-
processing step on the detected clusters. Basically this step removes any dan-
gling nodes from a cluster provided if the total weight of connections from a
node to the rest of the cluster is less than x times the average node weight in the
cluster (where x is the argument of the switch), the node will be removed. The
process is iterated until there are no further nodes to be removed. Alike fluff,
this method is applied before the size and density filters.
7. –max-overlap - indicates the maximum allowed overlapping proteins between
two clusters. This is measured by the match coefficient which takes the size
of the overlap squared, divided by the product of the sizes of the two clusters
being considered, as in the paper of Bader and Hogue[45].
8. –similarity - used to set the similarity function to be used in the merging step.
Specifically, this argument controls which scoring function is to be used to de-
cide whether two complexes overlap significantly or not. This option has the
following possible values:
a. merge calculates the intersection size squared, divided by the product of the
sizes of the two complexes. This is also called the matching score and is the
default value.
b. meet/min or simpson calculates the Simpson coefficient i.e. the intersection
size over the size of the smaller complex.
c. jaccard calculates the Jaccard similarity coefficient i.e. the intersection size
over the size of the union of two complexes.
d. dice calculates the Dice similarity coefficient i.e. twice the intersection size
over the sum of the sizes of the two complexes.
9. –merge-method - specifies the method to be used to merge highly overlapping
clusters. This option has the following values:
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a. single calculates similarity scores between all pairs of complexes and creates
a graph where the nodes are the complexes and the two nodes are connected
if the corresponding complexes are highly overlapping. Complexes in the
same connected component of the graph will then be merged and by its des-
ignation, this is a single-pass method.
b. multi calculates similarity scores between all pairs of complexes and stores
those pairs that have a score larger than a given threshold. The highest
scoring pair is merged and the similarity of the merged complex towards
its neighbours is recalculated. This process is iterated until there are no
more highly overlapping complexes remaining. As its label suggests, this is
a multi-pass method where similarities are recalculated after each merging
step.
10. –penalty - sets a penalty value for the inclusion of each node. For any penalty
value x, ClusterONE assumes that this node has an extra boundary weight of
x when it considers the addition of the node to a cluster. This option can then
be utilised to model the possibility of uncharted connections for each node, so
nodes with only a single weak connection to a cluster will not be added to the
cluster as the penalty value will nullify the benefits of adding the node. The
default penalty value is 2.
11. –seed-method specifies the seed generation method to use. The following val-
ues are accepted:
a. nodes - every node will be used as a seed.
b. unused_nodes - nodes will be tested in the descending order of their weights
(where the weight of a node is the sum of the weights on its incident edges).
If a cluster is found in this search, these nodes will be excluded from the list
of potential seeds. In other words, the node with the largest weight that does
not participate in the clusters found thus far will be selected as the next seed.
c. edges - every edge will be considered once, each yielding a seed consisting
of the two endpoints of the edge.
d. cliques - every maximal clique of the graph is considered as a seed.
e. file(*filename*) - seeds will be generated from the nodes listed in the given
file. Each line must contain a space separated list of node IDs that will be a
part of the seed. If a line contains a single * character only, this means that
besides the seeds given in the file, every node that is not part of any of the
seeds will also be considered as a potential seed on its own.
f. single(*node1*,*node2*,. . . ) - a single seed will be used with the given
nodes as members. Node names must be separated by commas or spaces.
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g. stdin - seeds will be given on the standard input, one by line. Each line must
contain a space-separated list of node IDs that will be a part of the seed. It
may be useful to use this method together with –no-merge if the result of
earlier seedings shouldn’t interfere the result of the later ones.
Among these parameters, only the –merge-method was set to multi, to merge highly
overlapping complexes. For all other parameters, their corresponding default values
were used. We subjected the Hu.PPI network to different values of min.size, starting
from 25 to 100, beyond which the number of clusters obtained didn’t differ in their
size. In order to define optimal size for the clustering, we utilised 6 network centrali-
ties and 2 semantic similarity measures.
The rationale for choosing these measures was 2 fold; firstly, incorporating network
topology in the analysis allows for a topological perspective on the enriched subnet-
works and secondly, the semantic measures to check the quality of clustering. Mean
values of all these measures were calculated for every subnetwork. Initially, subnet-
works significantly enriched with RNAi hits were filtered. From these, those subnet-
works with size identical to their random-hit-enriched counterparts were considered
for difference of mean test. These random-hit-enriched subnetworks were determined
in the following manner. We randomly sampled identical number of hits for each
virus from the HPIN and used them to compute hit-enriched modules in the 2nd step
(see 2.1). Alike their hit-enriched counterparts, mean values of all the 8 network
centrality and semantic similarity measures were computed. These scores were then
utilised to determine topologically significant subnetworks, from within hit-enriched
and random-hit-enriched subnetworks, of identical sizes.
For this purpose, we used the Wilcox test to compute significance of mean between
these 2 sets, for every network centrality. Subnetwork sizes that yielded significant
difference of mean for every network centrality at a significance level of 5%, were
considered for further analysis.
As mentioned before, the analysis was carried out for every hit-set, i.e. individually
for each virus and also by combining hits for all the 3 viruses. Given the stringency
of the criterion, the range of significant subnetwork sizes obtained, were few. Only
subnetworks for HIV of size 52 and 66 passed this criterion(see 2.6). In other cases,
subnetworks significant for most network centralities were chosen. For instance, in
the case of HCV, subnetworks of size 62, 64 were significant for all network measures
and Wang semantic similarity of GO.CC class but not for GO.BP and GO.MF. This
trend was consistent with combined hits. With the exception of GO.MF, subnetworks
of size 46 and 52 were significant for all measures, for the combined hits dataset. For
WNV, none of the subnetworks were significant for any of these measures.
The motivation behind this topology-based filtering was that viruses alike other pathogens
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Centrality Hit enriched subnet-
work
Random-hit-enriched
subnetwork
p-value
Mean-Betweenness 35.279 34.9533 0.0247
Mean-Closeness 0.0092 0.0093 0.0247
Mean-Clust-Coefficient 0.365 0.238 0.0247
Mean-PGR 0.0233 0.0233 NA
Mean-Degree 20.698 21.163 0.0247
Mean-PathLength 2.68 2.66 0.0247
Mean-DiceSim 0.211 0.1882 0.0247
Mean-WangSim-GO.BP 0.221 0.206 0.592
Mean-WangSim-GO.CC 0.489 0.464 0.592
Mean-WangSim-GO.MF 0.385 0.402 0.0497
TABLE 2.5: Wilcox test results for significance of mean between hit-enriched and random-hit-
enriched subnetworks. Both subnetworks are of size 43. As evident from the p-values, not all
p-values are significant. These are highlighted by grey coloured cells.
target centrally located proteins in the HPIN[60, 71, 95]. In order to predict such pro-
teins and more importantly, hotspots within the HPIN that harbour such proteins, we
performed this test of significance for the 6 centrality measures mentioned above. We
discuss the results of these double-enriched that is, subnetworks enriched with hits as
well as topology, in the Results section.
2.2.4 Functional Analysis of filtered subnetworks
All Reactome pathway and GO based enrichments were computed using the Biocon-
ductor packages,"clusterProfiler" and "ReactomePA"[66, 96–98]. Semantic similari-
ties were computed using the "GOSemSim" package[99].
2.3 Novel Hit Prediction
One of the main objectives of this study was to develop a computational basis for
prediction of novel host factors for these viruses. Since the subnetworks are already
enriched with hits and are topologically significant, we employ a simple neighbour-
hood search to predict novel host factors. This step is supplemented with multiple
data sources to put forth plausible hypothesis of the predicted host factors and their
regulation.
2.3.1 Mapping Tissue-specific expression data on filtered subnetworks
As mentioned above, we utilised tissue-specific gene expression data from Human
Protein in association with the enriched subnetworks, for novel hit prediction. In
particular, we selected cell-lines/tissues, favoured by the viruses in consideration and
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filtered for genes with moderate/high expression. These filtered genes were over-
laid on the subnetworks and the overlaps were further assessed for their role in viral
infection/replication. In some cases, the overlaps yielded well-studied proteins like
JAK2(Janus Kinase 2) in case of HCV while others were yet uncharacterised. This
validated our approach in a way and the latter, thus formed "Putative Novel Hits" or
"Predicted Novel Hits"
2.3.2 Mapping virus-host interactions on filtered subnetworks
We used multiple sources to map virus-host interactions for their overlay on subnet-
works. For the HCV subnetworks, we utilised the first experimentally determined
viral protein- host protein interaction network by de Chassey et al.[70]. For the HIV
subnetworks, we used the HIV-1 NIAID database[53]. For WNV, we utilised the
VirHostNet knowledgebase[52]. However, the number of interactions between WNV
proteins and human proteins were quite limited (17) and thus, we didn’t find any
WNV-human protein interactions with any subnetworks. This observation holds true
only for the "Combi" subnetworks as WNV hit-set didn’t lead to any enriched subnet-
works, with the previously described steps.
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Chapter 3
Results & Discussion
This chapter highlights the functional characteristics of all the subnetworks. Based on
enriched pathways, GO ontologies and their interacting partners, we further postulate
novel regulatory mechanisms and putative novel host factors for each virus.
3.1 Functional properties of subnetworks
3.1.1 Enrichment Specificity
From both analyses types (with virus-specific and Combined hit sets), we observed
that all subnetworks showed specificity on the level of enriched pathway and GO
terms. A general observation from these subnetworks is that their the enriched path-
way and GO terms are "functionally specific". In other words, these subnetworks
show enriched pathway terms of a specific biological process when compared to en-
riched terms of their corresponding hit-list. For e.g, The Brass HIV screens’ enriched
Reactome pathways included; Immune System, HIV infection, Gene Expression and
Disease (see Figure 3.3). On the other hand, the enriched Reactome pathways for the
HIV-s52 network included; Transcriptional Regulation of White Adipocyte Differen-
tiation,Developmental Biology, Generic Transcription pathway and SMAD2/SMAD3/SMAD4
heterotrimer regulates transcription and Gene expression. We also observed this trend
in the enrichment analyses of HCV subnetworks, thus indicating that interpreting
these subnetworks over individual hit-lists proves to be more informative.
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(A)
FIGURE 3.1: Reactome Pathway Enrichment: Comparative analysis of enriched Reactome
pathway terms in subnetworks and corresponding screens. The size of data points indicate
the percentage of genes present in a pathway term whereas color shades indicates p-values.
(A)-Pathway enrichment comparisons in all RNAi screens vs. "Combined" subnetworks
3.2 HIV-1 Meta-analysis Results
For HIV, we identified 2 subnetworks, namely, the HIV_s52 and the HIV_s66 subnet-
work. The suffix s is short for subnetwork size while the number denotes the numeri-
cal size of the subnetwork. Each of these subnetworks emphasise different aspects of
HDFs involved in HIV infection. While HIV_s52 subnetwork predominates in tran-
scription, the HIV_s66 subnetwork consists several small complexes that serve dif-
ferent processes during the HIV life-cycle. These are summarised in the enrichment
plots of Reactome pathway and GO terms given below. As compared to individual
screen hit-lists, the filtered subnetworks have specific biological processes/pathways
that are enriched in them. We describe each of these subnetworks in detail, in the
following subsections.
42
(B)
FIGURE 3.2: Reactome Pathway Enrichment: Comparative analysis of enriched Reactome
pathway terms in subnetworks and corresponding screens. The size of data points indicate
the percentage of genes present in a pathway term whereas color shades indicates p-values.
(B)-Pathway enrichment comparisons in HIV-1 RNAi screens vs. HIV-1 subnetworks
3.2.1 HIV_s52 Subnetwork
3.2.1.1 Mediator Complex
The HIV_s52 subnetwork consisted primarily genes involved in the transcription,
where Mediator complex subunits were the most dominant (Appendix-I). The Media-
tor complex is a large multi-subunit complex consisting of 26 subunits and weighs 1.2
Mda[100]. A unique feature of this complex is that it is present only in eukaryotes as
evidence for Mediator-like activity in microbes is lacking. Additionally, the general
transcription factors (GTFs) that include TFIIE, TFIIH, and TFIID are also absent
in microbes. The parallel co-evolution of these GTFs along with mediator suggest
that these complexes function coordinately to regulate expression of protein coding
genes. Thus, this complex is a preferred target for viruses. This result is consistent
with the fact that being retrovirus, HIV hijacks and employs the host transcription
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FIGURE 3.3: Reactome pathway and GO enrichment terms comparison between individual
HIV-1 RNAi screens and filtered HIV-1 subnetworks, as obtained from our analysis. Both sub-
networks show functional specificity at the pathway and GO terms, as compared to individual
screen hit-lists.
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(a) The HIV_s52 subnetwork.
B
Non-screened Proteins
HIV Hits
Screened Proteins
FIGURE 3.4: A) Mediator complex subunits in the HIV_s52 subnetwork, highlighted in the
red circle. B) The HIV_s52 subnetwork45
machinery for its replication. The Mediator complex subunits were major hits in the
meta-analysis by Bushman et al.[9]. The discovery of Mediator complex as a major
hit in these RNAi screens[2, 3] have provided different hypotheses of its involvement
in HIV infection. Zhou et al. suggest that mediator complex subunits are required for
Tat-activated transcription while Koenig et al. suggest that they may be required in
reverse transcription.
An important submodule within the Mediator complex is the CDK8 submodule which
also contains cyclin C, MED12, and MED13. CDK8 plays a repressive role in tran-
scription wherein CDK-Mediator complex fail to activate transcription while the Me-
diator complex without CDK8 achieved transcriptional activation[100]. The presence
of the CDK8 submodule in our subnetwork implies the repressive mechanism prob-
ably being employed by the host cell as a countermeasure against HIV infection. It
might also be aided by another protein of this subnetwork, namely Cyclin C, which is
known to activate CDK8 and inhibit transcription initiation.
However, the precise and detailed mechanism of how the full Mediator complex is
hijacked by HIV is yet to be studied.
3.2.1.2 Host epigenetic mechanisms during HIV infection
In addition to the mediator complex, our subnetwork also included several other in-
teracting proteins (with the Mediator complex subunits), that might shed more light in
the details of transcription hijack mechanisms of HIV. For instance, the subnetwork
contains a lysine-specific demethylase 4B(KDM4B). This hints to epigenetic regu-
lation in HIV-1 infection. Indeed, recent studies show that methylation at the host
and viral protein levels has been a strategic mechanism employed by HIV-1 for in-
ducing latency. Several studies point out to this process [101–104]. Studies from the
Karn lab demonstrate that histone lysine methyltransferases (HKMTs) play a specific
role in latency of HIV-1 in the Jurkat cells [101]. The authors showed that concurrent
knockdown of EZH2, a key component of the Polycomb repressive complex 2 (PRC2)
silencing machinery, and the enzyme which is required for trimethyl histone lysine 27
(H3K27me3) synthesis lead to induction of upto 40% of the latent HIV proviruses.
In a second study from the same lab, chromatin immunoprecipitation (ChIP) assays
confirm that the levels of HIV-1 Tat are restricted in latently infected cells but they
increase stepwise during reactivation of provirus [102]. Moreover, ChIP assays of
latently infected cells showed that latent proviruses had high levels of deacetylated
histones and trimethylated histones. These levels of trimethylated histone H3 and
HP1-α associated with HIV proviruses reduced rapidly after tumour necrosis fac-
tor alpha(TNF-α) activation. Dimethylation at H3 Lys9 (H3K9) methyltransferase
46
G9a[105] and monomethylation at lysine 51 (K51) at the RNA binding domain of Tat
maintains viral latency [106]. Another interesting perspective of the involvement of
long non-coding RNAs(lncRNAs) in transcriptional regulation including the mediator
complexes comes from a recent study by Lai et al. [107]. They show that a special
class of lncRNAs, called ncRNA-activating (ncRNA-a), that activate genes through
a cis-mediated mechanism[108, 109], require subunits of Mediator complex for their
mechanism. Given the highly intricate and complicated intervention by HIV pro-
teins, interaction between mediator subunits could influence the genes regulated by
this mechanism. Broadly speaking, this HIV-specific subnetwork is associated with
transcription directly/indirectly targeted by HIV.
3.2.2 HIV_s66 Subnetwork
The HIV_s66 subnetwork consists of several functional complexes that are involved
in varied biological processes of the HIV life-cycle. Predominant among these are
the heterogeneous ribonuclear proteins (hnRNPs), RNA-binding proteins (RBMPs)
and Serine/Arginine rich splicing factors (SRPs) which co-ordinately regulate RNA
metabolism [110, 111]. Among these, hnRNPs play diverse roles in RNA metabolism;
many hnRNPs participate in pre-mRNA processing such as splicing and influence
mRNA export, localization, translation, and stability[111]. They are associated with
mRNA during its different stages of transport that includes passing through nuclear
pores, ribosomes, hence undergoing nuclear-cytoplasmic shuttling[111]. Being a
retrovirus, it is thus evident why HIV-1 would target these host protein complexes
during its infection course. Alike hnRNPs, the SRPs too have multiple roles in RNA
regulation that profoundly include alternative splicing events and post splicing activi-
ties like mRNA nuclear export, nonsense-mediated mRNA decay and mRNA transla-
tion [112].
Overall, this subnetwork consists of proteins that seem to play a crucial role not only
in RNA metabolism but RNA metabolism during HIV-1 infection.
3.2.2.1 Novel hnRNP subunits and their probable role in HIV infection
Our analysis agrees with Bushman et al. and Murali et al., who also revealed hn-
RNP subunits in their meta-analysis of the 3 HIV screens [9, 43]. Generally, if one
or more subunits of a protein complex (here, hnRNPs) are exploited by the pathogen,
the whole protein complex itself is considered to be vital. For e.g. If "Proteasome"
complex is significant in a genome-wide studies, the interpretation would be that all
subunits of the Proteasome contribute in identical fashion towards the disease state, as
the complex as a whole is significant and the complex has one function i.e proteolytic
degradation. The hnRNPs in our subnetwork may be an exception to this rule. A
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FIGURE 3.5: A The HIV_s66 subnetwork. B The HIV_s66 subnetwork with highlighted
protein complexes; the Heterogeneous ribonucleoproteins (HNRNPs) and the Serine/Arginine
splicing factors (SRSF)
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recent RNAi screen by Lund et al.[113] showed mechanistic details of hnRNP com-
plex subunits and their varied roles in HIV-1 infection. For e.g. they showed that
hnRNP A1 subunit increases the expression of Gag and Env viral proteins but no sub-
sequent increase of HIV-1 RNAs. On the other hand, silencing hnRNP A2 resulted
in an increase of Gag protein expression followed by an increase with HIV-1 RNA.
Furthermore, different isoforms of hnRNP D also play different roles in HIV-1 infec-
tion. Isoform p42, p45 are favourable HIV replication while isoform p37, p40 create a
non-permissive state. However, other hnRNP subunits, namely, A2, E1 and E2 exhibit
antiviral properties[114, 115]. Thus, hnRNP subunits were generally antiviral in na-
ture but a detailed inspection shows that there are exceptions within the complex itself.
For better hypothesis generation, we asked if these hnRNP subunits were expressed in
HIV-1 susceptible tissues(see Materials and Methods), by overlaying tissue-specific
expression data obtained from the Human Protein Atlas[116]. We found that 8 hnRNP
subunits(C1/C2, D0, K, L, M, U, A1, A2/B1) of the subunits were highly expressed
in macrophages. From these 8 subunits, 4 subunits (K, L, M, U) have not been char-
acterised yet with respect to HIV-1 infection and thus, are putative novel hits, based
on our results.
3.2.2.2 RNA-binding motif-proteins & Splicing Factors
This subnetwork also consisted of several RNA-binding proteins (RBM11, RBM41,
RBM42, RBM4B, RBM7) that may have hitherto unexplored, specific roles in mRNA
export during HIV replication. Cellular RNAs are bound to RNA-binding proteins
(RBPs) to form ribonucleoprotein (RNP) complexes. These RBPs govern the struc-
ture and function of RNAs and as such, play a vital role in their biogenesis, stability,
function, transport and cellular localization [117]. They are found in huge numbers in
humans (> 500) and due to their involvement in so many aspects of RNA regulation,
any disruption in their activity leads to complicated diseases [118]. Their dynamic
interactions with RNAs in their coding, untranslated and non-protein-coding RNAs
that comprise the RNPs allows the RBPs to bound stably to the RNA throughout its
journey from synthesis to degradation[118]. Given such broad array of functions of
the RBPs, it is likely that HIV utilises the functions of these RBM proteins for its own
RNA metabolism.
The subnetwork further consists of several Serine/Arginine splicing factors (SRSF3,
SRSF4, SRSF6, SRSF7, SRSF9, SRSF10) of which 3 (SRSF6, SRSF7, SRSF9) have
direct interactions with viral proteins, as listed in the HIV-1 NIAID database[53] (see
Table 3.1). It is clear from the table that despite belonging to the same functional class
of proteins. Moreover, different viral proteins have different type of interactions with
these proteins. The involvement of a splicing factor ASF/SF-2, which is a member of
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Sr.No Viral Pro-
tein
Host Pro-
tein
Interaction
1 Gag,Pr55 SRSF6 SR proteins, particularly SRp40 and SRp55, in-
crease HIV-1 Gag translation from unspliced viral
RNA. The second RNA recognition motif and the
arginine-serine (RS) domain are determinants of SR
protein activity
2 capsid SRSF6 SRp55 induces production of extracellular p24gag
from a rev-defective HIV-1 provirus
3 Tat,p14 SRSF7 HIV-1 Tat synergizes with type I activators, such as
Sp1 and CTF, to enhance transcript elongation and
exon skipping, suggesting Tat function leads to the
inhibition of splicing factors SF2/ASF and 9G8
4 Vif,p23 SRSF4 A novel exonic splicing enhancer (ESE) element
within the 5’-proximal region of HIV-1 mRNA exon
2 facilitates both exon inclusion and Vif expression.
This ESE binds specifically to the cellular SR pro-
tein SRp75
TABLE 3.1: HIV-1 protein interactions with SRSF proteins of the HIV_s66 subnetwork, as
extracted from the HIV-1 Human protein interactions database.
the SR (serine/arginine-rich) family of splicing factors, in HIV-1 infection was iden-
tified by a proteomic approach by Berro et al.[119]. Berro et al. also found p32 and
other proteins preferentially bound to AcTat(acetylated Tat). p32 was recruited by the
HIV genome, that suggest a mechanism by which Tat acetylation may inhibit HIV-1
splicing needed for the production of full length transcripts. Indeed, SR proteins has
essential functions during spliceosome assembly and they interact with RNA regula-
tory sequences on the pre-mRNA as well as with multiple cofactors. Collectively, they
recognise multiple splice sites with broad specificity and are at the core of regulation
pathways that lead to the choice of alternative splice sites [120]. To that end, SRSF3,
SRSF4 and SRSF10 might be involved in similar host-virus protein interactions with
varied yet specific roles, just like the above mentioned members of the same family.
Besides these functional complexes, this subnetwork included several other proteins
(See Appendix-I) that might serve an associative role in the above mentioned pro-
cesses.
3.3 HCV Meta-analysis Results
Similar to the HIV subnetworks, we obtained 2 HCV subnetworks of different sizes;
HCV_s43 and HCV_s66. These networks were also consisted of unique functional
complexes that denote different aspects of cellular hijack during HCV infection.
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FIGURE 3.6: Reactome pathway and GO enrichment terms comparison between individual
HCV-1 RNAi screens and filtered HCV-1 subnetworks, as obtained from our analysis. Both
subnetworks show functional specificity at the pathway and GO terms, as compared to individ-
ual screen hit-lists.
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FIGURE 3.7: Reactome pathway and GO enrichment terms comparison between individual
HCV-1 RNAi screens and filtered HCV-1 subnetworks, as obtained from our analysis. Both
subnetworks show functional specificity at the pathway and GO terms, as compared to individ-
ual screen hit-lists.
3.3.1 HCV_s43 Subnetwork
The HCV_s43 subnetwork primarily consisted of proteins from these functional classes;
Crystallin Proteins (Alpha, Beta & Gamma) Dual specificity protein phosphatase
(Subunits 1, 2, 4, 6, 8-10, 16), Mitogen-activated protein kinases (MAPK-11, 12, 14)
and MAP kinase-activated protein kinase (MAPKAPK-2, 3, 5). A common aspect
of each of the above mentioned proteins, is that their are all associated with hepato-
cellular carcinoma, the end-stage of HCV infection. Each of these proteins had their
unique role in the HCV life-cycle in the host cells, which we describe in the following
subsections.
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3.3.1.1 Intricacies of MAPK signaling during HCV infection
From the protein annotations, it is clear that this subnetwork consists of components of
the Mitogen activated protein kinase (MAPK) signaling cascade (see figure 3.9,3.10).
Mitogen activated protein kinases or MAPKs play an important role in multiple cel-
lular functions, prominently cell growth and proliferation[121, 122]. MAPKs can be
activated in a variety of ways; by hormones (e.g.,insulin), growth factors (e.g.,platelet-
derived growth factor (PDGF), epidermal growth factor (EGF) and fibroblast growth
factor (FGF) inflammatory cytokines of tumour necrosis factor (TNF) family and en-
vironmental stresses such as radiation,osmotic shock and ischemic injury[123]. With
such important association of cellular processes with it, the MAPK signaling path-
way is also a preferred target by HCV. Macdonald et al.[124] showed how NS5A
inhibited the activity of the mitogenic and stress-activated transcription factor acti-
vating protein-1 (AP1). They showed that this inhibition is dependent upon a class
II polyproline motif within NS5A. By combining dominant active and negative mu-
tants of components of the MAPK signaling pathways, selective inhibitors, together
with immunoblotting with phospho-specific and phosphorylation-independent anti-
bodies, Macdonald et al. found that this inhibition is mediated via the ERK signaling
pathway. This observation was consistent in both stable NS5A-expressing cells and
Huh-7-derived cells harbouring subgenomic hepatitis C virus (HCV) replicons.
Ndjomou et al.[125] further showed that MEK/ERK signaling pathway, of which
MAPKs are major players, act as a second line of defence against the virus, paral-
lel to IFN-α signaling. They revealed how MEK/ERK inhibitors and negative mu-
tants enhance HCV replication, RNA and protein syntheses. They also suggest that
since inhibition of MEK signaling leads to up-regulation of HCV replication, usage
of MEK inhibitors in treatment of hepatocellular carcinoma, induced in later stages of
HCV infection, should be carefully monitored.
The downstream components of the ERK signaling cascade consists of ribosomal
protein S6 kinases, two alpha subunits of these kinases are present in this subnetwork
(RPS6KA4, RPS6KA5). Ribosomal protein S6 (rpS6) is a component of the 40s ribo-
some. Phosphorylation signals mitigated through mitogens from this cascade, at sev-
eral Serine residues of the ribosomal protein S6 (rpS6), leads to translation initiation
at the 7-methylguanosine cap complex[126]. However, rpS6 also requires phosphory-
lation at specific Serine residues, Ser235/236, by a specific kinase, namely, ribosomal
S6 kinase (RSK). Thus, a dual phosphorylation signal through the RAS/ERK signal-
ing and the RSK is required for rpS6 function and thus, translation initiation. Roux et
al.[126] also note that this mechanism is independent of the mammalian target of ra-
pamycin (mTOR) pathway that modulate translation initiation. Intriguingly, the HCV
non-structural protein NS5A, up-regulates host cap-dependent translation machinery
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FIGURE 3.8: A The HCV_s43 subnetwork.B The HCV_s43 subnetwork and its protein com-
plexes.
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FIGURE 3.9: MAPK and ERK12 signaling from Metacore pathway maps c© in uninfected cells.
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FIGURE 3.10: MAPK and ERK12 signaling from Metacore pathway maps c© in uninfected
cells.
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in Huh7.5 cells, by simultaneous activation of mTORC1 and eukaryotic translation
initiation factor 4E (eIF4E)[127]. Furthermore, NS5A phosphorylated eIF4E through
the MAPK-MNK pathway. These 2 studies, in the context of our results, suggest 2
mechanisms of translation during HCV infection;
a) According to Roux et al., since rPS6 kinase mediated translation initiation is inde-
pendent of mTOR-based modulation, it is likely that cellular translation is redirected
during HCV infection, as mTOR-based translational initiation pathway is hijacked by
HCV.
b) On the other hand, George et al. show a rather contrasting result, that involves rPS6
kinase itself in mTOR-based translation initiation and this process as up-regulated via
NS5A interaction with 4E-binding protein (4EBP). Moreover, they also suggest a
mTORC2 based activation of translational initiation, again via NS5A.
The HCV_s43 subnetwork consisted of 3 MAPKs, 3 MAPKAPKs, rPS6-kinase-α-4
and rPS6-kinase-α-5 subunit. It can be intriguing to explore which of the above routes
of translation initiation occurs during HCV replication.
3.3.1.2 HCV induced stress induces molecular chaperones
This subnetwork further consisted of heat shock proteins (HSPs) and crystallin com-
plexes, both act as chaperones or proteins that protect, fold or unfold protein substrates
in a context-dependent manner[128–130]. Intuitively, this implies the induction of a
defence mechanism of the cell, responding to the stress initiated from the viral replica-
tion. A couple of independent studies, indeed identified and described how the HCV
viral protein, NS5A modulates Hsp72 levels. Chen et al. identified interacting pro-
teins of NS5A by tandem affinity purification (TAP) from cells expressing NS5A and
from mass spectrometry which included Hsp72[131]. Its association with the HCV
replicase complex, that comprises of NS5A, NS5B and NS3, Hsp72 plays a positive
regulatory role in HCV RNA replication as it increases levels of the replication com-
plex. This was supported by increased stability of the viral proteins in the complex or
to the enhanced translational activity of the internal ribosome entry site of HCV, both
constitutive functions of HSPs. In the second study that identified Hsp72 and its inter-
action with NS5A, Lim et al. showed that NS5A increases levels of Hsp72 through 2
transcription factors, HSF1 and NFAT5[132]. Silencing the expression of the former,
reduces HCV replication and viral release. Our subnetwork consists of several HSPs
(see Appendix I) that may have similar function as Hsp72 in HCV replication.
A second class of HSPs are the crystallin proteins[129, 130].A recent study by Huang
et al. shows that a second route of modulation occurs through the αβ -Crystallin
complexes which subsequently promotes hepatocellular carcinoma (HCC) progres-
sion in vivo and in vitro[133]. αβ -Crystallin forms a complex with 14− 3− 3ζ
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protein and also elevates its basal concentration. This leads to an up-regulation in
ERK1/2 activity and accelerates HCC progression. Furthermore, overexpression of
αβ -Crystallin impairs Sorafenib treatment, a multi-kinase inhibitor which is widely
used in HCC treatment. HCC is triggered in patients at later stages of HCV infection
and thus, αβ -Crystallin complexes are potential targets for reducing HCC progression
and improve survival rates in patients. Our subnetwork also consisted several subunits
of αβ -Crystallin (CRYBAA, CRYBAB, CRYBA1, CRYBA2, CRYBA4, CRYBA1,
CRYBB1, CRYBB2, CRYBB3) which could play similar role as described in this
study.
Either way, the presence of these kinase cascades in this subnetwork warrants a further
detailed study of this cascade, in light of these studies. This specific subnetwork thus
highlights the intricacies in cellular signaling during a viral infection.
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3.3.2 HCV_s64 Subnetwork
The HCV_s64 subnetwork consisted functionally diverse set of proteins that included
Interleukins, Insulin receptor substrates, Suppressor of cytokine signaling (SOCS)
and multiple types of Tyrosine-protein phosphatase non-receptors. Being so diverse
in function, the biological interpretations of this subnetwork were interesting in their
own right.
3.3.2.1 Role of Interleukins in HCV therapies
Interleukins form an integral component of the cellular immune response. By def-
inition, they are secreted proteins that bind to specific receptors and play a role in
leukocyte communication. With such attributed function in cellular immunity, their
role in host defence against infection, viral infection in particular, is of considerable
importance.
This subnetwork predominantly included members of the IL-12 family of interleukins
(See Appendix-I) [134]. IL-12 induces the production of IFN−γ through TH1 and NK
cells and thus mediates development and maintenance of TH1 cells. IFN−γ itself is
a potent inhibitor of HCV replication[135, 136]. In HCV infection and replication,
interleukins play a key role in suppression of infection. For e.g. In patients suffer-
ing from chronic hepatitis C, IL-12 enhances cytokine production by PBMCs in some
patients[137]. Furthermore, T cell immunoglobulin mucin domain protein 3 (Tim-3)
expression has a direct effect on IL-12/IL-23 in human CD14 +monocytes in patients
with chronic HCV infection[138]. In these patients, Tim-3 are highly expressed and
IL-17 is upregulated in CD4+ T cells. Blocking Tim-3 signaling restores normal reg-
ulation of IL-12/IL-23 through STAT3 signaling and reduces the IL-17 levels both ex
vivo and in vitro.
Additional resistance to IL-12 and its antiviral properties comes through the virus
itself. Particularly, HCV core-gC1qR interaction with the cell surface of monocyte/-
macrophages inhibits the production of IL-12p70 upon lipopolysaccharide stimula-
tion. This response is specific to IL-12 as other interleukins, namely IL-6, IL-8 and IL-
1β production were unaffected[139].Other interleukins, such as IL-10, whose block-
ing leads to a favourable balance of CD4+ cells, that enhances their proliferation in
response to HCV antigens[140]. Certain interleukins, like IL-27, have antiviral prop-
erties for multiple viruses. IL-27, which inhibits HIV-1 replication in CD4+ cells, also
inhibits HCV replication in HuH7.5 cell line. This happens via IFN-α like antiviral
response which includes induction of antiviral genes without IFN-α induction[141].
On the other hand, a recent study suggests incorporation of interleukins in IFN-α
therapy. For instance, a recombinant form of human interleukin 28B (rhIL28B) in
combination with IFN-α inhibited HCV production in culture[142]. Inclusive or not,
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(A)
(B)
FIGURE 3.11: (A) HCV_s64 subnetwork (B) HCV_s64 with its protein complexes that in-
clude; Interleukin receptors and subunits, Suppressor of cytokine signaling, Insulin receptor
with receptor substrates and Tyrosine protein phosphatase non-receptor
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different family members of interleukins play an important role in eliciting an antiviral
response that can be utilised in different combinations, depending upon the immuno-
logical repertoire of the patient and thus can lead to better therapeutics against HCV.
3.3.2.2 Insulin resistance and HCV
Insulin resistance is an outcome of chronic HCV infection in many patients[143–146].
Insulin resistance primarily affects IFN-α treatment and its associated with major
pathway modulations. For instance, overexpression of the suppressor of cytokine sig-
naling 3 (SOCS3) in liver tissue results in poor treatment outcome in patients with
chronic hepatitis C viral genotype 1[143]. Since, antiviral therapy response is lower
in patients with genotype-1 than those with genotype-2 of the virus, SOCS3 signaling
should be monitored and lowered to basal levels in the former type of patients. This
holds true for SOCS-1, where its silencing enhances IFN-signaling[147]. Contrary
to this, SOCS-2 overexpression inhibits HCV replication in presence of a plant gly-
coside, Saponin which directly increases SOCS-2[148]. Thus, SOCS signaling may
interfere with therapeutic IFN signaling for HCV but some SOCS genes function as
antivirals when modulated by small molecules. This subnetwork includes all the three
SOCS genes described above and thus the subnetwork also points to SOCS as an im-
portant component in affected signaling pathways during HCV.
Another level of insulin resistance occurs through the degradation of insulin recep-
tor substrate 1(IRS-1) in human hepatoma cells (HuH-7) expressing core protein of
HCV genotypes 3a and 1b[144]. This is also associated with upregulation of SOCS7
and downregulation of peroxisome proliferator-activated receptor γ (PPARγ). The
second insulin receptor substrate (IRS-2), the knockdown of which induces insulin
resistance[149]. Similar to IRS-1, the silencing of IRS-2 suppresses IFN-α response.
This increases protein-tyrosine phosphatase (PTP) protein-tyrosine phosphatase 1B
(PTP-1B) activity, which when silenced with Metformin improves the IFN-α re-
sponse. In summary, SOCS signaling (through various SOCS family members), In-
sulin signaling and their regulation by PTPs form a crucial factor in determining the
efficacy of IFN-α treatment.
This subnetwork consists of 4 PTPs (including PTP-1B described above, for others see
Appendix-I), SOCS-1, SOCS-2, SOCS-3 described above) which could be attributed
to similar roles in insulin resistance and IFN-α responses. Overall, this subnetwork
shows tendency towards insulin resistance and how HCV modulates through various
signaling pathways. It remains to be seen how these highly similar proteins, to the
ones investigated in these aspects of HCV infection, play a role in the HCV life cycle
and disease progression.
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3.4 HIV, HCV & WNV Combined, Meta-analysis Results
3.4.1 Combi_s52 Subnetwork
This network is identical to the HIV_s52 subnetwork (see HIV _s52 Subnetwork 3.4).
3.4.2 Combi_s239 Subnetwork
The Combi _s239 Subnetwork is the largest subnetwork found in our analysis and
as such contains many complexes that play specific roles in viral life cycle (see table
A.7). We further split this section on virus specific interpretations, as the number of
complexes found in this subnetwork point to some differential as well as common
aspects of virus infection.
3.4.2.1 Src family of kinases and their role in virus infection
The Src family of kinases (SFKs) have different roles in the life cycles of all the 3
viruses in this study. A common observation is that SFKs are activated or upregulated
in virus infected cells, although the effects of their activation differs between virus
species. For instance, the SFK, c-Yes during WNV infection shows an increase in
its expression[150]. This is followed by a decrease in 2-4 log decrease in viral titers
which indicates that c-Yes activity is required for WNV replication. Inhibition by
chemical inhibition (PP2) and by RNAi mediated silencing showed similar results.
However, PP2 didn’t reduce intracellular levels of either viral RNA or protein imply-
ing that the drug doesn’t influence early stages of replication. Enzymatic digestion of
viral envelope glycoprotein E by endoglycosidase H (endoH) revealed that E doesn’t
localise beyond the endoplasmic reticulum (ER). Electron microscopy of PP2-treated
WNV-infected cells revealed that WNV virions accumulated within ER compartments
as compared to their control counterparts. Thus, c-Yes inhibition didn’t interfere with
virus assembly but restricted transition of virions through the secretory pathway and
it is an important problem in WNV assembly.
In case of HIV, SFKs are differentially activated which is achieved by Nef protein
and in the presence of SFK-negative regulatory kinase Csk[151]. Expression of Fgr,
Fyn, Hck, Lck, Lyn, and Yes as well as c-Src in yeast revealed that each kinase was
active and induced growth expression in yeast. Co-expression of these SFKs with Nef
showed that Nef strongly activated Hck, Lyn, and c-Src but didn’t significantly alter
expression levels of Fgr, Fyn, Lck, or Yes. Nef contains the PXXP motif essential for
SH3 domain binding, mutagenesis of which reduced the effect of Nef on Hck, Lyn,
and c-Src. This occurs due to allosteric displacement of intra-molecular SH3-linker
interactions. Thus these selectively activated SFKs in HIV infected cells can serve as
potential targets for HIV antivirals.
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Non-screened Proteins
HCV Hits
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Common Hits (HCV-HIV)
Common Hits (HCV-WNV)
FIGURE 3.12: Combi_s239 subnetwork
Alike HIV, HCV also recruits more than one SFK at various stages of its life-cycle.
Specifically, the nonstructural proteins, NS5A interacts with many SFKs through
their respective SH3 domains and induces aberrant phosphorylation events[152–154].
Along with these proteins, the Combi_s239 contained several interleukin subunits, re-
ceptor tyrosine-protein phosphatases, receptor tyrosine protein kinases; their biology
and predicted mechanisms have been discussed in subsections above.
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3.5 Putative Novel Hits: Mapping tissue-specific expression
data
One of the complications in secondary screening of RNAi screen hits, is the selec-
tion of "interesting" candidate genes. This is partly because in genome-wide screens,
the number of false-positives is large[155, 156]. Secondly, the novel host factor has
to have therapeutic potential and thus, tissue specificity plays an important role.We
utilised the Human Protein Atlas dataset[116] in conjunction with subnetworks to pro-
pose novel host factors and regulators mechanisms. Specifically, we used moderate-
highly expressing genes from cell-lines/tissues which were attacked by the viruses in
consideration (For e.g. Hepatocytes in case of HCV, macrophages for HIV). These
genes were then overlaid on virus-specific subnetwork to predict novel host factors
and/or mechanisms.
For instance, the intersection between moderate-highly expressed proteins in hep-
atocytes and the HCV_s64 subnetwork yielded three proteins, namely, Tankyrase-
1 (TNKS1), Sarcoplasmic/endoplasmic reticulum calcium ATPase1 (SERCA1) and
Tyrosine-protein kinase (JAK-2), of which TNKS1 and SERCA1 are non-hits (weren’t
identified as hits in any HCV screen). HCV core protein induces endoplasmic retic-
ulum(ER) stress and deregulates cellular apoptosis by modifying the calcium signal-
ing pathway. Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2), an
ATPase of the same class as SERCA1, shows an impairment in its Ca2+ pumping
leading to deregulated calcium uptake from the cytosol to the ER during the HCV-
Core expression. As SERCA1 belongs to the same enzyme family as SERCA2,
it would be interesting to verify SERCA1’s role in similar conditions. HCV Core
protein also modifies Janus kinase-(JAK)-signal transducer and activator transcrip-
tion factor (STAT) pathway after stimulation from interleukin-6 (IL6) and interferon
(IFN)-γ [157]. However, HCV core modifies this signaling cascade in different ways;
it increased phosphorylation of JAK1-2, STAT1 and STAT1 mediated transcription
under IFN-γ stimulation while JAK1-2, STAT3 and STAT3-mediated transcription
were prevented under IL-6 stimulation. Moreover, HCV nonstructural proteins also
induce oxidative stress via STAT3 activation, which is of a constitutive type in HCV
replicon-expressing cells[158]. Amongst these proteins, is Tankyrase-1 which is a
Poly-ADP-ribosyltransferase and its probable mechanisms in relation to HCV infec-
tion, we describe in the subsequent sections.
In the case of HIV, we observed that heterogeneous ribonuclear proteins (hnRNPs)
were expressed in moderate-high levels in macrophages and were also part of the
HIV_s66 subnetwork. As outlined in the subsection above (see figure 3.5), hnRNP
subunits can play diverse roles in HIV-1 replication and infection processes and thus,
need to be tested individually for understanding their involvement. Broadly, hnRNPs
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are involved in mRNA metabolism that includes RNA export, transport among others,
a stage-wise inhibition of these subunits can reduce viral replication in a cell.
3.6 Putative Novel Hits: Mapping CORUM protein com-
plexes
Majortiy of graph based clustering algorithms, focused on protein complex predic-
tion, utilise a gold-standard dataset of protein complexes to test biological relevance
of their clustering[73, 159–161]. We use the human CORUM complexes in a similar
fashion to overlay on these subnetworks to determine putative novel hits and mecha-
nisms relating to the viral infection[76]. We computed the Jaccard index of each com-
plex with each subnetwork and overlaid the complexes with Jaccard index > 0 . As
ClusterOne allowed overlaps between complexes, all subnetworks contained overlap-
ping complexes. For instance, The HCV-s64 subnetwork contained 3 complexes, viz.
TRF1 telomere length regulation complex, TRF-Rap1 complex I, 2MD and Tankyrin
1-tankyrin 2-TRF1 complex (see figure 3.13). Interestingly, TNKS1 belonged to all
three complexes. All these complexes were related to telomere length regulation and
telomere dynamics. This implies that TNKS1 has a probable link in telomere length
regulation and HCV infection.
Another example is the HIV_s66 subnetwork which included 40 CORUM complexes,
majority of those implicating RNA splicing (see table A.8). Many protein from the
subnetwork are heterogeneous nuclear ribonucleoprotein (hnRNP) which also be-
longed to multiple overlaid CORUM complexes. How do hnRNPs and associated
splicing events play a role in HIV infection? Using these cues from these overlaid
complexes, we propose probable mechanisms in the following subsections.
3.6.1 Alternative therapies: Tankyrase & HCV induced Hepatocellular
Carcinoma(HCC)
Tankyrase 1(TANK1) is a human telomeric poly(ADP-ribose) polymerase(PARP) is
a positive regulator of telomere length. By adding ribosyl residues to TRF-1, a telom-
eric DNA-binding protein, TANK1 inhibits the latter’s binding to telomeric DNA, thus
facilitating its elongation by telomerase[162–164].¯ Telomere shortening has been ob-
served in leukocytes of HCV infected patients [165]. More importantly, HCV infected
patients showed shorter telomere lengths than patients in remission. Telomere length
is also associated with poor overall survival rates of patients [166]. Indeed, rela-
tive telomere length has been established as an independent prognostic marker for
HCC patients. Secondly, chronic HCV infection leads to subsequent induction of
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HCC, majority of which is associated with expression of HCV non-structural pro-
teins [167, 168]. Taking these studies into account, it is evident that HCV infection
leads to HCC in advanced stages of the disease. It is thus, important to determine
molecular determinants that accelerate this progression or those that can be modu-
lated to check it. The Wnt signaling pathway has been widely studied in this con-
text, which controls the concentration of β -catenin, a transcriptional activator. β -
catenin is regulated by proteasome-dependent degradation which is under the control
of APC and Axin1[167]. Axin1 gene mutations are reported in ¯substantial portion
of HCCs[169, 170]. Hence Satoh et.al suggest that Axin administration can be an
effective therapeutic molecule to suppress growth of HCC.
A recent chemical genetic screen identified a small molecule, XAV939 which stim-
ulates β -catenin degradation by stabilising axin[171]. XAV939 inhibits the PARP
enzymes, TANK1 and TANK2 which are responsible for ubiquitin mediated degrada-
tion of axin. Inhibition of TANK1/2 results in accumulation of cytosolic axin which
then forms the β -catenin destruction complex along with glycogen synthase kinase
3α/β (GSK3α/β ) and adenomatous polyposis coli (APC). Putting this finding in the
perspective of the overlaid complexes on the HCV_s64 subnetwork (see figure 3.13)
we suggest that TANK1/2 inhibition can be an additional therapeutic alternative to
the IFN-α-ribavarin therapy for HCV patients. Such combined therapies would en-
sure early measures to keep the secondary effects of a viral infection, in this case
HCC, in check.
3.6.2 hnRNPs in the HIV life-cycle
One of the major complexes found in the HIV subnetworks were the heterogeneous
ribonuclear proteins (hnRNPs). As mentioned in previous subsection, hnRNPs were
prominent in the HIV_s66 subnetwork. Their importance is also validated by our
functional analyses involving overlay of tissue-specific gene expression data and CO-
RUM complexes. Despite belonging to the same complex, different subunits of hn-
RNPs have different roles in the HIV life cycle; majority of these are antiviral in
nature while some, like hnRNP-A1 are proviral in nature[113]. Moreover, hnRNP
H subunits also play in important role in mRNA splicing, particularly of viral gene
transcripts. Schaub et al. have shown that hnRNPs H, H’, F, 2H9, and GRSF-1 to
form a multimeric complex by binding at the consensus motif DGGGD (where D can
be either of U, G or A)[172]. This complex is involved in splicing of gene substrate
derived from the HIV-1 tat gene via ATP-dependent spliceosomal complexes. Its im-
portant to note there that hnRNP subunits came up in both the secondary analyses
and in the HIV_s66 subnetwork itself, thus pointing to multiple lines of evidence and
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FIGURE 3.13: Tankyrase-1 is also one of the proteins expressed in hepatocytes and also part
of the 3 CORUM complexes(TRF1 telomere length regulation complex, TRF-Rap1 complex I,
2MD and Tankyrin 1-tankyrin 2-TRF1 complex) overlaid on HCV_s64 subnetwork.
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emphasising their presence in this subnetwork. Hence, it helps in prioritising can-
didate proteins/complexes from the already few, specific subnetworks obtained from
our analysis. In this case, although the hnRNPs have been studied elsewhere, a double
or multiple knockdown of these subunits in macrophage infected HIV cells may lead
to interesting observations.
3.7 Putative Novel Hits: Mapping virus-host interaction data
A third approach to predict novel hits from within these subnetworks is to overlay
virus-host interaction data. If a viral protein interacts with a host-protein that is a
non-hit, such proteins along with hits can be interpreted collectively. The confidence
of such non-hits increases if, from a group of such non-hits, some are hits.
3.7.1 Rev,p19 and its interactions with heterogeneous ribonuclear pro-
teins (hnRNPs)
The HIV viral protein, Rev or otherwise known as p19, is an adaptor protein known
for its function of nuclear export of HIV RNAs. To understand the details of its
mechanisms, Hadian et al.[173] showed how Rev interacts with a a large family of
multifunctional host factors call hnRNPs. Rev utilises amino acids 9-14, specifically
to bind heterogeneous ribonucleoproteins (hnRNP) A1, Q, K, R and U. The HIV-1
NIAID Database [53] even lists several hnRNP subunits that interact with Rev. These
include A/B isoform b, A1 isoform a, A3, D-like isoform a, D0 isoform d, F, H, H2,
H3 isoform a, K isoform a, M isoform a, Q isoform 1, R isoform 2, U isoform b,
A2/B1 isoform A2 and C1/C2 isoform b. The HIV_s66 subnetwork contains almost
all of these subunits, if not the exact isoforms of these genes. We have already dis-
cussed the multifunctional properties of hnRNPs above (see figure 3.5).
3.7.2 Interactions of HCV NS3-4A protein
We utilised the virus-host interactions dataset of de Chassey et al.[70]. When overlay-
ing the host genes detected to be interacting with viral proteins, on the HCV subnet-
works, we found that NS3-4A protein interacted with with 2 proteins; RNA-binding
protein 4 (RBM4) and E3 ubiquitin-protein ligase SMURF2 (SMURF2). Of these 2
proteins, SMURF2 is a hit while RBM4 is a non-hit. HCV nonstructural proteins in-
terfere with TGF-β signaling via SMURF2, which is a negative regulator of this path-
way. As described above, TGF-β stimulation led to an increase of SMAD-dependent
genes[174]. However, this stimulated signaling was suppressed by SMURF2 while
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FIGURE 3.14: HIV_s66 subnetwork with interacting HIV-1 proteins
FIGURE 3.15: HCV_s46 subnetwork with interacting HCV-NS3 proteins
and mimicked upon SMURF2 silencing. Importantly, Verga-Gérard et al. showed
that the ubiquitin ligase activity or NS3-4A protease activity wasn’t required to mod-
ulate TGF-β signaling.
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Chapter 4
Discussion
4.1 Integrative approaches reveal significant biology
Our results illustrate that using various kinds of datasets to analyse a genome-wide
RNAi screens reveal multiple perspectives of underlying biological mechanisms. This
is otherwise not possible from traditional enrichment analyses methods. Our analyses
are one of the many that have used RNAi screen data to understand virus-host interac-
tions and their biology. Noteworthy among these studies are from Bushman et al. who
performed a comprehensive meta-analysis of all the published HIV-1 RNAi screens;
Macpherson et al. who utilised the HIV-1 human protein interaction database (HH-
PID) in conjunction with the published HIV-1 RNAi screens to reveal perturbed host
subsystems[1–3, 9, 53, 54]; Dickerson et al. who utilised the same dataset (HHPID)
to reveal topological features of the most targeted host genes by HIV[175]; Murali et
al. who developed a machine learning approach to predict novel HDFs using protein
interaction network and the published RNAi screens [43] and finally, Schneider et al.
who used a large number of RNAi screens and applied single cell analysis with some
novel statistical functions to illustrate variation in identified hits [176]. Each of these
analyses utilised RNAi screens with more than one data type (except Schneider et al.)
to provide insights within the virus-host interactions. Since none of these studies have
a common algorithmic basis except for the data used, it is not straightforward to com-
pare their results. Particularly, except for Schneider et al., all these studies focus on
HIV-1 screens whereas our analyses encompass HCV and WNV too. However, de-
spite the difference in methodology and its application, if certain biological processes
among these studies converge towards a specific set of biological processes/pathways
for a particular virus, it provides a second level of validation about these processes/-
pathways and helps in confirming their application as novel drug targets/therapeutics.
For instance, our analysis along with Bushman et al. and Murali et al., showed that
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HNRNPs are important HDFs of HIV-1, using the published RNAi screen data. It thus
validates the fact that among other hits identified from these studies, HNRNPs should
be focused for a secondary experimental validation amongst other potentially novel
hits, as they are predicted hits from all these studies. This also applies to the Mediator
complex, again a prominent result from all the above mentioned studies as well as our
analysis. Such multiple validations of certain biological processes/protein complexes
is essential if these hits are to be considered for therapeutic use. Additionally, even
¯from our analysis; tissue-specific expression data and protein complex overlays iden-
tified HNRNPs as a prominent result. This is in contrast when compared exclusively
to the computational studies mentioned above wherein we further highlight the im-
portance of certain hits considering its expression. Theoretical predictions often leads
to multiple hits with a fair chance of false-positives, similar to the experimental coun-
terparts. However, by adjusting the stringency of scoring functions, it is relatively
easy to control the rate of false-positives in such computational predictions. Despite
such measures, more often there are still considerable number of potential novel hits
to tackle with. Herein along with importance of hits their relevance should be con-
sidered, which, is the expression of such hits in a specific tissue. If a hit is highly
expressed in host tissue most susceptible to virus as compared to other, such hit is
more relevant than others in the list. This is where our network-based meta analysis
differs from the other studies. We predicted tissue specific hits that may potentially
have an important role in HCV infection and its progression towards HCC. We also
hypothesize about possible small-molecule drug treatments for one of the identified
enzymes, Tankyrase that might have a role in controlling hepatocytic progression of
HCC.
In summary, multiple lines of evidence show that certain processes/pathways/pro-
tein complexes from within a hit-list of RNAi screen are more important over others.
These may have poor statistical confidence (p≤0.05, yet towards the higher side) but
when analysed with supplementary datasets, their biological relevance and signifi-
cance becomes clearer. Thus, our approach allows for Hit-prioritisation from within
hit-list(s) of a RNAi screen(s).
4.2 Host factors shared between virus species
A unique differentiation of our analysis as compared to others mentioned above, is
comparative analysis of inter-species viral RNAi screens and identification of subnet-
works enriched for HDFs for one or more virus species. Schneider et al. did utilise
multiple screens of different virus species, however, they didn’t point out functional
subnetworks. From our combined analysis of hit-lists from RNAi screens of differ-
ent virus species, we determined common HDFs required by HIV and HCV. In some
71
cases, such as the Src family of kinases, encompassing a large number of kinases
with varied functions, our analysis shows that they are required by all three viruses
(considered in our study); HIV, HCV and WNV. Such results open further avenues in
therapeutics and at times are essential when it comes to cases of co-infection. For e.g.
HIV patients co-infected with HCV. Although from different families, both HIV and
HCV are RNA viruses and as such, determining these common HDFs from within
these subnetwork helps in hypothesizing interactions within such patients and subse-
quently, devise unique therapeutic measures for them. Such strategies are otherwise
extremely difficult to determine purely by experimentation and thus, such computa-
tional prediction leverage this task to a great extent .
Determining these common subnetworks becomes even more intriguing in the case
where the viruses in consideration are from the same family. For instance, a particular
subnetwork enriched for HDFs/HRFs for RNAi hits from viral screens of HCV, WNV
an Dengue virus (family Flaviviridae), allows for studying finer level of interaction
mechanisms between the commonly targeted host proteins by all three viruses. Con-
versely, other proteins that are specifically targeted by only one species also helps in
understanding why different virus species of the same family target different proteins
within the same functional subnetwork. Thus, such subnetwork becomes more im-
portant over other statistically significant hits, as identified from classical enrichment
methods.
4.3 Multiple approaches of integrative analyses and results
In data-integrative meta-analyses of RNAi screens, some biological processes/path-
ways/protein complexes are more significant than others (HNRNPs in case of HIV),
irrespective of the underlying methodology. An argument can be made about the
reliability of such processes/pathways, that since such analyses involved protein in-
teraction networks, which are susceptible to a large number of false positives. This
is further marred by the fact that for many predicted interactions, interactions derived
from literature and high throughput studies have ascertainment bias towards certain
proteins over others[177, 178]. Macpherson et al. did account for this bias and ap-
plied a corrective measure in their analysis[54]. A stricter filtering of interactions can
be at the level of interaction detection type wherein only experimentally verified reac-
tions are considered. However, this is a compromise for coverage as such interactions
aren’t comprehensive and are neither mutually exclusive[177]. Furthermore, this also
risks losing out false-negatives from the dataset. We observed this in our analyses too
where we obtained few or no subnetworks using our 2-step filtering process, when
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using experimentally-verified interactions alone. Thus, we chose for broader cover-
age to detect such functional subnetworks and subsequently, "hot spots" within the
human PINs with a risk of having potential false-positives than missing out false neg-
atives. Since we propose these subnetworks for therapeutics the risk of losing out
true-negatives is more than having false-positives in the dataset. In order to enhance
reliability and confidence of the subnetworks, we therefore utilised tissue-specific ex-
pression and known human protein complexes, to interpret these subnetworks. These
steps keep false-positives in check as unrelated interactions and spurious interactions
observed after these steps can then be tested with greater caution
In our methodology, a second possible factor that might influence the resulting sub-
networks is the choice of the clustering algorithm, initially used to cluster the human
PIN. Indeed, different clustering algorithms can lead to different clusters and as a con-
sequence, might change the final resulting clusters. This can indeed be the case when
the initial clustering is performed by an algorithm that doesn’t account for overlaps.
However, as we mentioned earlier, certain hits from a RNAi screen are robust and
thus, despite change in clustering, scoring etc. didn’t alter the results for these hits.
It then becomes interesting to study interaction partners of such robust hits and hy-
pothesize on their interaction mechanisms within the subnetwork that is enriched. On
the other hand, the difference in the subnetworks obtained due to choice of clustering
algorithms would then become a comparative analysis of the algorithms in question,
which is beyond the scope of the thesis.
It also follows that in the topological filtering step in our methodology, larger subnet-
works will have larger mean centrality values (in particular, Degree and Betweenness,
see Appendix I) and thus, will lead to larger subnetworks that are diverse in function.
But their filtering based on these mean centrality measures when compared to non-hit
subnetworks of the same size (see Materials and methods) ensured that we got reason-
ably sized subnetworks. This is reflected in our results as well. With the exception of
Combi_s239, all our subnetworks ranged from 40-64. Given these possible shortcom-
ings, the biological hypotheses deduced from such analysis is evidently multi-faceted.
Each facet of these subnetworks further enhances our understanding of virus-host in-
teractions and provides a computational basis for drug design and effective therapy.
4.4 Applications of the methodology
Our methodology relies on large protein interaction networks and multiple gene hit
lists from a study or gene hit list from multiple studies, aimed towards a biological
process or identifying key determinants of a disease. Thus, practically our method-
ology can be applied to datasets that fulfil these criteria and allow for an integrative
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meta-analysis of such datasets. One prominent application area being identification
of up-regulated/down-regulated subnetworks for different cancer types. The predicted
common subnetworks can then be targeted with specific inhibitor/enhancer molecules
to regulate those cancers for which the subnetworks are common for. On the other
hand, the subnetworks specific to a particular cancer can then be included with the
common subnetworks’ therapy for an even more effective and personalised treatment.
Moreover, as described above, inclusion of multiple, relevant data sources (such as
drug-target interactions, ligand-receptor interactions, expression data) can then be
utilised to delve into further intricacies. Despite some of its shortcomings mentioned
above, such approaches hold the key to utilise big, multiple data sources to understand
biology and more so, develop new-age therapeutics for complex human diseases.
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Chapter 5
Conclusion
We developed a data-driven, integrative bioinformatics framework for analysing genome-
wide RNAi screens. Genome-wide knockdown screens have accelerated the rate at
which novel host factors of viral diseases are identified. Although such screens are
promising, they pose significant data-specific challenges of their own. In particular,
screens with similar experimental setup for the same virus show relatively poor over-
lap between identified hit-sets. This leads one to infer that these screens aren’t repro-
ducible and are highly noisy. These inferences might be true but integrative statistical
analyses can overcome this problem. Specifically, incorporating network information
with RNAi hits can significantly improve our interpretation and understanding of the
hits.
Initially we built a host protein interaction network collating interactions from pub-
lic repositories. This network consisted of 15383 proteins and 337413 interactions.
We then subject this network to an overlapping complex prediction algorithm, Clus-
terOne, to identify overlapping clusters. We chose an algorithm that predicts overlap-
ping complexes to identify potential multifunction proteins. More so, as we chose to
analyse multiple RNAi screens of different virus species and multifunction, druggable
proteins can serve as drug targets for more than one virus. We included 7 genome-
wide screens consisting of 3 HIV screens, 3 HCV screens and a WNV screen. From
amongst the predicted clusters, we calculated hit enrichment in the clusters in 2 ways;
with virus-specific hit-sets and combining hits from all screens. These clusters were
then subjected to a 2-step filtering; in the 1st step, statistically significant clusters (at
5% significance) were filtered and in the 2nd step, was subjected to topology based
filtering. We utilised 6 network topological measures, technically known as Network
Centralities and 2 semantic similarity measures (Dice and Wang) for this 2nd step
filtering. We calculated mean values for all these measures and used these mean val-
ues to filter subnetworks (i.e. clusters) based on size. Subnetworks of identical sizes,
those enriched with hits and those not enriched with hits, were filtered based on the
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mean values of network centralities and similarity measures using Wilcox test. Thus,
subnetworks filtered in this step were statistically significant in 2 ways; enriched with
hits and significant in topology compared to their non-enriched counterparts.
For further characterisation, GO and pathway enrichment of these subnetworks were
performed to determine the role of these subnetworks in viral infection. We found that,
for virus-specific subnetworks, GO and pathway terms were highly specific. This has
to be attributed to the underlying clustering as well as the topological filtering step,
as these subnetworks not only contained well characterised hits (e.g. hnRNPs in HIV
infection) and identified as hits in RNAi screens but other potentially novel hit candi-
dates in their neighbourhood. Using tissue-specific gene expression data and known
protein complexes allowed for further specific characterisation and confidence for pre-
dicted novel hits. Moreover, it also allowed for hypothesising mechanisms of infection
with known and unknown proteins. This helped to revisit known pathways and com-
plexes for a detailed analysis to elucidate interaction mechanisms of such proteins
in viral infection. In summary, our approach provides a computational, integrative
frame-work for meta-analysis of genome-wide studies.
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Appendix A
Appendix A
A.1 Subnetwork Protein Annotations
Entry Entry name Status Protein names Cross-
reference
GENEID
P54793 ARSF_HUMAN reviewed Arylsulfatase F (ASF) (EC 3.1.6.-) 416
P20807 CAN3_HUMAN reviewed Calpain-3 (EC 3.4.22.54) (Calcium-
activated neutral proteinase 3) (CANP
3) (Calpain L3) (Calpain p94) (Muscle-
specific calcium-activated neutral protease
3) (New calpain 1) (nCL-1)
825
O95319 CELF2_HUMAN reviewed CUGBP Elav-like family member 2
(CELF-2) (Bruno-like protein 3) (CUG
triplet repeat RNA-binding protein 2)
(CUG-BP2) (CUG-BP- and ETR-3-like
factor 2) (ELAV-type RNA-binding
protein 3) (ETR-3) (Neuroblastoma
apoptosis-related RNA-binding pro-
tein) (hNAPOR) (RNA-binding protein
BRUNOL-3)
10659
P49711 CTCF_HUMAN reviewed Transcriptional repressor CTCF (11-zinc
finger protein) (CCCTC-binding factor)
(CTCFL paralog)
10664
Q92499 DDX1_HUMAN reviewed ATP-dependent RNA helicase DDX1 (EC
3.6.4.13) (DEAD box protein 1) (DEAD
box protein retinoblastoma) (DBP-RB)
1653
Q8N1I0 DOCK4_HUMAN reviewed Dedicator of cytokinesis protein 4 9732
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O75319 DUS11_HUMAN reviewed RNA/RNP complex-1-interacting phos-
phatase (EC 3.1.3.-) (Dual specificity pro-
tein phosphatase 11) (Phosphatase that in-
teracts with RNA/RNP complex 1)
8446
Q7Z6M2 FBX33_HUMAN reviewed F-box only protein 33 254170
P35637 FUS_HUMAN reviewed RNA-binding protein FUS (75 kDa DNA-
pairing protein) (Oncogene FUS) (Onco-
gene TLS) (POMp75) (Translocated in li-
posarcoma protein)
2521
P31943 HNRH1_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
H (hnRNP H) [Cleaved into: Hetero-
geneous nuclear ribonucleoprotein H, N-
terminally processed]
3187
P55795 HNRH2_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
H2 (hnRNP H2) (FTP-3) (Heterogeneous
nuclear ribonucleoprotein H’) (hnRNP H’)
3188
P07910 HNRPC_HUMAN reviewed Heterogeneous nuclear ribonucleoproteins
C1/C2 (hnRNP C1/C2)
3183
Q14103 HNRPD_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
D0 (hnRNP D0) (AU-rich element RNA-
binding protein 1)
3184
P52597 HNRPF_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
F (hnRNP F) (Nucleolin-like protein
mcs94-1) [Cleaved into: Heterogeneous
nuclear ribonucleoprotein F, N-terminally
processed]
3185
P61978 HNRPK_HUMAN reviewed Heterogeneous nuclear ribonucleopro-
tein K (hnRNP K) (Transformation
up-regulated nuclear protein) (TUNP)
3190
P14866 HNRPL_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
L (hnRNP L)
3191
P52272 HNRPM_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
M (hnRNP M)
4670
O43390 HNRPR_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
R (hnRNP R)
10236
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Q00839 HNRPU_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
U (hnRNP U) (Scaffold attachment factor
A) (SAF-A) (p120) (pp120)
3192
P48200 IREB2_HUMAN reviewed Iron-responsive element-binding protein 2
(IRE-BP 2) (Iron regulatory protein 2)
(IRP2)
3658
Q5VWX1 KHDR2_HUMAN reviewed KH domain-containing, RNA-binding,
signal transduction-associated protein 2
(Sam68-like mammalian protein 1) (SLM-
1) (hSLM-1)
202559
O75525 KHDR3_HUMAN reviewed KH domain-containing, RNA-binding,
signal transduction-associated protein 3
(RNA-binding protein T-Star) (Sam68-
like mammalian protein 2) (SLM-2)
(Sam68-like phosphotyrosine protein)
10656
Q09161 NCBP1_HUMAN reviewed Nuclear cap-binding protein subunit 1 (80
kDa nuclear cap-binding protein) (CBP80)
(NCBP 80 kDa subunit)
4686
P52298 NCBP2_HUMAN reviewed Nuclear cap-binding protein subunit 2 (20
kDa nuclear cap-binding protein) (Cell
proliferation-inducing gene 55 protein)
(NCBP 20 kDa subunit) (CBP20) (NCBP-
interacting protein 1) (NIP1)
22916
P51513 NOVA1_HUMAN reviewed RNA-binding protein Nova-1 (Neuro-
oncological ventral antigen 1) (Onconeu-
ral ventral antigen 1) (Paraneoplastic Ri
antigen) (Ventral neuron-specific protein
1)
4857
Q86U42 PABP2_HUMAN reviewed Polyadenylate-binding protein 2 (PABP-
2) (Poly(A)-binding protein 2) (Nu-
clear poly(A)-binding protein 1)
(Poly(A)-binding protein II) (PABII)
(Polyadenylate-binding nuclear protein 1)
8106
Q15365 PCBP1_HUMAN reviewed Poly(rC)-binding protein 1 (Alpha-CP1)
(Heterogeneous nuclear ribonucleoprotein
E1) (hnRNP E1) (Nucleic acid-binding
protein SUB2.3)
5093
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Q15366 PCBP2_HUMAN reviewed Poly(rC)-binding protein 2 (Alpha-CP2)
(Heterogeneous nuclear ribonucleoprotein
E2) (hnRNP E2)
5094
P57723 PCBP4_HUMAN reviewed Poly(rC)-binding protein 4 (Alpha-CP4) 57060
P26599 PTBP1_HUMAN reviewed Polypyrimidine tract-binding protein 1
(PTB) (57 kDa RNA-binding protein
PPTB-1) (Heterogeneous nuclear ribonu-
cleoprotein I) (hnRNP I)
5725
Q00577 PURA_HUMAN reviewed Transcriptional activator protein Pur-alpha
(Purine-rich single-stranded DNA-binding
protein alpha)
5813
Q96PU8 QKI_HUMAN reviewed Protein quaking (Hqk) (HqkI) 9444
Q9BTL3 RAM_HUMAN reviewed RNMT-activating mini protein (RAM)
(Protein FAM103A1)
83640
P57052 RBM11_HUMAN reviewed Splicing regulator RBM11 (RNA-binding
motif protein 11)
54033
Q96IZ5 RBM41_HUMAN reviewed RNA-binding protein 41 (RNA-binding
motif protein 41)
55285
Q9BTD8 RBM42_HUMAN reviewed RNA-binding protein 42 (RNA-binding
motif protein 42)
79171
Q9BQ04 RBM4B_HUMAN reviewed RNA-binding protein 4B (RNA-binding
motif protein 30) (RNA-binding motif
protein 4B) (RNA-binding protein 30)
83759
Q9Y580 RBM7_HUMAN reviewed RNA-binding protein 7 (RNA-binding
motif protein 7)
10179
P38159 RBMX_HUMAN reviewed RNA-binding motif protein, X chromo-
some (Glycoprotein p43) (Heterogeneous
nuclear ribonucleoprotein G) (hnRNP G)
[Cleaved into: RNA-binding motif pro-
tein, X chromosome, N-terminally pro-
cessed]
27316
P0DJD3 RBY1A_HUMAN reviewed RNA-binding motif protein, Y chromo-
some, family 1 member A1 (RNA-binding
motif protein 1) (RNA-binding motif pro-
tein 2) (Y chromosome RNA recognition
motif 1) (hRBMY)
5940
80
P0DJD4 RBY1C_HUMAN reviewed RNA-binding motif protein, Y chromo-
some, family 1 member C
O75526 RMXL2_HUMAN reviewed RNA-binding motif protein, X-linked-
like-2 (Testis-specific heterogeneous nu-
clear ribonucleoprotein G-T) (hnRNP G-
T)
27288
Q13151 ROA0_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
A0 (hnRNP A0)
10949
P09651 ROA1_HUMAN reviewed Heterogeneous nuclear ribonucleoprotein
A1 (hnRNP A1) (Helix-destabilizing pro-
tein) (Single-strand RNA-binding protein)
(hnRNP core protein A1)
3178
P22626 ROA2_HUMAN reviewed Heterogeneous nuclear ribonucleoproteins
A2/B1 (hnRNP A2/B1)
3181
Q8TA86 RP9_HUMAN reviewed Retinitis pigmentosa 9 protein (Pim-1-
associated protein) (PAP-1)
6100
P08621 RU17_HUMAN reviewed U1 small nuclear ribonucleoprotein 70
kDa (U1 snRNP 70 kDa) (U1-70K)
(snRNP70)
6625
P31645 SC6A4_HUMAN reviewed Sodium-dependent serotonin transporter
(5HT transporter) (5HTT) (Solute carrier
family 6 member 4)
6532
Q15428 SF3A2_HUMAN reviewed Splicing factor 3A subunit 2 (SF3a66)
(Spliceosome-associated protein 62) (SAP
62)
8175
Q8WXA9 SREK1_HUMAN reviewed Splicing regulatory glutamine/lysine-rich
protein 1 (Serine/arginine-rich-splicing
regulatory protein 86) (SRrp86) (Splicing
factor, arginine/serine-rich 12) (Splicing
regulatory protein 508) (SRrp508)
140890
81
O75494 SRS10_HUMAN reviewed Serine/arginine-rich splicing factor 10
(40 kDa SR-repressor protein) (SRrp40)
(FUS-interacting serine-arginine-rich pro-
tein 1) (Splicing factor SRp38) (Splicing
factor, arginine/serine-rich 13A) (TLS-
associated protein with Ser-Arg repeats)
(TASR) (TLS-associated protein with SR
repeats) (TLS-associated serine-arginine
protein) (TLS-associated SR protein)
100996657
10772
P84103 SRSF3_HUMAN reviewed Serine/arginine-rich splicing factor 3 (Pre-
mRNA-splicing factor SRP20) (Splicing
factor, arginine/serine-rich 3)
6428
Q08170 SRSF4_HUMAN reviewed Serine/arginine-rich splicing fac-
tor 4 (Pre-mRNA-splicing factor
SRP75) (SRP001LB) (Splicing fac-
tor, arginine/serine-rich 4)
6429
Q13247 SRSF6_HUMAN reviewed Serine/arginine-rich splicing factor 6 (Pre-
mRNA-splicing factor SRP55) (Splicing
factor, arginine/serine-rich 6)
6431
Q16629 SRSF7_HUMAN reviewed Serine/arginine-rich splicing factor 7
(Splicing factor 9G8) (Splicing factor,
arginine/serine-rich 7)
6432
Q13242 SRSF9_HUMAN reviewed Serine/arginine-rich splicing factor 9 (Pre-
mRNA-splicing factor SRp30C) (Splicing
factor, arginine/serine-rich 9)
8683
Q8IWZ8 SUGP1_HUMAN reviewed SURP and G-patch domain-containing
protein 1 (RNA-binding protein RBP)
(Splicing factor 4)
57794
Q13595 TRA2A_HUMAN reviewed Transformer-2 protein homolog al-
pha (TRA-2 alpha) (TRA2-alpha)
(Transformer-2 protein homolog A)
29896
P62995 TRA2B_HUMAN reviewed Transformer-2 protein homolog beta
(TRA-2 beta) (TRA2-beta) (hTRA2-beta)
(Splicing factor, arginine/serine-rich 10)
(Transformer-2 protein homolog B)
6434
82
P67809 YBOX1_HUMAN reviewed Nuclease-sensitive element-binding pro-
tein 1 (CCAAT-binding transcription fac-
tor I subunit A) (CBF-A) (DNA-binding
protein B) (DBPB) (Enhancer factor I sub-
unit A) (EFI-A) (Y-box transcription fac-
tor) (Y-box-binding protein 1) (YB-1)
4904
Q9HA38 ZMAT3_HUMAN reviewed Zinc finger matrin-type protein 3 (Zinc fin-
ger protein WIG-1) (p53-activated gene
608 protein)
64393
O95218 ZRAB2_HUMAN reviewed Zinc finger Ran-binding domain-
containing protein 2 (Zinc finger protein
265) (Zinc finger, splicing)
9406
Q5JQ65 Q5JQ65_HUMAN unreviewed RNA binding motif protein, X-linked
(Fragment)
Q8IYQ9 Q8IYQ9_HUMAN unreviewed Importin subunit alpha 3839
Q5T6W5 Q5T6W5_HUMAN unreviewed Heterogeneous nuclear ribonucleoprotein
K
Q12771 Q12771_HUMAN unreviewed P37 AUF1
Q9H4D4 Q9H4D4_HUMAN unreviewed ZNF143 protein (Fragment)
TABLE A.1: HIV-s66 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
Q96N21 AP4AT_HUMAN reviewed AP-4 complex accessory subunit tepsin
(ENTH domain-containing protein 2)
(Epsin for AP-4) (Tetra-epsin)
146705
Q9BZE3 BARH1_HUMAN reviewed BarH-like 1 homeobox protein 56751
P24863 CCNC_HUMAN reviewed Cyclin-C (SRB11 homolog) (hSRB11) 892
Q9BWU1 CDK19_HUMAN reviewed Cyclin-dependent kinase 19 (EC
2.7.11.22) (CDC2-related protein ki-
nase 6) (Cell division cycle 2-like protein
kinase 6) (Cell division protein ki-
nase 19) (Cyclin-dependent kinase 11)
(Death-preventing kinase)
23097
83
P49336 CDK8_HUMAN reviewed Cyclin-dependent kinase 8 (EC 2.7.11.22)
(EC 2.7.11.23) (Cell division protein ki-
nase 8) (Mediator complex subunit CDK8)
(Mediator of RNA polymerase II tran-
scription subunit CDK8) (Protein kinase
K35)
1024
Q6IAN0 DRS7B_HUMAN reviewed Dehydrogenase/reductase SDR family
member 7B (EC 1.1.-.-)
25979
Q9UPW0 FOXJ3_HUMAN reviewed Forkhead box protein J3 22887
Q9H0H0 INT2_HUMAN reviewed Integrator complex subunit 2 (Int2) 57508
Q68E01 INT3_HUMAN reviewed Integrator complex subunit 3 (Int3) (SOSS
complex subunit A) (Sensor of single-
strand DNA complex subunit A) (SOSS-
A) (Sensor of ssDNA subunit A)
65123
Q7L273 KCTD9_HUMAN reviewed BTB/POZ domain-containing protein
KCTD9
54793
O94953 KDM4B_HUMAN reviewed Lysine-specific demethylase 4B (EC
1.14.11.-) (JmjC domain-containing his-
tone demethylation protein 3B) (Jumonji
domain-containing protein 2B)
23030
Q9UBF1 MAGC2_HUMAN reviewed Melanoma-associated antigen C2 (Can-
cer/testis antigen 10) (CT10) (Hepatocel-
lular carcinoma-associated antigen 587)
(MAGE-C2 antigen) (MAGE-E1 antigen)
51438
Q71F56 MD13L_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 13-like (Mediator com-
plex subunit 13-like) (Thyroid hormone
receptor-associated protein 2) (Thyroid
hormone receptor-associated protein com-
plex 240 kDa component-like)
23389
Q9BTT4 MED10_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 10 (Mediator complex
subunit 10) (Transformation-related gene
17 protein) (TRG-17) (Transformation-
related gene 20 protein) (TRG-20)
84246
84
Q9P086 MED11_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 11 (Mediator complex subunit
11)
400569
Q93074 MED12_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 12 (Activator-recruited cofac-
tor 240 kDa component) (ARC240) (CAG
repeat protein 45) (Mediator complex sub-
unit 12) (OPA-containing protein) (Thy-
roid hormone receptor-associated protein
complex 230 kDa component) (Trap230)
(Trinucleotide repeat-containing gene 11
protein)
9968
Q9UHV7 MED13_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 13 (Activator-recruited
cofactor 250 kDa component) (ARC250)
(Mediator complex subunit 13) (Thyroid
hormone receptor-associated protein 1)
(Thyroid hormone receptor-associated
protein complex 240 kDa compo-
nent) (Trap240) (Vitamin D3 receptor-
interacting protein complex component
DRIP250) (DRIP250)
9969
O60244 MED14_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 14 (Activator-recruited cofac-
tor 150 kDa component) (ARC150) (Co-
factor required for Sp1 transcriptional ac-
tivation subunit 2) (CRSP complex sub-
unit 2) (Mediator complex subunit 14)
(RGR1 homolog) (hRGR1) (Thyroid hor-
mone receptor-associated protein complex
170 kDa component) (Trap170) (Tran-
scriptional coactivator CRSP150) (Vita-
min D3 receptor-interacting protein com-
plex 150 kDa component) (DRIP150)
9282
85
Q9Y2X0 MED16_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 16 (Mediator complex subunit
16) (Thyroid hormone receptor-associated
protein 5) (Thyroid hormone receptor-
associated protein complex 95 kDa com-
ponent) (Trap95) (Vitamin D3 receptor-
interacting protein complex 92 kDa com-
ponent) (DRIP92)
10025
Q9NVC6 MED17_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 17 (Activator-recruited cofac-
tor 77 kDa component) (ARC77) (Cofac-
tor required for Sp1 transcriptional activa-
tion subunit 6) (CRSP complex subunit 6)
(Mediator complex subunit 17) (Thyroid
hormone receptor-associated protein com-
plex 80 kDa component) (Trap80) (Tran-
scriptional coactivator CRSP77) (Vitamin
D3 receptor-interacting protein complex
80 kDa component) (DRIP80)
9440
Q9BUE0 MED18_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 18 (Mediator complex subunit
18) (p28b)
54797
A0JLT2 MED19_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 19 (Lung cancer metastasis-
related protein 1) (Mediator complex sub-
unit 19)
219541
86
Q15648 MED1_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 1 (Activator-recruited cofac-
tor 205 kDa component) (ARC205) (Me-
diator complex subunit 1) (Peroxisome
proliferator-activated receptor-binding
protein) (PBP) (PPAR-binding protein)
(Thyroid hormone receptor-associated
protein complex 220 kDa component)
(Trap220) (Thyroid receptor-interacting
protein 2) (TR-interacting protein 2)
(TRIP-2) (Vitamin D receptor-interacting
protein complex component DRIP205)
(p53 regulatory protein RB18A)
5469
Q9H944 MED20_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 20 (Mediator complex sub-
unit 20) (TRF-proximal protein homolog)
(hTRFP)
9477
Q13503 MED21_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 21 (Mediator complex
subunit 21) (RNA polymerase II holoen-
zyme component SRB7) (RNAPII com-
plex component SRB7) (hSrb7)
9412
Q15528 MED22_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 22 (Mediator complex subunit
22) (Surfeit locus protein 5) (Surf-5)
6837
Q9ULK4 MED23_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 23 (Activator-recruited cofac-
tor 130 kDa component) (ARC130) (Co-
factor required for Sp1 transcriptional ac-
tivation subunit 3) (CRSP complex subunit
3) (Mediator complex subunit 23) (Pro-
tein sur-2 homolog) (hSur-2) (Transcrip-
tional coactivator CRSP130) (Vitamin D3
receptor-interacting protein complex 130
kDa component) (DRIP130)
9439
87
O75448 MED24_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 24 (Activator-recruited co-
factor 100 kDa component) (ARC100)
(Cofactor required for Sp1 transcriptional
activation subunit 4) (CRSP complex
subunit 4) (Mediator complex subunit
24) (Thyroid hormone receptor-associated
protein 4) (Thyroid hormone receptor-
associated protein complex 100 kDa com-
ponent) (Trap100) (hTRAP100) (Vitamin
D3 receptor-interacting protein complex
100 kDa component) (DRIP100)
9862
Q71SY5 MED25_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 25 (Activator interaction
domain-containing protein 1) (Activator-
recruited cofactor 92 kDa component)
(ARC92) (Mediator complex subunit 25)
(p78)
81857
O95402 MED26_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 26 (Activator-recruited cofac-
tor 70 kDa component) (ARC70) (Cofac-
tor required for Sp1 transcriptional acti-
vation subunit 7) (CRSP complex subunit
7) (Mediator complex subunit 26) (Tran-
scriptional coactivator CRSP70)
9441
Q6P2C8 MED27_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 27 (Cofactor required
for Sp1 transcriptional activation subunit
8) (CRSP complex subunit 8) (Mediator
complex subunit 27) (P37 TRAP/SMC-
C/PC2 subunit) (Transcriptional coactiva-
tor CRSP34)
9442
Q9H204 MED28_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 28 (Endothelial-derived pro-
tein 1) (Mediator complex subunit 28)
(Merlin and Grb2-interacting cytoskeletal
protein) (Magicin) (Tumor angiogenesis
marker EG-1)
80306
88
Q9NX70 MED29_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 29 (Intersex-like protein)
(Mediator complex subunit 29)
55588
Q96HR3 MED30_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 30 (Mediator complex subunit
30) (TRAP/Mediator complex component
TRAP25) (Thyroid hormone receptor-
associated protein 6) (Thyroid hormone
receptor-associated protein complex 25
kDa component) (Trap25)
90390
Q9NPJ6 MED4_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 4 (Activator-recruited cofac-
tor 36 kDa component) (ARC36) (Me-
diator complex subunit 4) (TRAP/SMC-
C/PC2 subunit p36 subunit) (Vitamin D3
receptor-interacting protein complex 36
kDa component) (DRIP36)
29079
O75586 MED6_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 6 (Activator-recruited cofac-
tor 33 kDa component) (ARC33) (Medi-
ator complex subunit 6) (hMed6) (Renal
carcinoma antigen NY-REN-28)
10001
O43513 MED7_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 7 (hMED7) (Activator-
recruited cofactor 34 kDa component)
(ARC34) (Cofactor required for Sp1 tran-
scriptional activation subunit 9) (CRSP
complex subunit 9) (Mediator complex
subunit 7) (RNA polymerase transcrip-
tional regulation mediator subunit 7
homolog) (Transcriptional coactivator
CRSP33)
9443
Q96G25 MED8_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 8 (Activator-recruited cofac-
tor 32 kDa component) (ARC32) (Media-
tor complex subunit 8)
112950
89
Q9NWA0 MED9_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 9 (Mediator complex subunit
9)
55090
Q9H4Z3 PCIF1_HUMAN reviewed Phosphorylated CTD-interacting factor 1 63935
P24928 RPB1_HUMAN reviewed DNA-directed RNA polymerase II sub-
unit RPB1 (RNA polymerase II sub-
unit B1) (EC 2.7.7.6) (DNA-directed
RNA polymerase II subunit A) (DNA-
directed RNA polymerase III largest sub-
unit) (RNA-directed RNA polymerase II
subunit RPB1) (EC 2.7.7.48)
5430
Q7RTU7 SCX_HUMAN reviewed Basic helix-loop-helix transcription factor
scleraxis (Class A basic helix-loop-helix
protein 41) (bHLHa41) (Class A basic
helix-loop-helix protein 48) (bHLHa48)
100129885,642658
P48436 SOX9_HUMAN reviewed Transcription factor SOX-9 6662
Q9H668 STN1_HUMAN reviewed CST complex subunit STN1
(Oligonucleotide/oligosaccharide-binding
fold-containing protein 1) (Suppressor of
cdc thirteen homolog)
79991
O95379 TFIP8_HUMAN reviewed Tumor necrosis factor alpha-induced
protein 8 (TNF alpha-induced pro-
tein 8) (Head and neck tumor and
metastasis-related protein) (MDC-3.13)
(NF-kappa-B-inducible DED-containing
protein) (NDED) (SCC-S2) (TNF-induced
protein GG2-1)
25816
Q8TB05 UBAD1_HUMAN reviewed UBA-like domain-containing protein 1 124402
Q96K76 UBP47_HUMAN reviewed Ubiquitin carboxyl-terminal hydrolase 47
(EC 3.4.19.12) (Deubiquitinating enzyme
47) (Ubiquitin thioesterase 47) (Ubiquitin-
specific-processing protease 47)
55031
Q70CQ1 UBP49_HUMAN reviewed Ubiquitin carboxyl-terminal hydrolase 49
(EC 3.4.19.12) (Deubiquitinating enzyme
49) (Ubiquitin thioesterase 49) (Ubiquitin-
specific-processing protease 49)
25862
90
Q16587 ZNF74_HUMAN reviewed Zinc finger protein 74 (Zinc finger protein
520) (hZNF7)
7625
Q9H2M2 Q9H2M2_HUMAN unreviewed Estrogen receptor alpha
TABLE A.2: HIV-s52 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
O14983 AT2A1_HUMAN reviewed Sarcoplasmic/endoplasmic reticulum cal-
cium ATPase 1 (SERCA1) (SR Ca(2+)-
ATPase 1) (EC 3.6.3.8) (Calcium pump 1)
(Calcium-transporting ATPase sarcoplas-
mic reticulum type, fast twitch skeletal
muscle isoform) (Endoplasmic reticulum
class 1/2 Ca(2+) ATPase)
487
Q99704 DOK1_HUMAN reviewed Docking protein 1 (Downstream of tyro-
sine kinase 1) (p62(dok)) (pp62)
1796
P22413 ENPP1_HUMAN reviewed Ectonucleotide pyrophosphatase/phos-
phodiesterase family member 1 (E-NPP
1) (Membrane component chromosome
6 surface marker 1) (Phosphodiesterase
I/nucleotide pyrophosphatase 1) (Plasma-
cell membrane glycoprotein PC-1)
[Includes: Alkaline phosphodiesterase I
(EC 3.1.4.1) Nucleotide pyrophosphatase
(NPPase) (EC 3.6.1.9)]
5167
O95936 EOMES_HUMAN reviewed Eomesodermin homolog (T-box brain pro-
tein 2) (T-brain-2) (TBR-2)
8320
P10912 GHR_HUMAN reviewed Growth hormone receptor (GH receptor)
(Somatotropin receptor) [Cleaved into:
Growth hormone-binding protein (GH-
binding protein) (GHBP) (Serum-binding
protein)]
2690
91
P10144 GRAB_HUMAN reviewed Granzyme B (EC 3.4.21.79) (C11)
(CTLA-1) (Cathepsin G-like 1)
(CTSGL1) (Cytotoxic T-lymphocyte
proteinase 2) (Lymphocyte protease)
(Fragmentin-2) (Granzyme-2) (Human
lymphocyte protein) (HLP) (SECT)
(T-cell serine protease 1-3E)
3002
Q13322 GRB10_HUMAN reviewed Growth factor receptor-bound protein
10 (GRB10 adapter protein) (Insulin
receptor-binding protein Grb-IR)
2887
Q14449 GRB14_HUMAN reviewed Growth factor receptor-bound protein 14
(GRB14 adapter protein)
2888
P42701 I12R1_HUMAN reviewed Interleukin-12 receptor subunit beta-1 (IL-
12 receptor subunit beta-1) (IL-12R sub-
unit beta-1) (IL-12R-beta-1) (IL-12RB1)
(IL-12 receptor beta component) (CD anti-
gen CD212)
3594
Q99665 I12R2_HUMAN reviewed Interleukin-12 receptor subunit beta-2 (IL-
12 receptor subunit beta-2) (IL-12R sub-
unit beta-2) (IL-12R-beta-2) (IL-12RB2)
3595
P78552 I13R1_HUMAN reviewed Interleukin-13 receptor subunit alpha-1
(IL-13 receptor subunit alpha-1) (IL-13R
subunit alpha-1) (IL-13R-alpha-1) (IL-
13RA1) (Cancer/testis antigen 19) (CT19)
(CD antigen CD213a1)
3597
P08069 IGF1R_HUMAN reviewed Insulin-like growth factor 1 receptor
(EC 2.7.10.1) (Insulin-like growth fac-
tor I receptor) (IGF-I receptor) (CD anti-
gen CD221) [Cleaved into: Insulin-like
growth factor 1 receptor alpha chain
Insulin-like growth factor 1 receptor beta
chain]
3480
P29459 IL12A_HUMAN reviewed Interleukin-12 subunit alpha (IL-12A)
(Cytotoxic lymphocyte maturation factor
35 kDa subunit) (CLMF p35) (IL-12 sub-
unit p35) (NK cell stimulatory factor chain
1) (NKSF1)
3592
92
P29460 IL12B_HUMAN reviewed Interleukin-12 subunit beta (IL-12B) (Cy-
totoxic lymphocyte maturation factor 40
kDa subunit) (CLMF p40) (IL-12 subunit
p40) (NK cell stimulatory factor chain 2)
(NKSF2)
3593
Q9UHD0 IL19_HUMAN reviewed Interleukin-19 (IL-19) (Melanoma
differentiation-associated protein-like
protein) (NG.1)
29949
Q9NPF7 IL23A_HUMAN reviewed Interleukin-23 subunit alpha (IL-23 sub-
unit alpha) (IL-23-A) (Interleukin-23 sub-
unit p19) (IL-23p19)
51561
Q5VWK5 IL23R_HUMAN reviewed Interleukin-23 receptor (IL-23 receptor)
(IL-23R)
149233
Q13007 IL24_HUMAN reviewed Interleukin-24 (IL-24) (Melanoma
differentiation-associated gene 7 protein)
(MDA-7) (Suppression of tumorigenicity
16 protein)
11009
Q8NEV9 IL27A_HUMAN reviewed Interleukin-27 subunit alpha (IL-27 sub-
unit alpha) (IL-27-A) (IL27-A) (p28)
246778
P15260 INGR1_HUMAN reviewed Interferon gamma receptor 1 (IFN-gamma
receptor 1) (IFN-gamma-R1) (CDw119)
(CD antigen CD119)
3459
P38484 INGR2_HUMAN reviewed Interferon gamma receptor 2 (IFN-gamma
receptor 2) (IFN-gamma-R2) (Interferon
gamma receptor accessory factor 1) (AF-
1) (Interferon gamma transducer 1)
3460
P14616 INSRR_HUMAN reviewed Insulin receptor-related protein (IRR) (EC
2.7.10.1) (IR-related receptor) [Cleaved
into: Insulin receptor-related protein alpha
chain Insulin receptor-related protein beta
chain]
3645
P06213 INSR_HUMAN reviewed Insulin receptor (IR) (EC 2.7.10.1) (CD
antigen CD220) [Cleaved into: Insulin re-
ceptor subunit alpha Insulin receptor sub-
unit beta]
3643
P35568 IRS1_HUMAN reviewed Insulin receptor substrate 1 (IRS-1) 3667
Q9Y4H2 IRS2_HUMAN reviewed Insulin receptor substrate 2 (IRS-2) 8660
93
O60674 JAK2_HUMAN reviewed Tyrosine-protein kinase JAK2 (EC
2.7.10.2) (Janus kinase 2) (JAK-2)
3717
Q5VV43 K0319_HUMAN reviewed Dyslexia-associated protein KIAA0319 9856
Q7Z3Y8 K1C27_HUMAN reviewed Keratin, type I cytoskeletal 27
(Cytokeratin-27) (CK-27) (Keratin-
25C) (K25C) (Keratin-27) (K27) (Type I
inner root sheath-specific keratin-K25irs3)
342574
P10721 KIT_HUMAN reviewed Mast/stem cell growth factor receptor
Kit (SCFR) (EC 2.7.10.1) (Piebald trait
protein) (PBT) (Proto-oncogene c-Kit)
(Tyrosine-protein kinase Kit) (p145 c-
kit) (v-kit Hardy-Zuckerman 4 feline sar-
coma viral oncogene homolog) (CD anti-
gen CD117)
3815
Q9UIQ6 LCAP_HUMAN reviewed Leucyl-cystinyl aminopeptidase (Cystinyl
aminopeptidase) (EC 3.4.11.3) (Insulin-
regulated membrane aminopeptidase)
(Insulin-responsive aminopeptidase)
(IRAP) (Oxytocinase) (OTase) (Placen-
tal leucine aminopeptidase) (P-LAP)
[Cleaved into: Leucyl-cystinyl aminopep-
tidase, pregnancy serum form]
4012
Q66K74 MAP1S_HUMAN reviewed Microtubule-associated protein 1S
(MAP-1S) (BPY2-interacting protein 1)
(Microtubule-associated protein 8) (Vari-
able charge Y chromosome 2-interacting
protein 1) (VCY2-interacting protein
1) (VCY2IP-1) [Cleaved into: MAP1S
heavy chain MAP1S light chain]
55201
94
Q92569 P55G_HUMAN reviewed Phosphatidylinositol 3-kinase regulatory
subunit gamma (PI3-kinase regulatory
subunit gamma) (PI3K regulatory sub-
unit gamma) (PtdIns-3-kinase regulatory
subunit gamma) (Phosphatidylinositol 3-
kinase 55 kDa regulatory subunit gamma)
(PI3-kinase subunit p55-gamma) (PtdIns-
3-kinase regulatory subunit p55-gamma)
(p55PIK)
8503
P05164 PERM_HUMAN reviewed Myeloperoxidase (MPO) (EC 1.11.2.2)
[Cleaved into: Myeloperoxidase 89 kDa
myeloperoxidase 84 kDa myeloper-
oxidase Myeloperoxidase light chain
Myeloperoxidase heavy chain]
4353
O75420 PERQ1_HUMAN reviewed PERQ amino acid-rich with GYF domain-
containing protein 1 (GRB10-interacting
GYF protein 1)
64599
Q8WWQ0PHIP_HUMAN reviewed PH-interacting protein (PHIP) (IRS-1 PH
domain-binding protein) (WD repeat-
containing protein 11)
55023
P16471 PRLR_HUMAN reviewed Prolactin receptor (PRL-R) 5618
P18031 PTN1_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 1 (EC 3.1.3.48) (Protein-
tyrosine phosphatase 1B) (PTP-1B)
5770
P17706 PTN2_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 2 (EC 3.1.3.48) (T-cell
protein-tyrosine phosphatase) (TCPTP)
5771
P26045 PTN3_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 3 (EC 3.1.3.48) (Protein-
tyrosine phosphatase H1) (PTP-H1)
5774
P43378 PTN9_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 9 (EC 3.1.3.48) (Protein-
tyrosine phosphatase MEG2) (PTPase
MEG2)
5780
95
Q9HD43 PTPRH_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase H (R-PTP-H) (EC 3.1.3.48)
(Stomach cancer-associated pro-
tein tyrosine phosphatase 1) (SAP-1)
(Transmembrane-type protein-tyrosine
phosphatase type H)
5794
Q9HD89 RETN_HUMAN reviewed Resistin (Adipose tissue-specific secretory
factor) (ADSF) (C/EBP-epsilon-regulated
myeloid-specific secreted cysteine-rich
protein) (Cysteine-rich secreted protein
A12-alpha-like 2) (Cysteine-rich secreted
protein FIZZ3)
56729
Q9NRF2 SH2B1_HUMAN reviewed SH2B adapter protein 1 (Pro-rich, PH and
SH2 domain-containing signaling media-
tor) (PSM) (SH2 domain-containing pro-
tein 1B)
25970
O15524 SOCS1_HUMAN reviewed Suppressor of cytokine signaling 1
(SOCS-1) (JAK-binding protein) (JAB)
(STAT-induced STAT inhibitor 1) (SSI-1)
(Tec-interacting protein 3) (TIP-3)
8651
O14508 SOCS2_HUMAN reviewed Suppressor of cytokine signaling 2
(SOCS-2) (Cytokine-inducible SH2
protein 2) (CIS-2) (STAT-induced STAT
inhibitor 2) (SSI-2)
8835
O14543 SOCS3_HUMAN reviewed Suppressor of cytokine signaling 3
(SOCS-3) (Cytokine-inducible SH2
protein 3) (CIS-3) (STAT-induced STAT
inhibitor 3) (SSI-3)
9021
P01242 SOM2_HUMAN reviewed Growth hormone variant (GH-V) (Growth
hormone 2) (Placenta-specific growth hor-
mone)
2689
P01241 SOMA_HUMAN reviewed Somatotropin (Growth hormone) (GH)
(GH-N) (Growth hormone 1) (Pituitary
growth hormone)
2688
Q9NRA0 SPHK2_HUMAN reviewed Sphingosine kinase 2 (SK 2) (SPK 2) (EC
2.7.1.91)
56848
96
Q14765 STAT4_HUMAN reviewed Signal transducer and activator of tran-
scription 4
6775
Q9H169 STMN4_HUMAN reviewed Stathmin-4 (Stathmin-like protein B3)
(RB3)
81551
Q9C0C2 TB182_HUMAN reviewed 182 kDa tankyrase-1-binding protein 85456
P42680 TEC_HUMAN reviewed Tyrosine-protein kinase Tec (EC 2.7.10.2) 7006
O95271 TNKS1_HUMAN reviewed Tankyrase-1 (TANK1) (EC 2.4.2.30)
(ADP-ribosyltransferase diphtheria toxin-
like 5) (ARTD5) (Poly [ADP-ribose]
polymerase 5A) (TNKS-1) (TRF1-
interacting ankyrin-related ADP-ribose
polymerase) (Tankyrase I)
8658
Q9H2K2 TNKS2_HUMAN reviewed Tankyrase-2 (TANK2) (EC 2.4.2.30)
(ADP-ribosyltransferase diphtheria toxin-
like 6) (ARTD6) (Poly [ADP-ribose] poly-
merase 5B) (TNKS-2) (TRF1-interacting
ankyrin-related ADP-ribose polymerase
2) (Tankyrase II) (Tankyrase-like protein)
(Tankyrase-related protein)
80351
Q9H1D0 TRPV6_HUMAN reviewed Transient receptor potential cation chan-
nel subfamily V member 6 (TrpV6) (CaT-
like) (CaT-L) (Calcium transport protein
1) (CaT1) (Epithelial calcium channel 2)
(ECaC2)
55503
P29597 TYK2_HUMAN reviewed Non-receptor tyrosine-protein kinase
TYK2 (EC 2.7.10.2)
7297
O14599 VCY2_HUMAN reviewed Testis-specific basic protein Y 2 (Basic
charge, Y-linked 2) (Variably charged pro-
tein Y 2)
442867,4428689083
O60595 O60595_HUMAN unreviewed Interleukin 12 (Interleukin 12, P35) (Inter-
leukin 12A (Natural killer cell stimulatory
factor 1, cytotoxic lymphocyte maturation
factor 1, p35)) (Interleukin 12A (Natural
killer cell stimulatory factor 1, cytotoxic
lymphocyte maturation factor 1, p35), iso-
form CRA_a)
3592
Q14620 Q14620_HUMAN Merged into P05019.
97
TABLE A.3: HCV-s64 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
Q96F63 CCD97_HUMAN reviewed Coiled-coil domain-containing protein 97 90324
P05813 CRBA1_HUMAN reviewed Beta-crystallin A3 [Cleaved into: Beta-
crystallin A3, isoform A1, Delta4 form
Beta-crystallin A3, isoform A1, Delta7
form Beta-crystallin A3, isoform A1,
Delta8 form]
1411
P53672 CRBA2_HUMAN reviewed Beta-crystallin A2 (Beta-A2 crystallin) 1412
P53673 CRBA4_HUMAN reviewed Beta-crystallin A4 (Beta-A4 crystallin) 1413
P53674 CRBB1_HUMAN reviewed Beta-crystallin B1 (Beta-B1 crystallin) 1414
P43320 CRBB2_HUMAN reviewed Beta-crystallin B2 (Beta-B2 crystallin)
(Beta-crystallin Bp)
1415
P26998 CRBB3_HUMAN reviewed Beta-crystallin B3 (Beta-B3 crystallin)
[Cleaved into: Beta-crystallin B3, N-
terminally processed]
1417
P07315 CRGC_HUMAN reviewed Gamma-crystallin C (Gamma-C-
crystallin) (Gamma-crystallin 2-1)
(Gamma-crystallin 3)
1420
P02489 CRYAA_HUMAN reviewed Alpha-crystallin A chain (Heat shock
protein beta-4) (HspB4) [Cleaved into:
Alpha-crystallin A chain, short form]
1409
P02511 CRYAB_HUMAN reviewed Alpha-crystallin B chain (Alpha(B)-
crystallin) (Heat shock protein beta-5)
(HspB5) (Renal carcinoma antigen NY-
REN-27) (Rosenthal fiber component)
1410
Q9Y6W6 DUS10_HUMAN reviewed Dual specificity protein phosphatase 10
(EC 3.1.3.16) (EC 3.1.3.48) (Mitogen-
activated protein kinase phosphatase 5)
(MAP kinase phosphatase 5) (MKP-5)
11221
Q9BY84 DUS16_HUMAN reviewed Dual specificity protein phosphatase 16
(EC 3.1.3.16) (EC 3.1.3.48) (Mitogen-
activated protein kinase phosphatase 7)
(MAP kinase phosphatase 7) (MKP-7)
80824
98
P28562 DUS1_HUMAN reviewed Dual specificity protein phosphatase 1 (EC
3.1.3.16) (EC 3.1.3.48) (Dual specificity
protein phosphatase hVH1) (Mitogen-
activated protein kinase phosphatase 1)
(MAP kinase phosphatase 1) (MKP-1)
(Protein-tyrosine phosphatase CL100)
1843
Q05923 DUS2_HUMAN reviewed Dual specificity protein phosphatase 2 (EC
3.1.3.16) (EC 3.1.3.48) (Dual specificity
protein phosphatase PAC-1)
1844
Q13115 DUS4_HUMAN reviewed Dual specificity protein phosphatase 4 (EC
3.1.3.16) (EC 3.1.3.48) (Dual specificity
protein phosphatase hVH2) (Mitogen-
activated protein kinase phosphatase 2)
(MAP kinase phosphatase 2) (MKP-2)
1846
Q16828 DUS6_HUMAN reviewed Dual specificity protein phosphatase 6 (EC
3.1.3.16) (EC 3.1.3.48) (Dual specificity
protein phosphatase PYST1) (Mitogen-
activated protein kinase phosphatase 3)
(MAP kinase phosphatase 3) (MKP-3)
1848
Q13202 DUS8_HUMAN reviewed Dual specificity protein phosphatase 8 (EC
3.1.3.16) (EC 3.1.3.48) (Dual specificity
protein phosphatase hVH-5)
1850
Q99956 DUS9_HUMAN reviewed Dual specificity protein phosphatase 9
(EC 3.1.3.16) (EC 3.1.3.48) (Mitogen-
activated protein kinase phosphatase 4)
(MAP kinase phosphatase 4) (MKP-4)
1852
P28324 ELK4_HUMAN reviewed ETS domain-containing protein Elk-4
(Serum response factor accessory protein
1) (SAP-1) (SRF accessory protein 1)
2005
Q6PJG2 EMSA1_HUMAN reviewed ELM2 and SANT domain-containing pro-
tein 1
91748
P50549 ETV1_HUMAN reviewed ETS translocation variant 1 (Ets-related
protein 81)
2115
99
P04792 HSPB1_HUMAN reviewed Heat shock protein beta-1 (HspB1) (28
kDa heat shock protein) (Estrogen-
regulated 24 kDa protein) (Heat shock 27
kDa protein) (HSP 27) (Stress-responsive
protein 27) (SRP27)
3315
Q16082 HSPB2_HUMAN reviewed Heat shock protein beta-2 (HspB2)
(DMPK-binding protein) (MKBP)
3316
O14558 HSPB6_HUMAN reviewed Heat shock protein beta-6 (HspB6) (Heat
shock 20 kDa-like protein p20)
126393
Q9UBY9 HSPB7_HUMAN reviewed Heat shock protein beta-7 (HspB7) (Car-
diovascular heat shock protein) (cvHsp)
27129
Q9UJY1 HSPB8_HUMAN reviewed Heat shock protein beta-8 (HspB8)
(Alpha-crystallin C chain) (E2-induced
gene 1 protein) (Protein kinase H11)
(Small stress protein-like protein HSP22)
26353
O75676 KS6A4_HUMAN reviewed Ribosomal protein S6 kinase alpha-4
(S6K-alpha-4) (EC 2.7.11.1) (90 kDa ri-
bosomal protein S6 kinase 4) (Nuclear
mitogen- and stress-activated protein ki-
nase 2) (Ribosomal protein kinase B)
(RSKB)
8986
O75582 KS6A5_HUMAN reviewed Ribosomal protein S6 kinase alpha-5
(S6K-alpha-5) (EC 2.7.11.1) (90 kDa ri-
bosomal protein S6 kinase 5) (Nuclear
mitogen- and stress-activated protein ki-
nase 1) (RSK-like protein kinase) (RSKL)
9252
P33241 LSP1_HUMAN reviewed Lymphocyte-specific protein 1 (47 kDa
actin-binding protein) (52 kDa phos-
phoprotein) (pp52) (Lymphocyte-specific
antigen WP34)
4046
P49137 MAPK2_HUMAN reviewed MAP kinase-activated protein kinase
2 (MAPK-activated protein kinase 2)
(MAPKAP kinase 2) (MAPKAP-K2)
(MAPKAPK-2) (MK-2) (MK2) (EC
2.7.11.1)
9261
100
Q16644 MAPK3_HUMAN reviewed MAP kinase-activated protein kinase
3 (MAPK-activated protein kinase 3)
(MAPKAP kinase 3) (MAPKAP-K3)
(MAPKAPK-3) (MK-3) (EC 2.7.11.1)
(Chromosome 3p kinase) (3pK)
7867
Q8IW41 MAPK5_HUMAN reviewed MAP kinase-activated protein kinase
5 (MAPK-activated protein kinase 5)
(MAPKAP kinase 5) (MAPKAP-K5)
(MAPKAPK-5) (MK-5) (MK5) (EC
2.7.11.1) (p38-regulated/activated protein
kinase) (PRAK)
8550
Q15759 MK11_HUMAN reviewed Mitogen-activated protein kinase 11
(MAP kinase 11) (MAPK 11) (EC
2.7.11.24) (Mitogen-activated protein
kinase p38 beta) (MAP kinase p38 beta)
(p38b) (Stress-activated protein kinase
2b) (SAPK2b) (p38-2)
5600
P53778 MK12_HUMAN reviewed Mitogen-activated protein kinase 12
(MAP kinase 12) (MAPK 12) (EC
2.7.11.24) (Extracellular signal-regulated
kinase 6) (ERK-6) (Mitogen-activated
protein kinase p38 gamma) (MAP kinase
p38 gamma) (Stress-activated protein
kinase 3)
6300
Q16539 MK14_HUMAN reviewed Mitogen-activated protein kinase 14
(MAP kinase 14) (MAPK 14) (EC
2.7.11.24) (Cytokine suppressive anti-
inflammatory drug-binding protein)
(CSAID-binding protein) (CSBP) (MAP
kinase MXI2) (MAX-interacting protein
2) (Mitogen-activated protein kinase p38
alpha) (MAP kinase p38 alpha) (Stress-
activated protein kinase 2a) (SAPK2a)
1432
Q8NEM7 SP20H_HUMAN reviewed Transcription factor SPT20 homolog (p38-
interacting protein) (p38IP)
55578
101
Q07352 TISB_HUMAN reviewed Zinc finger protein 36, C3H1 type-
like 1 (Butyrate response factor 1)
(EGF-response factor 1) (ERF-1) (Protein
TIS11B)
677
P52746 ZN142_HUMAN reviewed Zinc finger protein 142 (HA4654) 7701
O43257 ZNHI1_HUMAN reviewed Zinc finger HIT domain-containing pro-
tein 1 (Cyclin-G1-binding protein 1) (Zinc
finger protein subfamily 4A member 1)
(p18 Hamlet)
10467
Q1RMC8 Q1RMC8_HUMAN unreviewed ROBO1 protein 6091
TABLE A.4: HCV-s43 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
Q96N21 AP4AT_HUMAN reviewed AP-4 complex accessory subunit tepsin
(ENTH domain-containing protein 2)
(Epsin for AP-4) (Tetra-epsin)
146705
Q9BZE3 BARH1_HUMAN reviewed BarH-like 1 homeobox protein 56751
P24863 CCNC_HUMAN reviewed Cyclin-C (SRB11 homolog) (hSRB11) 892
Q9BWU1 CDK19_HUMAN reviewed Cyclin-dependent kinase 19 (EC
2.7.11.22) (CDC2-related protein ki-
nase 6) (Cell division cycle 2-like protein
kinase 6) (Cell division protein ki-
nase 19) (Cyclin-dependent kinase 11)
(Death-preventing kinase)
23097
P49336 CDK8_HUMAN reviewed Cyclin-dependent kinase 8 (EC 2.7.11.22)
(EC 2.7.11.23) (Cell division protein ki-
nase 8) (Mediator complex subunit CDK8)
(Mediator of RNA polymerase II tran-
scription subunit CDK8) (Protein kinase
K35)
1024
Q6IAN0 DRS7B_HUMAN reviewed Dehydrogenase/reductase SDR family
member 7B (EC 1.1.-.-)
25979
Q9UPW0 FOXJ3_HUMAN reviewed Forkhead box protein J3 22887
Q9H0H0 INT2_HUMAN reviewed Integrator complex subunit 2 (Int2) 57508
102
Q68E01 INT3_HUMAN reviewed Integrator complex subunit 3 (Int3) (SOSS
complex subunit A) (Sensor of single-
strand DNA complex subunit A) (SOSS-
A) (Sensor of ssDNA subunit A)
65123
Q7L273 KCTD9_HUMAN reviewed BTB/POZ domain-containing protein
KCTD9
54793
O94953 KDM4B_HUMAN reviewed Lysine-specific demethylase 4B (EC
1.14.11.-) (JmjC domain-containing his-
tone demethylation protein 3B) (Jumonji
domain-containing protein 2B)
23030
Q9UBF1 MAGC2_HUMAN reviewed Melanoma-associated antigen C2 (Can-
cer/testis antigen 10) (CT10) (Hepatocel-
lular carcinoma-associated antigen 587)
(MAGE-C2 antigen) (MAGE-E1 antigen)
51438
Q71F56 MD13L_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 13-like (Mediator com-
plex subunit 13-like) (Thyroid hormone
receptor-associated protein 2) (Thyroid
hormone receptor-associated protein com-
plex 240 kDa component-like)
23389
Q9BTT4 MED10_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 10 (Mediator complex
subunit 10) (Transformation-related gene
17 protein) (TRG-17) (Transformation-
related gene 20 protein) (TRG-20)
84246
Q9P086 MED11_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 11 (Mediator complex subunit
11)
400569
Q93074 MED12_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 12 (Activator-recruited cofac-
tor 240 kDa component) (ARC240) (CAG
repeat protein 45) (Mediator complex sub-
unit 12) (OPA-containing protein) (Thy-
roid hormone receptor-associated protein
complex 230 kDa component) (Trap230)
(Trinucleotide repeat-containing gene 11
protein)
9968
103
Q9UHV7 MED13_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 13 (Activator-recruited
cofactor 250 kDa component) (ARC250)
(Mediator complex subunit 13) (Thyroid
hormone receptor-associated protein 1)
(Thyroid hormone receptor-associated
protein complex 240 kDa compo-
nent) (Trap240) (Vitamin D3 receptor-
interacting protein complex component
DRIP250) (DRIP250)
9969
O60244 MED14_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 14 (Activator-recruited cofac-
tor 150 kDa component) (ARC150) (Co-
factor required for Sp1 transcriptional ac-
tivation subunit 2) (CRSP complex sub-
unit 2) (Mediator complex subunit 14)
(RGR1 homolog) (hRGR1) (Thyroid hor-
mone receptor-associated protein complex
170 kDa component) (Trap170) (Tran-
scriptional coactivator CRSP150) (Vita-
min D3 receptor-interacting protein com-
plex 150 kDa component) (DRIP150)
9282
Q9Y2X0 MED16_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 16 (Mediator complex subunit
16) (Thyroid hormone receptor-associated
protein 5) (Thyroid hormone receptor-
associated protein complex 95 kDa com-
ponent) (Trap95) (Vitamin D3 receptor-
interacting protein complex 92 kDa com-
ponent) (DRIP92)
10025
104
Q9NVC6 MED17_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 17 (Activator-recruited cofac-
tor 77 kDa component) (ARC77) (Cofac-
tor required for Sp1 transcriptional activa-
tion subunit 6) (CRSP complex subunit 6)
(Mediator complex subunit 17) (Thyroid
hormone receptor-associated protein com-
plex 80 kDa component) (Trap80) (Tran-
scriptional coactivator CRSP77) (Vitamin
D3 receptor-interacting protein complex
80 kDa component) (DRIP80)
9440
Q9BUE0 MED18_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 18 (Mediator complex subunit
18) (p28b)
54797
A0JLT2 MED19_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 19 (Lung cancer metastasis-
related protein 1) (Mediator complex sub-
unit 19)
219541
Q15648 MED1_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 1 (Activator-recruited cofac-
tor 205 kDa component) (ARC205) (Me-
diator complex subunit 1) (Peroxisome
proliferator-activated receptor-binding
protein) (PBP) (PPAR-binding protein)
(Thyroid hormone receptor-associated
protein complex 220 kDa component)
(Trap220) (Thyroid receptor-interacting
protein 2) (TR-interacting protein 2)
(TRIP-2) (Vitamin D receptor-interacting
protein complex component DRIP205)
(p53 regulatory protein RB18A)
5469
Q9H944 MED20_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 20 (Mediator complex sub-
unit 20) (TRF-proximal protein homolog)
(hTRFP)
9477
105
Q13503 MED21_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 21 (Mediator complex
subunit 21) (RNA polymerase II holoen-
zyme component SRB7) (RNAPII com-
plex component SRB7) (hSrb7)
9412
Q15528 MED22_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 22 (Mediator complex subunit
22) (Surfeit locus protein 5) (Surf-5)
6837
Q9ULK4 MED23_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 23 (Activator-recruited cofac-
tor 130 kDa component) (ARC130) (Co-
factor required for Sp1 transcriptional ac-
tivation subunit 3) (CRSP complex subunit
3) (Mediator complex subunit 23) (Pro-
tein sur-2 homolog) (hSur-2) (Transcrip-
tional coactivator CRSP130) (Vitamin D3
receptor-interacting protein complex 130
kDa component) (DRIP130)
9439
O75448 MED24_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 24 (Activator-recruited co-
factor 100 kDa component) (ARC100)
(Cofactor required for Sp1 transcriptional
activation subunit 4) (CRSP complex
subunit 4) (Mediator complex subunit
24) (Thyroid hormone receptor-associated
protein 4) (Thyroid hormone receptor-
associated protein complex 100 kDa com-
ponent) (Trap100) (hTRAP100) (Vitamin
D3 receptor-interacting protein complex
100 kDa component) (DRIP100)
9862
Q71SY5 MED25_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 25 (Activator interaction
domain-containing protein 1) (Activator-
recruited cofactor 92 kDa component)
(ARC92) (Mediator complex subunit 25)
(p78)
81857
106
O95402 MED26_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 26 (Activator-recruited cofac-
tor 70 kDa component) (ARC70) (Cofac-
tor required for Sp1 transcriptional acti-
vation subunit 7) (CRSP complex subunit
7) (Mediator complex subunit 26) (Tran-
scriptional coactivator CRSP70)
9441
Q6P2C8 MED27_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 27 (Cofactor required
for Sp1 transcriptional activation subunit
8) (CRSP complex subunit 8) (Mediator
complex subunit 27) (P37 TRAP/SMC-
C/PC2 subunit) (Transcriptional coactiva-
tor CRSP34)
9442
Q9H204 MED28_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 28 (Endothelial-derived pro-
tein 1) (Mediator complex subunit 28)
(Merlin and Grb2-interacting cytoskeletal
protein) (Magicin) (Tumor angiogenesis
marker EG-1)
80306
Q9NX70 MED29_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 29 (Intersex-like protein)
(Mediator complex subunit 29)
55588
Q96HR3 MED30_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 30 (Mediator complex subunit
30) (TRAP/Mediator complex component
TRAP25) (Thyroid hormone receptor-
associated protein 6) (Thyroid hormone
receptor-associated protein complex 25
kDa component) (Trap25)
90390
Q9NPJ6 MED4_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 4 (Activator-recruited cofac-
tor 36 kDa component) (ARC36) (Me-
diator complex subunit 4) (TRAP/SMC-
C/PC2 subunit p36 subunit) (Vitamin D3
receptor-interacting protein complex 36
kDa component) (DRIP36)
29079
107
O75586 MED6_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 6 (Activator-recruited cofac-
tor 33 kDa component) (ARC33) (Medi-
ator complex subunit 6) (hMed6) (Renal
carcinoma antigen NY-REN-28)
10001
O43513 MED7_HUMAN reviewed Mediator of RNA polymerase II tran-
scription subunit 7 (hMED7) (Activator-
recruited cofactor 34 kDa component)
(ARC34) (Cofactor required for Sp1 tran-
scriptional activation subunit 9) (CRSP
complex subunit 9) (Mediator complex
subunit 7) (RNA polymerase transcrip-
tional regulation mediator subunit 7
homolog) (Transcriptional coactivator
CRSP33)
9443
Q96G25 MED8_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 8 (Activator-recruited cofac-
tor 32 kDa component) (ARC32) (Media-
tor complex subunit 8)
112950
Q9NWA0 MED9_HUMAN reviewed Mediator of RNA polymerase II transcrip-
tion subunit 9 (Mediator complex subunit
9)
55090
Q9H4Z3 PCIF1_HUMAN reviewed Phosphorylated CTD-interacting factor 1 63935
P24928 RPB1_HUMAN reviewed DNA-directed RNA polymerase II sub-
unit RPB1 (RNA polymerase II sub-
unit B1) (EC 2.7.7.6) (DNA-directed
RNA polymerase II subunit A) (DNA-
directed RNA polymerase III largest sub-
unit) (RNA-directed RNA polymerase II
subunit RPB1) (EC 2.7.7.48)
5430
Q7RTU7 SCX_HUMAN reviewed Basic helix-loop-helix transcription factor
scleraxis (Class A basic helix-loop-helix
protein 41) (bHLHa41) (Class A basic
helix-loop-helix protein 48) (bHLHa48)
100129885,642658
P48436 SOX9_HUMAN reviewed Transcription factor SOX-9 6662
108
Q9H668 STN1_HUMAN reviewed CST complex subunit STN1
(Oligonucleotide/oligosaccharide-binding
fold-containing protein 1) (Suppressor of
cdc thirteen homolog)
79991
O95379 TFIP8_HUMAN reviewed Tumor necrosis factor alpha-induced
protein 8 (TNF alpha-induced pro-
tein 8) (Head and neck tumor and
metastasis-related protein) (MDC-3.13)
(NF-kappa-B-inducible DED-containing
protein) (NDED) (SCC-S2) (TNF-induced
protein GG2-1)
25816
Q8TB05 UBAD1_HUMAN reviewed UBA-like domain-containing protein 1 124402
Q96K76 UBP47_HUMAN reviewed Ubiquitin carboxyl-terminal hydrolase 47
(EC 3.4.19.12) (Deubiquitinating enzyme
47) (Ubiquitin thioesterase 47) (Ubiquitin-
specific-processing protease 47)
55031
Q70CQ1 UBP49_HUMAN reviewed Ubiquitin carboxyl-terminal hydrolase 49
(EC 3.4.19.12) (Deubiquitinating enzyme
49) (Ubiquitin thioesterase 49) (Ubiquitin-
specific-processing protease 49)
25862
Q16587 ZNF74_HUMAN reviewed Zinc finger protein 74 (Zinc finger protein
520) (hZNF7)
7625
Q9H2M2 Q9H2M2_HUMAN unreviewed Estrogen receptor alpha
TABLE A.5: Combi-s52 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
Entry Entry name Status Protein names Cross-
reference
(GENEID)
Q96NW4 ANR27_HUMAN reviewed Ankyrin repeat domain-containing protein
27 (VPS9 domain-containing protein)
84079
109
O43307 ARHG9_HUMAN reviewed Rho guanine nucleotide exchange fac-
tor 9 (Collybistin) (PEM-2 homolog)
(Rac/Cdc42 guanine nucleotide exchange
factor 9)
23229
Q9NR48 ASH1L_HUMAN reviewed Histone-lysine N-methyltransferase
ASH1L (EC 2.1.1.43) (ASH1-like pro-
tein) (huASH1) (Absent small and
homeotic disks protein 1 homolog)
(Lysine N-methyltransferase 2H)
55870
Q9P0P8 CF203_HUMAN reviewed Uncharacterized protein C6orf203 51250
Q9NWM3CUED1_HUMAN reviewed CUE domain-containing protein 1 404093
Q7LFL8 CXXC5_HUMAN reviewed CXXC-type zinc finger protein 5 (CF5)
(Putative MAPK-activating protein PM08)
(Putative NF-kappa-B-activating protein
102) (Retinoid-inducible nuclear factor)
(RINF)
51523
Q8TB52 FBX30_HUMAN reviewed F-box only protein 30 84085
P69892 HBG2_HUMAN reviewed Hemoglobin subunit gamma-2 (Gamma-
2-globin) (Hb F Ggamma) (Hemoglobin
gamma-2 chain) (Hemoglobin gamma-G
chain)
3048
P31273 HXC8_HUMAN reviewed Homeobox protein Hox-C8 (Homeobox
protein Hox-3A)
3224
Q9H160 ING2_HUMAN reviewed Inhibitor of growth protein 2 (Inhibitor
of growth 1-like protein) (ING1Lp) (p32)
(p33ING2)
3622
Q96PE3 INP4A_HUMAN reviewed Type I inositol 3,4-bisphosphate 4-
phosphatase (EC 3.1.3.66) (Inositol
polyphosphate 4-phosphatase type I)
3631
Q9Y2U8 MAN1_HUMAN reviewed Inner nuclear membrane protein Man1
(LEM domain-containing protein 3)
23592
Q9ULH7 MKL2_HUMAN reviewed MKL/myocardin-like protein 2
(Megakaryoblastic leukemia 2)
(Myocardin-related transcription fac-
tor B) (MRTF-B)
57496
Q9NXD2 MTMRA_HUMAN reviewed Myotubularin-related protein 10 54893
110
Q92886 NGN1_HUMAN reviewed Neurogenin-1 (NGN-1) (Class A ba-
sic helix-loop-helix protein 6) (bHLHa6)
(Neurogenic basic-helix-loop-helix pro-
tein) (Neurogenic differentiation factor 3)
(NeuroD3)
4762
Q8WUA2 PPIL4_HUMAN reviewed Peptidyl-prolyl cis-trans isomerase-like 4
(PPIase) (EC 5.2.1.8) (Cyclophilin-like
protein PPIL4) (Rotamase PPIL4)
85313
P51817 PRKX_HUMAN reviewed cAMP-dependent protein kinase cat-
alytic subunit PRKX (PrKX) (Protein
kinase X) (Protein kinase X-linked)
(Serine/threonine-protein kinase PRKX)
(EC 2.7.11.1) (Protein kinase PKX1)
5613
Q15771 RAB30_HUMAN reviewed Ras-related protein Rab-30 27314
Q9BWF3 RBM4_HUMAN reviewed RNA-binding protein 4 (Lark homolog)
(hLark) (RNA-binding motif protein 4)
(RNA-binding motif protein 4a)
5936
Q6ZNA4 RN111_HUMAN reviewed E3 ubiquitin-protein ligase Arkadia (EC
6.3.2.-) (RING finger protein 111)
54778
Q9NUM3 S39A9_HUMAN reviewed Zinc transporter ZIP9 (Solute carrier fam-
ily 39 member 9) (Zrt- and Irt-like protein
9) (ZIP-9)
55334
O75995 SASH3_HUMAN reviewed SAM and SH3 domain-containing protein
3 (SH3 protein expressed in lymphocytes
homolog)
54440
Q15797 SMAD1_HUMAN reviewed Mothers against decapentaplegic homolog
1 (MAD homolog 1) (Mothers against
DPP homolog 1) (JV4-1) (Mad-related
protein 1) (SMAD family member 1)
(SMAD 1) (Smad1) (hSMAD1) (Trans-
forming growth factor-beta-signaling pro-
tein 1) (BSP-1)
4086
Q99717 SMAD5_HUMAN reviewed Mothers against decapentaplegic homolog
5 (MAD homolog 5) (Mothers against
DPP homolog 5) (JV5-1) (SMAD family
member 5) (SMAD 5) (Smad5) (hSmad5)
4090
111
O43541 SMAD6_HUMAN reviewed Mothers against decapentaplegic homolog
6 (MAD homolog 6) (Mothers against
DPP homolog 6) (SMAD family member
6) (SMAD 6) (Smad6) (hSMAD6)
4091
O15105 SMAD7_HUMAN reviewed Mothers against decapentaplegic homolog
7 (MAD homolog 7) (Mothers against
DPP homolog 7) (Mothers against de-
capentaplegic homolog 8) (MAD homolog
8) (Mothers against DPP homolog 8)
(SMAD family member 7) (SMAD 7)
(Smad7) (hSMAD7)
4092
Q9HCE7 SMUF1_HUMAN reviewed E3 ubiquitin-protein ligase SMURF1
(hSMURF1) (EC 6.3.2.-) (SMAD ubiq-
uitination regulatory factor 1) (SMAD-
specific E3 ubiquitin-protein ligase
1)
57154
Q9HAU4 SMUF2_HUMAN reviewed E3 ubiquitin-protein ligase SMURF2
(hSMURF2) (EC 6.3.2.-) (SMAD ubiq-
uitination regulatory factor 2) (SMAD-
specific E3 ubiquitin-protein ligase
2)
64750
P35711 SOX5_HUMAN reviewed Transcription factor SOX-5 6660
Q9BT81 SOX7_HUMAN reviewed Transcription factor SOX-7 83595
Q9Y3F4 STRAP_HUMAN reviewed Serine-threonine kinase receptor-
associated protein (MAP activator with
WD repeats) (UNR-interacting protein)
(WD-40 repeat protein PT-WD)
11171
O95625 ZBT11_HUMAN reviewed Zinc finger and BTB domain-containing
protein 11
27107
Q8NCP5 ZBT44_HUMAN reviewed Zinc finger and BTB domain-containing
protein 44 (BTB/POZ domain-containing
protein 15) (Zinc finger protein 851)
29068
Q9NYG2 ZDHC3_HUMAN reviewed Palmitoyltransferase ZDHHC3 (EC
2.3.1.-) (Protein DHHC1) (Zinc finger
DHHC domain-containing protein 3)
(DHHC-3) (Zinc finger protein 373)
51304
Q9Y2H8 ZN510_HUMAN reviewed Zinc finger protein 510 22869
112
P36508 ZNF76_HUMAN reviewed Zinc finger protein 76 (Zinc finger protein
523)
7629
P17098 ZNF8_HUMAN reviewed Zinc finger protein 8 (Zinc finger protein
HF.18)
7554
Q8NAM6 ZSCA4_HUMAN reviewed Zinc finger and SCAN domain-containing
protein 4 (Zinc finger protein 494)
201516
TABLE A.6: Combi-s46 Protein Annotation and GeneIDs
Entry Entry name Status Protein names Cross-
reference
GENEID
Entry Entry name Status Protein names Cross-
reference
(GENEID)
P78314 3BP2_HUMAN reviewed SH3 domain-binding protein 2 (3BP-2) 6452
P50406 5HT6R_HUMAN reviewed 5-hydroxytryptamine receptor 6 (5-HT-6)
(5-HT6) (Serotonin receptor 6)
3362
P42684 ABL2_HUMAN reviewed Abelson tyrosine-protein kinase 2 (EC
2.7.10.2) (Abelson murine leukemia vi-
ral oncogene homolog 2) (Abelson-related
gene protein) (Tyrosine-protein kinase
ARG)
27
Q9UM73 ALK_HUMAN reviewed ALK tyrosine kinase receptor (EC
2.7.10.1) (Anaplastic lymphoma kinase)
(CD antigen CD246)
238
Q9ULH1 ASAP1_HUMAN reviewed Arf-GAP with SH3 domain, ANK
repeat and PH domain-containing pro-
tein 1 (130 kDa phosphatidylinositol
4,5-bisphosphate-dependent ARF1
GTPase-activating protein) (ADP-
ribosylation factor-directed GTPase-
activating protein 1) (ARF GTPase-
activating protein 1) (Development and
differentiation-enhancing factor 1) (DEF-
1) (Differentiation-enhancing factor 1)
(PIP2-dependent ARF1 GAP)
50807
113
P56945 BCAR1_HUMAN reviewed Breast cancer anti-estrogen resistance pro-
tein 1 (CRK-associated substrate) (Cas
scaffolding protein family member 1)
(p130cas)
9564
P11274 BCR_HUMAN reviewed Breakpoint cluster region protein (EC
2.7.11.1) (Renal carcinoma antigen NY-
REN-26)
613
P51451 BLK_HUMAN reviewed Tyrosine-protein kinase Blk (EC 2.7.10.2)
(B lymphocyte kinase) (p55-Blk)
640
Q8WV28 BLNK_HUMAN reviewed B-cell linker protein (B-cell adapter con-
taining a SH2 domain protein) (B-cell
adapter containing a Src homology 2 do-
main protein) (Cytoplasmic adapter pro-
tein) (Src homology 2 domain-containing
leukocyte protein of 65 kDa) (SLP-65)
29760
Q06187 BTK_HUMAN reviewed Tyrosine-protein kinase BTK (EC
2.7.10.2) (Agammaglobulinemia tyrosine
kinase) (ATK) (B-cell progenitor kinase)
(BPK) (Bruton tyrosine kinase)
695
Q7Z6A9 BTLA_HUMAN reviewed B- and T-lymphocyte attenuator (B- and T-
lymphocyte-associated protein) (CD anti-
gen CD272)
151888
P04040 CATA_HUMAN reviewed Catalase (EC 1.11.1.6) 847
Q13191 CBLB_HUMAN reviewed E3 ubiquitin-protein ligase CBL-B (EC
6.3.2.-) (Casitas B-lineage lymphoma
proto-oncogene b) (RING finger protein
56) (SH3-binding protein CBL-B) (Signal
transduction protein CBL-B)
868
P22681 CBL_HUMAN reviewed E3 ubiquitin-protein ligase CBL (EC
6.3.2.-) (Casitas B-lineage lymphoma
proto-oncogene) (Proto-oncogene c-Cbl)
(RING finger protein 55) (Signal transduc-
tion protein CBL)
867
P15391 CD19_HUMAN reviewed B-lymphocyte antigen CD19 (B-
lymphocyte surface antigen B4) (Dif-
ferentiation antigen CD19) (T-cell surface
antigen Leu-12) (CD antigen CD19)
930
114
P20273 CD22_HUMAN reviewed B-cell receptor CD22 (B-lymphocyte cell
adhesion molecule) (BL-CAM) (Sialic
acid-binding Ig-like lectin 2) (Siglec-2)
(T-cell surface antigen Leu-14) (CD anti-
gen CD22)
933
P10747 CD28_HUMAN reviewed T-cell-specific surface glycoprotein CD28
(TP44) (CD antigen CD28)
940
Q9Y5K6 CD2AP_HUMAN reviewed CD2-associated protein (Adapter protein
CMS) (Cas ligand with multiple SH3 do-
mains)
23607
P20138 CD33_HUMAN reviewed Myeloid cell surface antigen CD33 (Sialic
acid-binding Ig-like lectin 3) (Siglec-3)
(gp67) (CD antigen CD33)
945
P04234 CD3D_HUMAN reviewed T-cell surface glycoprotein CD3 delta
chain (T-cell receptor T3 delta chain) (CD
antigen CD3d)
915
P07766 CD3E_HUMAN reviewed T-cell surface glycoprotein CD3 epsilon
chain (T-cell surface antigen T3/Leu-4 ep-
silon chain) (CD antigen CD3e)
916
P20963 CD3Z_HUMAN reviewed T-cell surface glycoprotein CD3 zeta chain
(T-cell receptor T3 zeta chain) (CD anti-
gen CD247)
919
P06127 CD5_HUMAN reviewed T-cell surface glycoprotein CD5 (Lympho-
cyte antigen T1/Leu-1) (CD antigen CD5)
921
P21854 CD72_HUMAN reviewed B-cell differentiation antigen CD72 (Lyb-
2) (CD antigen CD72)
971
P11912 CD79A_HUMAN reviewed B-cell antigen receptor complex-
associated protein alpha chain (Ig-
alpha) (MB-1 membrane glycoprotein)
(Membrane-bound immunoglobulin-
associated protein) (Surface IgM-
associated protein) (CD antigen CD79a)
973
P40259 CD79B_HUMAN reviewed B-cell antigen receptor complex-
associated protein beta chain (B-cell-
specific glycoprotein B29) (Ig-beta)
(Immunoglobulin-associated B29 protein)
(CD antigen CD79b)
974
115
P33681 CD80_HUMAN reviewed T-lymphocyte activation antigen CD80
(Activation B7-1 antigen) (BB1) (CTLA-
4 counter-receptor B7.1) (B7) (CD antigen
CD80)
941
P42081 CD86_HUMAN reviewed T-lymphocyte activation antigen CD86
(Activation B7-2 antigen) (B70) (BU63)
(CTLA-4 counter-receptor B7.2) (FUN-1)
(CD antigen CD86)
942
P01732 CD8A_HUMAN reviewed T-cell surface glycoprotein CD8 alpha
chain (T-lymphocyte differentiation anti-
gen T8/Leu-2) (CD antigen CD8a)
925
P10966 CD8B_HUMAN reviewed T-cell surface glycoprotein CD8 beta
chain (CD antigen CD8b)
926
Q9NSE2 CISH_HUMAN reviewed Cytokine-inducible SH2-containing pro-
tein (CIS) (CIS-1) (Protein G18) (Sup-
pressor of cytokine signaling) (SOCS)
1154
P46109 CRKL_HUMAN reviewed Crk-like protein 1399
P46108 CRK_HUMAN reviewed Adapter molecule crk (Proto-oncogene c-
Crk) (p38)
1398
P07333 CSF1R_HUMAN reviewed Macrophage colony-stimulating factor
1 receptor (CSF-1 receptor) (CSF-1-R)
(CSF-1R) (M-CSF-R) (EC 2.7.10.1)
(Proto-oncogene c-Fms) (CD antigen
CD115)
1436
Q99062 CSF3R_HUMAN reviewed Granulocyte colony-stimulating factor re-
ceptor (G-CSF receptor) (G-CSF-R) (CD
antigen CD114)
1441
P41240 CSK_HUMAN reviewed Tyrosine-protein kinase CSK (EC
2.7.10.2) (C-Src kinase) (Protein-tyrosine
kinase CYL)
1445
P16410 CTLA4_HUMAN reviewed Cytotoxic T-lymphocyte protein 4 (Cyto-
toxic T-lymphocyte-associated antigen 4)
(CTLA-4) (CD antigen CD152)
1493
P58505 CU058_HUMAN reviewed Uncharacterized protein C21orf58 54058
116
Q9UN19 DAPP1_HUMAN reviewed Dual adapter for phosphotyrosine and 3-
phosphotyrosine and 3-phosphoinositide
(hDAPP1) (B lymphocyte adapter protein
Bam32) (B-cell adapter molecule of 32
kDa)
27071
Q9UJU6 DBNL_HUMAN reviewed Drebrin-like protein (Cervical SH3P7)
(Cervical mucin-associated protein)
(Drebrin-F) (HPK1-interacting protein
of 55 kDa) (HIP-55) (SH3 domain-
containing protein 7)
28988
Q08345 DDR1_HUMAN reviewed Epithelial discoidin domain-containing re-
ceptor 1 (Epithelial discoidin domain re-
ceptor 1) (EC 2.7.10.1) (CD167 antigen-
like family member A) (Cell adhesion ki-
nase) (Discoidin receptor tyrosine kinase)
(HGK2) (Mammary carcinoma kinase 10)
(MCK-10) (Protein-tyrosine kinase 3A)
(Protein-tyrosine kinase RTK-6) (TRK E)
(Tyrosine kinase DDR) (Tyrosine-protein
kinase CAK) (CD antigen CD167a)
780
Q6P3S1 DEN1B_HUMAN reviewed DENN domain-containing protein 1B
(Connecdenn 2) (Protein FAM31B)
163486
Q99704 DOK1_HUMAN reviewed Docking protein 1 (Downstream of tyro-
sine kinase 1) (p62(dok)) (pp62)
1796
O60496 DOK2_HUMAN reviewed Docking protein 2 (Downstream of tyro-
sine kinase 2) (p56(dok-2))
9046
Q8TEW6 DOK4_HUMAN reviewed Docking protein 4 (Downstream of tyro-
sine kinase 4) (Insulin receptor substrate
5) (IRS-5) (IRS5)
55715
Q9P104 DOK5_HUMAN reviewed Docking protein 5 (Downstream of tyro-
sine kinase 5) (Insulin receptor substrate
6) (IRS-6) (IRS6)
55816
Q6PKX4 DOK6_HUMAN reviewed Docking protein 6 (Downstream of tyro-
sine kinase 6)
220164
117
P20827 EFNA1_HUMAN reviewed Ephrin-A1 (EPH-related receptor tyrosine
kinase ligand 1) (LERK-1) (Immediate
early response protein B61) (Tumor necro-
sis factor alpha-induced protein 4) (TNF
alpha-induced protein 4) [Cleaved into:
Ephrin-A1, secreted form]
1942
P00533 EGFR_HUMAN reviewed Epidermal growth factor receptor (EC
2.7.10.1) (Proto-oncogene c-ErbB-1) (Re-
ceptor tyrosine-protein kinase erbB-1)
1956
P01133 EGF_HUMAN reviewed Pro-epidermal growth factor (EGF)
[Cleaved into: Epidermal growth factor
(Urogastrone)]
1950
P29317 EPHA2_HUMAN reviewed Ephrin type-A receptor 2 (EC 2.7.10.1)
(Epithelial cell kinase) (Tyrosine-protein
kinase receptor ECK)
1969
P54762 EPHB1_HUMAN reviewed Ephrin type-B receptor 1 (EC 2.7.10.1)
(ELK) (EPH tyrosine kinase 2) (EPH-
like kinase 6) (EK6) (hEK6) (Neuronally-
expressed EPH-related tyrosine kinase)
(NET) (Tyrosine-protein kinase receptor
EPH-2)
2047
P54753 EPHB3_HUMAN reviewed Ephrin type-B receptor 3 (EC 2.7.10.1)
(EPH-like tyrosine kinase 2) (EPH-like
kinase 2) (Embryonic kinase 2) (EK2)
(hEK2) (Tyrosine-protein kinase TYRO6)
2049
P19235 EPOR_HUMAN reviewed Erythropoietin receptor (EPO-R) 2057
P01588 EPO_HUMAN reviewed Erythropoietin (Epoetin) 2056
P04626 ERBB2_HUMAN reviewed Receptor tyrosine-protein kinase erbB-2
(EC 2.7.10.1) (Metastatic lymph node
gene 19 protein) (MLN 19) (Proto-
oncogene Neu) (Proto-oncogene c-ErbB-
2) (Tyrosine kinase-type cell surface re-
ceptor HER2) (p185erbB2) (CD antigen
CD340)
2064
118
P21860 ERBB3_HUMAN reviewed Receptor tyrosine-protein kinase erbB-3
(EC 2.7.10.1) (Proto-oncogene-like pro-
tein c-ErbB-3) (Tyrosine kinase-type cell
surface receptor HER3)
2065
Q15303 ERBB4_HUMAN reviewed Receptor tyrosine-protein kinase erbB-
4 (EC 2.7.10.1) (Proto-oncogene-like
protein c-ErbB-4) (Tyrosine kinase-type
cell surface receptor HER4) (p180erbB4)
[Cleaved into: ERBB4 intracellular
domain (4ICD) (E4ICD) (s80HER4)]
2066
Q9UJM3 ERRFI_HUMAN reviewed ERBB receptor feedback inhibitor 1
(Mitogen-inducible gene 6 protein) (MIG-
6)
54206
Q05397 FAK1_HUMAN reviewed Focal adhesion kinase 1 (FADK 1) (EC
2.7.10.2) (Focal adhesion kinase-related
nonkinase) (FRNK) (Protein phosphatase
1 regulatory subunit 71) (PPP1R71)
(Protein-tyrosine kinase 2) (p125FAK)
(pp125FAK)
5747
Q14289 FAK2_HUMAN reviewed Protein-tyrosine kinase 2-beta (EC
2.7.10.2) (Calcium-dependent tyrosine
kinase) (CADTK) (Calcium-regulated
non-receptor proline-rich tyrosine kinase)
(Cell adhesion kinase beta) (CAK-beta)
(CAKB) (Focal adhesion kinase 2)
(FADK 2) (Proline-rich tyrosine kinase 2)
(Related adhesion focal tyrosine kinase)
(RAFTK)
2185
P12319 FCERA_HUMAN reviewed High affinity immunoglobulin epsilon re-
ceptor subunit alpha (Fc-epsilon RI-alpha)
(FcERI) (IgE Fc receptor subunit alpha)
2205
Q01362 FCERB_HUMAN reviewed High affinity immunoglobulin epsilon re-
ceptor subunit beta (FcERI) (Fc epsilon
receptor I beta-chain) (IgE Fc recep-
tor subunit beta) (Membrane-spanning 4-
domains subfamily A member 2)
2206
119
P30273 FCERG_HUMAN reviewed High affinity immunoglobulin epsilon
receptor subunit gamma (Fc receptor
gamma-chain) (FcRgamma) (Fc-epsilon
RI-gamma) (IgE Fc receptor subunit
gamma) (FceRI gamma)
2207
P12318 FCG2A_HUMAN reviewed Low affinity immunoglobulin gamma Fc
region receptor II-a (IgG Fc receptor II-a)
(CDw32) (Fc-gamma RII-a) (Fc-gamma-
RIIa) (FcRII-a) (CD antigen CD32)
2212
P31994 FCG2B_HUMAN reviewed Low affinity immunoglobulin gamma Fc
region receptor II-b (IgG Fc receptor II-b)
(CDw32) (Fc-gamma RII-b) (Fc-gamma-
RIIb) (FcRII-b) (CD antigen CD32)
2213
P12314 FCGR1_HUMAN reviewed High affinity immunoglobulin gamma Fc
receptor I (IgG Fc receptor I) (Fc-gamma
RI) (FcRI) (Fc-gamma RIA) (Fcgam-
maRIa) (CD antigen CD64)
2209
P09769 FGR_HUMAN reviewed Tyrosine-protein kinase Fgr (EC 2.7.10.2)
(Gardner-Rasheed feline sarcoma viral (v-
fgr) oncogene homolog) (Proto-oncogene
c-Fgr) (p55-Fgr) (p58-Fgr) (p58c-Fgr)
2268
P36888 FLT3_HUMAN reviewed Receptor-type tyrosine-protein kinase
FLT3 (EC 2.7.10.1) (FL cytokine re-
ceptor) (Fetal liver kinase-2) (FLK-2)
(Fms-like tyrosine kinase 3) (FLT-3)
(Stem cell tyrosine kinase 1) (STK-1) (CD
antigen CD135)
2322
Q8WU20 FRS2_HUMAN reviewed Fibroblast growth factor receptor sub-
strate 2 (FGFR substrate 2) (FGFR-
signaling adaptor SNT) (Suc1-associated
neurotrophic factor target 1) (SNT-1)
10818
O15117 FYB_HUMAN reviewed FYN-binding protein (Adhesion and
degranulation promoting adaptor protein)
(ADAP) (FYB-120/130) (p120/p130)
(FYN-T-binding protein) (SLAP-130)
(SLP-76-associated phosphoprotein)
2533
120
P06241 FYN_HUMAN reviewed Tyrosine-protein kinase Fyn (EC 2.7.10.2)
(Proto-oncogene Syn) (Proto-oncogene c-
Fyn) (Src-like kinase) (SLK) (p59-Fyn)
2534
Q13480 GAB1_HUMAN reviewed GRB2-associated-binding protein 1
(GRB2-associated binder 1) (Growth
factor receptor bound protein 2-associated
protein 1)
2549
Q9UQC2 GAB2_HUMAN reviewed GRB2-associated-binding protein 2
(GRB2-associated binder 2) (Growth
factor receptor bound protein 2-associated
protein 2) (pp100)
9846
Q9H706 GAREM_HUMAN reviewed GRB2-associated and regulator of MAPK
protein (GRB2-associated and regulator of
MAPK1)
64762
Q14393 GAS6_HUMAN reviewed Growth arrest-specific protein 6 (GAS-6)
(AXL receptor tyrosine kinase ligand)
2621
P39905 GDNF_HUMAN reviewed Glial cell line-derived neurotrophic factor
(hGDNF) (Astrocyte-derived trophic fac-
tor) (ATF)
2668
P56159 GFRA1_HUMAN reviewed GDNF family receptor alpha-1 (GDNF re-
ceptor alpha-1) (GDNFR-alpha-1) (GFR-
alpha-1) (RET ligand 1) (TGF-beta-
related neurotrophic factor receptor 1)
2674
O00451 GFRA2_HUMAN reviewed GDNF family receptor alpha-2 (GDNF re-
ceptor alpha-2) (GDNFR-alpha-2) (GFR-
alpha-2) (GDNF receptor beta) (GDNFR-
beta) (Neurturin receptor alpha) (NRTNR-
alpha) (NTNR-alpha) (RET ligand 2)
(TGF-beta-related neurotrophic factor re-
ceptor 2)
2675
P10912 GHR_HUMAN reviewed Growth hormone receptor (GH receptor)
(Somatotropin receptor) [Cleaved into:
Growth hormone-binding protein (GH-
binding protein) (GHBP) (Serum-binding
protein)]
2690
Q9HCN6 GPVI_HUMAN reviewed Platelet glycoprotein VI (GPVI) (Glyco-
protein 6)
51206
121
O75791 GRAP2_HUMAN reviewed GRB2-related adapter protein 2 (Adapter
protein GRID) (GRB-2-like protein)
(GRB2L) (GRBLG) (GRBX) (Grf40
adapter protein) (Grf-40) (Growth factor
receptor-binding protein) (Hematopoietic
cell-associated adapter protein GrpL)
(P38) (Protein GADS) (SH3-SH2-SH3
adapter Mona)
9402
Q13588 GRAP_HUMAN reviewed GRB2-related adapter protein 10750
Q13322 GRB10_HUMAN reviewed Growth factor receptor-bound protein
10 (GRB10 adapter protein) (Insulin
receptor-binding protein Grb-IR)
2887
Q14449 GRB14_HUMAN reviewed Growth factor receptor-bound protein 14
(GRB14 adapter protein)
2888
P62993 GRB2_HUMAN reviewed Growth factor receptor-bound protein 2
(Adapter protein GRB2) (Protein Ash)
(SH2/SH3 adapter GRB2)
2885
Q14451 GRB7_HUMAN reviewed Growth factor receptor-bound protein 7
(B47) (Epidermal growth factor receptor
GRB-7) (GRB7 adapter protein)
2886
P08631 HCK_HUMAN reviewed Tyrosine-protein kinase HCK (EC
2.7.10.2) (Hematopoietic cell kinase)
(Hemopoietic cell kinase) (p59-HCK/p60-
HCK) (p59Hck) (p61Hck)
3055
P13747 HLAE_HUMAN reviewed HLA class I histocompatibility antigen, al-
pha chain E (MHC class I antigen E)
3133
P08069 IGF1R_HUMAN reviewed Insulin-like growth factor 1 receptor
(EC 2.7.10.1) (Insulin-like growth fac-
tor I receptor) (IGF-I receptor) (CD anti-
gen CD221) [Cleaved into: Insulin-like
growth factor 1 receptor alpha chain
Insulin-like growth factor 1 receptor beta
chain]
3480
P01589 IL2RA_HUMAN reviewed Interleukin-2 receptor subunit alpha (IL-
2 receptor subunit alpha) (IL-2-RA) (IL-
2R subunit alpha) (IL2-RA) (TAC antigen)
(p55) (CD antigen CD25)
3559
122
P14784 IL2RB_HUMAN reviewed Interleukin-2 receptor subunit beta (IL-
2 receptor subunit beta) (IL-2R subunit
beta) (IL-2RB) (High affinity IL-2 recep-
tor subunit beta) (p70-75) (p75) (CD anti-
gen CD122)
3560
P31785 IL2RG_HUMAN reviewed Cytokine receptor common subunit
gamma (Interleukin-2 receptor subunit
gamma) (IL-2 receptor subunit gamma)
(IL-2R subunit gamma) (IL-2RG) (gam-
maC) (p64) (CD antigen CD132)
3561
P60568 IL2_HUMAN reviewed Interleukin-2 (IL-2) (T-cell growth factor)
(TCGF) (Aldesleukin)
3558
P26951 IL3RA_HUMAN reviewed Interleukin-3 receptor subunit alpha (IL-3
receptor subunit alpha) (IL-3R subunit al-
pha) (IL-3R-alpha) (IL-3RA) (CD antigen
CD123)
3563
P32927 IL3RB_HUMAN reviewed Cytokine receptor common subunit beta
(CDw131) (GM-CSF/IL-3/IL-5 recep-
tor common beta subunit) (CD antigen
CD131)
1439
P24394 IL4RA_HUMAN reviewed Interleukin-4 receptor subunit alpha (IL-
4 receptor subunit alpha) (IL-4R sub-
unit alpha) (IL-4R-alpha) (IL-4RA) (CD
antigen CD124) [Cleaved into: Soluble
interleukin-4 receptor subunit alpha (Sol-
uble IL-4 receptor subunit alpha) (Solu-
ble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-
binding protein) (IL4-BP)]
3566
P08887 IL6RA_HUMAN reviewed Interleukin-6 receptor subunit alpha (IL-
6 receptor subunit alpha) (IL-6R subunit
alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1)
(Membrane glycoprotein 80) (gp80) (CD
antigen CD126)
3570
123
P40189 IL6RB_HUMAN reviewed Interleukin-6 receptor subunit beta
(IL-6 receptor subunit beta) (IL-6R
subunit beta) (IL-6R-beta) (IL-6RB)
(CDw130) (Interleukin-6 signal trans-
ducer) (Membrane glycoprotein 130)
(gp130) (Oncostatin-M receptor subunit
alpha) (CD antigen CD130)
3572
P17181 INAR1_HUMAN reviewed Interferon alpha/beta receptor 1 (IFN-R-
1) (IFN-alpha/beta receptor 1) (Cytokine
receptor class-II member 1) (Cytokine
receptor family 2 member 1) (CRF2-1)
(Type I interferon receptor 1)
3454
P06213 INSR_HUMAN reviewed Insulin receptor (IR) (EC 2.7.10.1) (CD
antigen CD220) [Cleaved into: Insulin re-
ceptor subunit alpha Insulin receptor sub-
unit beta]
3643
P35568 IRS1_HUMAN reviewed Insulin receptor substrate 1 (IRS-1) 3667
Q9Y4H2 IRS2_HUMAN reviewed Insulin receptor substrate 2 (IRS-2) 8660
O14654 IRS4_HUMAN reviewed Insulin receptor substrate 4 (IRS-4) (160
kDa phosphotyrosine protein) (py160)
(Phosphoprotein of 160 kDa) (pp160)
8471
Q08881 ITK_HUMAN reviewed Tyrosine-protein kinase ITK/TSK (EC
2.7.10.2) (Interleukin-2-inducible T-cell
kinase) (IL-2-inducible T-cell kinase)
(Kinase EMT) (T-cell-specific kinase)
(Tyrosine-protein kinase Lyk)
3702
P23458 JAK1_HUMAN reviewed Tyrosine-protein kinase JAK1 (EC
2.7.10.2) (Janus kinase 1) (JAK-1)
3716
O60674 JAK2_HUMAN reviewed Tyrosine-protein kinase JAK2 (EC
2.7.10.2) (Janus kinase 2) (JAK-2)
3717
P52333 JAK3_HUMAN reviewed Tyrosine-protein kinase JAK3 (EC
2.7.10.2) (Janus kinase 3) (JAK-3)
(Leukocyte janus kinase) (L-JAK)
3718
Q96N16 JKIP1_HUMAN reviewed Janus kinase and microtubule-interacting
protein 1 (GABA-B receptor-binding pro-
tein) (Multiple alpha-helices and RNA-
linker protein 1) (Marlin-1)
152789
124
Q07666 KHDR1_HUMAN reviewed KH domain-containing, RNA-binding,
signal transduction-associated protein 1
(GAP-associated tyrosine phosphoprotein
p62) (Src-associated in mitosis 68 kDa
protein) (Sam68) (p21 Ras GTPase-
activating protein-associated p62) (p68)
10657
P43628 KI2L3_HUMAN reviewed Killer cell immunoglobulin-like receptor
2DL3 (CD158 antigen-like family mem-
ber B2) (KIR-023GB) (Killer inhibitory
receptor cl 2-3) (MHC class I NK cell
receptor) (NKAT2a) (NKAT2b) (Natural
killer-associated transcript 2) (NKAT-2)
(p58 natural killer cell receptor clone CL-
6) (p58 NK receptor CL-6) (p58.2 MHC
class-I-specific NK receptor) (CD antigen
CD158b2)
3804
P10721 KIT_HUMAN reviewed Mast/stem cell growth factor receptor
Kit (SCFR) (EC 2.7.10.1) (Piebald trait
protein) (PBT) (Proto-oncogene c-Kit)
(Tyrosine-protein kinase Kit) (p145 c-
kit) (v-kit Hardy-Zuckerman 4 feline sar-
coma viral oncogene homolog) (CD anti-
gen CD117)
3815
Q04759 KPCT_HUMAN reviewed Protein kinase C theta type (EC 2.7.11.13)
(nPKC-theta)
5588
P43405 KSYK_HUMAN reviewed Tyrosine-protein kinase SYK (EC
2.7.10.2) (Spleen tyrosine kinase) (p72-
Syk)
6850
Q6GTX8 LAIR1_HUMAN reviewed Leukocyte-associated immunoglobulin-
like receptor 1 (LAIR-1) (hLAIR1) (CD
antigen CD305)
3903
O43561 LAT_HUMAN reviewed Linker for activation of T-cells fam-
ily member 1 (36 kDa phospho-tyrosine
adapter protein) (pp36) (p36-38)
27040
125
Q8IWV1 LAX1_HUMAN reviewed Lymphocyte transmembrane adapter
1 (Linker for activation of X cells)
(Membrane-associated adapter protein
LAX)
54900
P06239 LCK_HUMAN reviewed Tyrosine-protein kinase Lck (EC
2.7.10.2) (Leukocyte C-terminal Src
kinase) (LSK) (Lymphocyte cell-specific
protein-tyrosine kinase) (Protein YT16)
(Proto-oncogene Lck) (T cell-specific
protein-tyrosine kinase) (p56-LCK)
3932
Q13094 LCP2_HUMAN reviewed Lymphocyte cytosolic protein 2 (SH2
domain-containing leukocyte protein of 76
kDa) (SLP-76 tyrosine phosphoprotein)
(SLP76)
3937
P48357 LEPR_HUMAN reviewed Leptin receptor (LEP-R) (HuB219) (OB
receptor) (OB-R) (CD antigen CD295)
3953
P29376 LTK_HUMAN reviewed Leukocyte tyrosine kinase receptor (EC
2.7.10.1) (Protein tyrosine kinase 1)
4058
Q14210 LY6D_HUMAN reviewed Lymphocyte antigen 6D (Ly-6D) (E48
antigen)
8581
P07948 LYN_HUMAN reviewed Tyrosine-protein kinase Lyn (EC 2.7.10.2)
(Lck/Yes-related novel protein tyrosine ki-
nase) (V-yes-1 Yamaguchi sarcoma vi-
ral related oncogene homolog) (p53Lyn)
(p56Lyn)
4067
Q92918 M4K1_HUMAN reviewed Mitogen-activated protein kinase kinase
kinase kinase 1 (EC 2.7.11.1) (Hematopoi-
etic progenitor kinase) (MAPK/ERK ki-
nase kinase kinase 1) (MEK kinase kinase
1) (MEKKK 1)
11184
Q9Y4K4 M4K5_HUMAN reviewed Mitogen-activated protein kinase kinase
kinase kinase 5 (EC 2.7.11.1) (Kinase ho-
mologous to SPS1/STE20) (KHS) (MAP-
K/ERK kinase kinase kinase 5) (MEK ki-
nase kinase 5) (MEKKK 5)
11183
Q13477 MADCA_HUMAN reviewed Mucosal addressin cell adhesion molecule
1 (MAdCAM-1) (hMAdCAM-1)
8174
126
Q12866 MERTK_HUMAN reviewed Tyrosine-protein kinase Mer (EC 2.7.10.1)
(Proto-oncogene c-Mer) (Receptor tyro-
sine kinase MerTK)
10461
P08581 MET_HUMAN reviewed Hepatocyte growth factor receptor (HGF
receptor) (EC 2.7.10.1) (HGF/SF recep-
tor) (Proto-oncogene c-Met) (Scatter fac-
tor receptor) (SF receptor) (Tyrosine-
protein kinase Met)
4233
P03956 MMP1_HUMAN reviewed Interstitial collagenase (EC 3.4.24.7)
(Fibroblast collagenase) (Matrix
metalloproteinase-1) (MMP-1) [Cleaved
into: 22 kDa interstitial collagenase 27
kDa interstitial collagenase]
4312
P22894 MMP8_HUMAN reviewed Neutrophil collagenase (EC 3.4.24.34)
(Matrix metalloproteinase-8) (MMP-8)
(PMNL collagenase) (PMNL-CL)
4317
O95297 MPZL1_HUMAN reviewed Myelin protein zero-like protein 1 (Protein
zero-related)
9019
O43639 NCK2_HUMAN reviewed Cytoplasmic protein NCK2 (Growth fac-
tor receptor-bound protein 4) (NCK adap-
tor protein 2) (Nck-2) (SH2/SH3 adaptor
protein NCK-beta)
8440
O14786 NRP1_HUMAN reviewed Neuropilin-1 (Vascular endothelial cell
growth factor 165 receptor) (CD antigen
CD304)
8829
Q99748 NRTN_HUMAN reviewed Neurturin 4902
Q9GZY6 NTAL_HUMAN reviewed Linker for activation of T-cells fam-
ily member 2 (Linker for activation
of B-cells) (Membrane-associated adapter
molecule) (Non-T-cell activation linker)
(Williams-Beuren syndrome chromoso-
mal region 15 protein) (Williams-Beuren
syndrome chromosomal region 5 protein)
7462
127
P04629 NTRK1_HUMAN reviewed High affinity nerve growth factor receptor
(EC 2.7.10.1) (Neurotrophic tyrosine ki-
nase receptor type 1) (TRK1-transforming
tyrosine kinase protein) (Tropomyosin-
related kinase A) (Tyrosine kinase recep-
tor) (Tyrosine kinase receptor A) (Trk-A)
(gp140trk) (p140-TrkA)
4914
O00750 P3C2B_HUMAN reviewed Phosphatidylinositol 4-phosphate 3-kinase
C2 domain-containing subunit beta (PI3K-
C2-beta) (PtdIns-3-kinase C2 subunit
beta) (EC 2.7.1.154) (C2-PI3K) (Phospho-
inositide 3-kinase-C2-beta)
5287
Q92569 P55G_HUMAN reviewed Phosphatidylinositol 3-kinase regulatory
subunit gamma (PI3-kinase regulatory
subunit gamma) (PI3K regulatory sub-
unit gamma) (PtdIns-3-kinase regulatory
subunit gamma) (Phosphatidylinositol 3-
kinase 55 kDa regulatory subunit gamma)
(PI3-kinase subunit p55-gamma) (PtdIns-
3-kinase regulatory subunit p55-gamma)
(p55PIK)
8503
P27986 P85A_HUMAN reviewed Phosphatidylinositol 3-kinase regulatory
subunit alpha (PI3-kinase regulatory sub-
unit alpha) (PI3K regulatory subunit al-
pha) (PtdIns-3-kinase regulatory subunit
alpha) (Phosphatidylinositol 3-kinase 85
kDa regulatory subunit alpha) (PI3-kinase
subunit p85-alpha) (PtdIns-3-kinase regu-
latory subunit p85-alpha)
5295
O00459 P85B_HUMAN reviewed Phosphatidylinositol 3-kinase regulatory
subunit beta (PI3-kinase regulatory sub-
unit beta) (PI3K regulatory subunit beta)
(PtdIns-3-kinase regulatory subunit beta)
(Phosphatidylinositol 3-kinase 85 kDa
regulatory subunit beta) (PI3-kinase sub-
unit p85-beta) (PtdIns-3-kinase regulatory
subunit p85-beta)
5296
128
P16284 PECA1_HUMAN reviewed Platelet endothelial cell adhesion molecule
(PECAM-1) (EndoCAM) (GPIIA’)
(PECA1) (CD antigen CD31)
5175
O75420 PERQ1_HUMAN reviewed PERQ amino acid-rich with GYF domain-
containing protein 1 (GRB10-interacting
GYF protein 1)
64599
P50542 PEX5_HUMAN reviewed Peroxisomal targeting signal 1 recep-
tor (PTS1 receptor) (PTS1R) (PTS1-BP)
(Peroxin-5) (Peroxisomal C-terminal tar-
geting signal import receptor) (Peroxi-
some receptor 1)
5830
P16234 PGFRA_HUMAN reviewed Platelet-derived growth factor receptor al-
pha (PDGF-R-alpha) (PDGFR-alpha) (EC
2.7.10.1) (Alpha platelet-derived growth
factor receptor) (Alpha-type platelet-
derived growth factor receptor) (CD140
antigen-like family member A) (CD140a
antigen) (Platelet-derived growth factor
alpha receptor) (Platelet-derived growth
factor receptor 2) (PDGFR-2) (CD antigen
CD140a)
5156
P09619 PGFRB_HUMAN reviewed Platelet-derived growth factor receptor
beta (PDGF-R-beta) (PDGFR-beta)
(EC 2.7.10.1) (Beta platelet-derived
growth factor receptor) (Beta-type
platelet-derived growth factor receptor)
(CD140 antigen-like family member B)
(Platelet-derived growth factor receptor 1)
(PDGFR-1) (CD antigen CD140b)
5159
Q9NWQ8 PHAG1_HUMAN reviewed Phosphoprotein associated with
glycosphingolipid-enriched mi-
crodomains 1 (Csk-binding protein)
(Transmembrane adapter protein PAG)
(Transmembrane phosphoprotein Cbp)
55824
Q9UKJ1 PILRA_HUMAN reviewed Paired immunoglobulin-like type 2 recep-
tor alpha (Cell surface receptor FDF03)
(Inhibitory receptor PILR-alpha)
29992
129
P42336 PK3CA_HUMAN reviewed Phosphatidylinositol 4,5-bisphosphate
3-kinase catalytic subunit alpha isoform
(PI3-kinase subunit alpha) (PI3K-alpha)
(PI3Kalpha) (PtdIns-3-kinase subunit
alpha) (EC 2.7.1.153) (Phosphatidyli-
nositol 4,5-bisphosphate 3-kinase 110
kDa catalytic subunit alpha) (PtdIns-3-
kinase subunit p110-alpha) (p110alpha)
(Phosphoinositide-3-kinase catalytic
alpha polypeptide) (Serine/threonine
protein kinase PIK3CA) (EC 2.7.11.1)
5290
P42338 PK3CB_HUMAN reviewed Phosphatidylinositol 4,5-bisphosphate 3-
kinase catalytic subunit beta isoform
(PI3-kinase subunit beta) (PI3K-beta)
(PI3Kbeta) (PtdIns-3-kinase subunit beta)
(EC 2.7.1.153) (Phosphatidylinositol 4,5-
bisphosphate 3-kinase 110 kDa catalytic
subunit beta) (PtdIns-3-kinase subunit
p110-beta) (p110beta)
5291
P19174 PLCG1_HUMAN reviewed 1-phosphatidylinositol 4,5-bisphosphate
phosphodiesterase gamma-1 (EC 3.1.4.11)
(PLC-148) (Phosphoinositide phospholi-
pase C-gamma-1) (Phospholipase C-II)
(PLC-II) (Phospholipase C-gamma-1)
(PLC-gamma-1)
5335
P16885 PLCG2_HUMAN reviewed 1-phosphatidylinositol 4,5-bisphosphate
phosphodiesterase gamma-2 (EC
3.1.4.11) (Phosphoinositide phospho-
lipase C-gamma-2) (Phospholipase C-IV)
(PLC-IV) (Phospholipase C-gamma-2)
(PLC-gamma-2)
5336
P49763 PLGF_HUMAN reviewed Placenta growth factor (PlGF) 5228
Q96NZ9 PRAP1_HUMAN reviewed Proline-rich acidic protein 1 (Epididymis
tissue protein Li 178) (Uterine-specific
proline-rich acidic protein)
118471
P16471 PRLR_HUMAN reviewed Prolactin receptor (PRL-R) 5618
O60542 PSPN_HUMAN reviewed Persephin (PSP) 5623
130
Q13882 PTK6_HUMAN reviewed Protein-tyrosine kinase 6 (EC 2.7.10.2)
(Breast tumor kinase) (Tyrosine-protein
kinase BRK)
5753
Q06124 PTN11_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 11 (EC 3.1.3.48) (Protein-
tyrosine phosphatase 1D) (PTP-1D)
(Protein-tyrosine phosphatase 2C)
(PTP-2C) (SH-PTP2) (SHP-2) (Shp2)
(SH-PTP3)
5781
Q05209 PTN12_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 12 (EC 3.1.3.48) (PTP-
PEST) (Protein-tyrosine phosphatase G1)
(PTPG1)
5782
P18031 PTN1_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 1 (EC 3.1.3.48) (Protein-
tyrosine phosphatase 1B) (PTP-1B)
5770
Q9Y2R2 PTN22_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 22 (EC 3.1.3.48)
(Hematopoietic cell protein-tyrosine
phosphatase 70Z-PEP) (Lymphoid
phosphatase) (LyP) (PEST-domain
phosphatase) (PEP)
26191
P26045 PTN3_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 3 (EC 3.1.3.48) (Protein-
tyrosine phosphatase H1) (PTP-H1)
5774
P29350 PTN6_HUMAN reviewed Tyrosine-protein phosphatase non-
receptor type 6 (EC 3.1.3.48) (Hematopoi-
etic cell protein-tyrosine phosphatase)
(Protein-tyrosine phosphatase 1C) (PTP-
1C) (Protein-tyrosine phosphatase SHP-1)
(SH-PTP1)
5777
P23467 PTPRB_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase beta (Protein-tyrosine phos-
phatase beta) (R-PTP-beta) (EC 3.1.3.48)
(Vascular endothelial protein tyrosine
phosphatase) (VE-PTP)
5787
131
P08575 PTPRC_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase C (EC 3.1.3.48) (Leukocyte
common antigen) (L-CA) (T200) (CD
antigen CD45)
5788
P23470 PTPRG_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase gamma (Protein-tyrosine phos-
phatase gamma) (R-PTP-gamma) (EC
3.1.3.48)
5793
Q12913 PTPRJ_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase eta (Protein-tyrosine phosphatase
eta) (R-PTP-eta) (EC 3.1.3.48) (Density-
enhanced phosphatase 1) (DEP-1) (HPTP
eta) (Protein-tyrosine phosphatase re-
ceptor type J) (R-PTP-J) (CD antigen
CD148)
5795
Q16827 PTPRO_HUMAN reviewed Receptor-type tyrosine-protein phos-
phatase O (R-PTP-O) (EC 3.1.3.48)
(Glomerular epithelial protein 1) (Protein
tyrosine phosphatase U2) (PTP-U2)
(PTPase U2)
5800
P20936 RASA1_HUMAN reviewed Ras GTPase-activating protein 1 (GAP)
(GTPase-activating protein) (RasGAP)
(Ras p21 protein activator) (p120GAP)
5921
P07949 RET_HUMAN reviewed Proto-oncogene tyrosine-protein kinase
receptor Ret (EC 2.7.10.1) (Cadherin
family member 12) (Proto-oncogene c-
Ret) [Cleaved into: Soluble RET kinase
fragment Extracellular cell-membrane an-
chored RET cadherin 120 kDa fragment]
5979
132
A7KAX9 RHG32_HUMAN reviewed Rho GTPase-activating protein 32
(Brain-specific Rho GTPase-activating
protein) (GAB-associated Cdc42/Rac
GTPase-activating protein) (GC-GAP)
(GTPase regulator interacting with TrkA)
(Rho-type GTPase-activating protein
32) (Rho/Cdc42/Rac GTPase-activating
protein RICS) (RhoGAP involved in
the beta-catenin-N-cadherin and NMDA
receptor signaling) (p200RhoGAP)
(p250GAP)
9743
P08922 ROS1_HUMAN reviewed Proto-oncogene tyrosine-protein kinase
ROS (EC 2.7.10.1) (Proto-oncogene c-
Ros) (Proto-oncogene c-Ros-1) (Receptor
tyrosine kinase c-ros oncogene 1) (c-Ros
receptor tyrosine kinase)
6098
Q13905 RPGF1_HUMAN reviewed Rap guanine nucleotide exchange fac-
tor 1 (CRK SH3-binding GNRP) (Gua-
nine nucleotide-releasing factor 2) (Pro-
tein C3G)
2889
P21583 SCF_HUMAN reviewed Kit ligand (Mast cell growth factor)
(MGF) (Stem cell factor) (SCF) (c-Kit lig-
and) [Cleaved into: Soluble KIT ligand
(sKITLG)]
4254
Q9NP31 SH22A_HUMAN reviewed SH2 domain-containing protein 2A (SH2
domain-containing adapter protein) (T
cell-specific adapter protein) (TSAd)
(VEGF receptor-associated protein)
9047
Q9NRF2 SH2B1_HUMAN reviewed SH2B adapter protein 1 (Pro-rich, PH and
SH2 domain-containing signaling media-
tor) (PSM) (SH2 domain-containing pro-
tein 1B)
25970
O14492 SH2B2_HUMAN reviewed SH2B adapter protein 2 (Adapter protein
with pleckstrin homology and Src homol-
ogy 2 domains) (SH2 and PH domain-
containing adapter protein APS)
10603
133
Q9UQQ2 SH2B3_HUMAN reviewed SH2B adapter protein 3 (Lymphocyte
adapter protein) (Lymphocyte-specific
adapter protein Lnk) (Signal transduction
protein Lnk)
10019
Q96B97 SH3K1_HUMAN reviewed SH3 domain-containing kinase-binding
protein 1 (CD2-binding protein 3)
(CD2BP3) (Cbl-interacting protein of 85
kDa) (Human Src family kinase-binding
protein 1) (HSB-1)
30011
Q15464 SHB_HUMAN reviewed SH2 domain-containing adapter protein B 6461
P29353 SHC1_HUMAN reviewed SHC-transforming protein 1 (SHC-
transforming protein 3) (SHC-
transforming protein A) (Src homology 2
domain-containing-transforming protein
C1) (SH2 domain protein C1)
6464
P98077 SHC2_HUMAN reviewed SHC-transforming protein 2 (Protein
Sck) (SHC-transforming protein B)
(Src homology 2 domain-containing-
transforming protein C2) (SH2 domain
protein C2)
25759
Q92529 SHC3_HUMAN reviewed SHC-transforming protein 3 (Neuronal
Shc) (N-Shc) (Protein Rai) (SHC-
transforming protein C) (Src homology 2
domain-containing-transforming protein
C3) (SH2 domain protein C3)
53358
Q92835 SHIP1_HUMAN reviewed Phosphatidylinositol 3,4,5-trisphosphate
5-phosphatase 1 (EC 3.1.3.86) (Inositol
polyphosphate-5-phosphatase of 145
kDa) (SIP-145) (SH2 domain-containing
inositol 5’-phosphatase 1) (SH2 domain-
containing inositol phosphatase 1)
(SHIP-1) (p150Ship) (hp51CN)
3635
134
O15357 SHIP2_HUMAN reviewed Phosphatidylinositol 3,4,5-trisphosphate
5-phosphatase 2 (EC 3.1.3.86) (Inositol
polyphosphate phosphatase-like protein 1)
(INPPL-1) (Protein 51C) (SH2 domain-
containing inositol 5’-phosphatase 2)
(SH2 domain-containing inositol phos-
phatase 2) (SHIP-2)
3636
Q9Y3P8 SIT1_HUMAN reviewed Signaling threshold-regulating transmem-
brane adapter 1 (SHP2-interacting trans-
membrane adapter protein) (Suppression-
inducing transmembrane adapter 1)
(gp30/40)
27240
Q86WV1 SKAP1_HUMAN reviewed Src kinase-associated phosphoprotein 1
(Src family-associated phosphoprotein 1)
(Src kinase-associated phosphoprotein of
55 kDa) (SKAP-55) (pp55)
8631
Q13291 SLAF1_HUMAN reviewed Signaling lymphocytic activation
molecule (CDw150) (IPO-3) (CD antigen
CD150)
6504
Q13239 SLAP1_HUMAN reviewed Src-like-adapter (Src-like-adapter protein
1) (SLAP-1) (hSLAP)
6503
Q9H6Q3 SLAP2_HUMAN reviewed Src-like-adapter 2 (Modulator of anti-
gen receptor signaling) (MARS) (Src-like
adapter protein 2) (SLAP-2)
84174
Q92959 SO2A1_HUMAN reviewed Solute carrier organic anion transporter
family member 2A1 (Prostaglandin trans-
porter) (PGT) (Solute carrier family 21
member 2)
6578
O15524 SOCS1_HUMAN reviewed Suppressor of cytokine signaling 1
(SOCS-1) (JAK-binding protein) (JAB)
(STAT-induced STAT inhibitor 1) (SSI-1)
(Tec-interacting protein 3) (TIP-3)
8651
O14508 SOCS2_HUMAN reviewed Suppressor of cytokine signaling 2
(SOCS-2) (Cytokine-inducible SH2
protein 2) (CIS-2) (STAT-induced STAT
inhibitor 2) (SSI-2)
8835
135
O14543 SOCS3_HUMAN reviewed Suppressor of cytokine signaling 3
(SOCS-3) (Cytokine-inducible SH2
protein 3) (CIS-3) (STAT-induced STAT
inhibitor 3) (SSI-3)
9021
Q07889 SOS1_HUMAN reviewed Son of sevenless homolog 1 (SOS-1) 6654
Q07890 SOS2_HUMAN reviewed Son of sevenless homolog 2 (SOS-2) 6655
Q9H2V7 SPNS1_HUMAN reviewed Protein spinster homolog 1 (HSpin1)
(Spinster-like protein 1)
83985
Q8WW59 SPRY4_HUMAN reviewed SPRY domain-containing protein 4 283377
O43597 SPY2_HUMAN reviewed Protein sprouty homolog 2 (Spry-2) 10253
P42229 STA5A_HUMAN reviewed Signal transducer and activator of tran-
scription 5A
6776
P51692 STA5B_HUMAN reviewed Signal transducer and activator of tran-
scription 5B
6777
Q9UGK3 STAP2_HUMAN reviewed Signal-transducing adaptor protein 2
(STAP-2) (Breast tumor kinase substrate)
(BRK substrate)
55620
Q8IYN2 TCAL8_HUMAN reviewed Transcription elongation factor A protein-
like 8 (TCEA-like protein 8) (Transcrip-
tion elongation factor S-II protein-like 8)
90843
P42680 TEC_HUMAN reviewed Tyrosine-protein kinase Tec (EC 2.7.10.2) 7006
Q63HR2 TENC1_HUMAN reviewed Tensin-like C1 domain-containing
phosphatase (EC 3.1.3.-) (C1 domain-
containing phosphatase and tensin
homolog) (C1-TEN) (Tensin-2)
23371
P40238 TPOR_HUMAN reviewed Thrombopoietin receptor (TPO-R)
(Myeloproliferative leukemia protein)
(Proto-oncogene c-Mpl) (CD antigen
CD110)
4352
P40225 TPO_HUMAN reviewed Thrombopoietin (C-mpl ligand) (ML)
(Megakaryocyte colony-stimulating fac-
tor) (Megakaryocyte growth and develop-
ment factor) (MGDF) (Myeloproliferative
leukemia virus oncogene ligand)
7066
Q6PIZ9 TRAT1_HUMAN reviewed T-cell receptor-associated transmembrane
adapter 1 (T-cell receptor-interacting
molecule) (TRIM) (pp29/30)
50852
136
P29597 TYK2_HUMAN reviewed Non-receptor tyrosine-protein kinase
TYK2 (EC 2.7.10.2)
7297
P30530 UFO_HUMAN reviewed Tyrosine-protein kinase receptor UFO (EC
2.7.10.1) (AXL oncogene)
558
P52735 VAV2_HUMAN reviewed Guanine nucleotide exchange factor VAV2
(VAV-2)
7410
Q9UKW4 VAV3_HUMAN reviewed Guanine nucleotide exchange factor VAV3
(VAV-3)
10451
P15498 VAV_HUMAN reviewed Proto-oncogene vav 7409
P15692 VEGFA_HUMAN reviewed Vascular endothelial growth factor A
(VEGF-A) (Vascular permeability factor)
(VPF)
7422
P17948 VGFR1_HUMAN reviewed Vascular endothelial growth factor recep-
tor 1 (VEGFR-1) (EC 2.7.10.1) (Fms-
like tyrosine kinase 1) (FLT-1) (Tyrosine-
protein kinase FRT) (Tyrosine-protein ki-
nase receptor FLT) (FLT) (Vascular per-
meability factor receptor)
2321
P35968 VGFR2_HUMAN reviewed Vascular endothelial growth factor recep-
tor 2 (VEGFR-2) (EC 2.7.10.1) (Fetal liver
kinase 1) (FLK-1) (Kinase insert domain
receptor) (KDR) (Protein-tyrosine kinase
receptor flk-1) (CD antigen CD309)
3791
Q9UPY6 WASF3_HUMAN reviewed Wiskott-Aldrich syndrome protein family
member 3 (WASP family protein member
3) (Protein WAVE-3) (Verprolin homol-
ogy domain-containing protein 3)
10810
P42768 WASP_HUMAN reviewed Wiskott-Aldrich syndrome protein
(WASp)
7454
O43516 WIPF1_HUMAN reviewed WAS/WASL-interacting protein family
member 1 (Protein PRPL-2) (Wiskott-
Aldrich syndrome protein-interacting pro-
tein) (WASP-interacting protein)
7456
P07947 YES_HUMAN reviewed Tyrosine-protein kinase Yes (EC 2.7.10.2)
(Proto-oncogene c-Yes) (p61-Yes)
7525
137
P43403 ZAP70_HUMAN reviewed Tyrosine-protein kinase ZAP-70 (EC
2.7.10.2) (70 kDa zeta-chain associated
protein) (Syk-related tyrosine kinase)
7535
Q5JNZ3 ZN311_HUMAN reviewed Zinc finger protein 311 (Zinc finger pro-
tein zfp-31)
282890
P17041 ZNF32_HUMAN reviewed Zinc finger protein 32 (C2H2-546) (Zinc
finger protein KOX30)
7580
Q71UZ1 Q71UZ1_HUMAN unreviewed Interleukin 10 (Fragment)
Q504X9 Q504X9_HUMAN unreviewed MAP1A protein (Fragment) 4130
A2NI60 A2NI60_HUMAN unreviewed BRE (Fragment)
Q92970 Q92970_HUMAN unreviewed Zinc finger protein zfp30 (Fragment)
Q6PYX1 Q6PYX1_HUMAN unreviewed Hepatitis B virus receptor binding protein
(Fragment)
Q9Y6X7 Q9Y6X7_HUMAN unreviewed KIAA0864 protein (Fragment)
Q92927 Q92927_HUMAN unreviewed Small GTP-binding protein (Fragment)
P78453 P78453_HUMAN unreviewed Tyrosine kinase (Fragment) 2268
Q5PY61 Q5PY61_HUMAN unreviewed Ubiquitin C splice variant
A2N8H4 A2N8H4_HUMAN unreviewed TCR Ti gamma-chain V8-J2 region (Frag-
ment)
Q5T1S1 Q5T1S1_HUMAN Deleted.
TABLE A.7: Combi-s239 Protein Annotation and GeneIDs
TABLE A.8: Jaccard indices of HCV subnetworks and CORUM complexes
ComplexName HCV-s43 HCV-s64
SNX complex (SNX1a, SNX2, SNX4,
INSR)
0 0.0149
TRF1 telomere length regulation com-
plex
0 0.0152
TRF-Rap1 complex I, 2MD 0 0.0145
Tankyrin 1-tankyrin 2-TRF1 complex 0 0.0308
IL12A homodimer complex 0 0.0156
IL12A-IL12B complex 0 0.0313
IL12A-IL12B-IL12RB1 complex 0 0.0469
IL12B-IL12RB1-IL12RB2 complex 0 0.0469
IL12A-IL12B-IL12RB2 complex 0 0.0469
138
IL12RB1-IL12RB2 complex 0 0.0313
JAK2-IL12RB2 complex 0 0.0313
ITGA1-ITGB1-PTPN2 complex 0 0.0152
Sam68-p85 P13K-IRS-1-IR signaling
complex
0 0.0303
Prolactin (PRL) - PRL receptor
(PRLR) complex
0 0.0154
PRL receptor (PRLR) dimer complex 0 0.0156
JAK2-PAFR-TYK2 complex 0 0.0308
IL-12 heterodimer complex 0 0.0313
IL-12 subunit p40 homodimer complex 0 0.0156
LMO4-gp130 complex 0 0.0147
SRCAP-associated chromatin remod-
eling complex
0.0192 0
BAG3-HSC70-HSPB8-CHIP complex 0.0217 0
ELK1-SRF-ELK4 complex 0.0222 0
TABLE A.9: Jaccard indices of HIV subnetworks and CORUM complexes
ComplexName HIV-s52 HIV-s66
C complex spliceosome 0.000 0.081
Large Drosha complex 0.000 0.062
DGCR8 multiprotein complex 0.000 0.055
Spliceosome 0.000 0.050
TRA2B1-SRp30c-SRp55 complex 0.000 0.045
DCS complex (PTBP1, PTBP2, HN-
RPH1, HNRPF)
0.000 0.045
Emerin complex 52 0.000 0.035
CBC complex (cap binding complex) 0.000 0.030
CBC complex (cap binding complex) 0.000 0.030
HNRPF-HNRPH1 complex 0.000 0.030
SRp30c-SRp55 complex 0.000 0.030
PHAX-CBC complex (cap binding
complex)
0.000 0.030
PGC-1-SRp40-SRp55-SRp75 complex 0.000 0.029
CRM1-RAN-PHAX-CBC complex
(cap binding complex)
0.000 0.029
SRm160/300 complex 0.000 0.029
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12S U11 snRNP 0.000 0.025
Emerin complex 25 0.000 0.025
Nop56p-associated pre-rRNA complex 0.000 0.024
NCBP-NIP1 complex 0.000 0.015
PIN1-AUF1 complex 0.000 0.015
YBX1-AKT1 complex 0.000 0.015
GR-hnRNP U complex 0.000 0.015
CTFC-TAF1 complex 0.000 0.015
CTCF-nucleophosmin complex 0.000 0.015
p23 protein complex 0.000 0.015
SF3A1-SF3A2-SF3A3 complex 0.000 0.015
SMAD3-SMAD4-CTCF protein-DNA
complex
0.000 0.015
Actin-ribonucleoprotein complex
(POLR2A, GTF2F1, HNRNPU)
0.019 0.015
Multiprotein complex (mRNA
turnover)
0.000 0.014
PABPC1-HSPA8-HNRPD-EIF4G1
complex
0.000 0.014
Toposome 0.000 0.014
CTCF-nucleophosmin-PARP-HIS-
KPNA-LMNA-TOP complex
0.000 0.014
H2AX complex, isolated from cells
without IR exposure
0.000 0.013
Emerin complex 24 0.000 0.013
CF IIAm complex (Cleavage factor
IIAm complex)
0.000 0.012
SNW1 complex 0.000 0.012
LARC complex (LCR-associated re-
modeling complex)
0.000 0.012
18S U11/U12 snRNP 0.000 0.011
CDC5L complex 0.000 0.011
17S U2 snRNP 0.000 0.010
TABLE A.10: Jaccard indices of Combi subnetworks and CORUM complexes
Complex Name Combi_s239 Combi_ s52 Combi_s46
Emerin complex 52 0.000 0.000 0.015
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Actin-ribonucleoprotein com-
plex (POLR2A, GTF2F1,
HNRNPU)
0.000 0.019 0.000
TRAP complex 0.000 0.111 0.000
CD28-transactivation complex 0.004 0.000 0.000
RNA polymerase II holoenzyme
complex
0.000 0.013 0.000
RNA polymerase II core com-
plex
0.000 0.016 0.000
CRSP complex 0.000 0.154 0.000
CRSP complex 0.000 0.154 0.000
SMCC complex 0.000 0.132 0.000
NAT complex 0.000 0.135 0.000
Mediator complex 0.000 0.556 0.000
ARC complex 0.000 0.241 0.000
CRSP complex 0.000 0.189 0.000
ARC-L complex 0.000 0.245 0.000
ARC complex 0.000 0.264 0.000
PC2 complex 0.000 0.185 0.000
SMCC complex 0.000 0.278 0.000
TFTC-type histone acetyl trans-
ferase complex
0.000 0.145 0.000
WIP-WASp-actin-myosin-IIa
complex
0.008 0.000 0.000
TRAP complex 0.000 0.236 0.000
SMCC complex 0.000 0.245 0.000
DRIP complex 0.000 0.222 0.000
DRIP complex 0.000 0.222 0.000
IFNB1-IFNAR1-IFNAR2- com-
plex
0.004 0.000 0.000
ASPP1-SAM68 complex 0.004 0.000 0.000
P2X7 receptor signalling com-
plex
0.004 0.000 0.000
CSA-POLIIa complex 0.000 0.015 0.000
RICH1/AMOT polarity com-
plex, Flag-Rich1 precipitated
0.008 0.000 0.000
141
TRAP-SMCC mediator com-
plex
0.000 0.192 0.000
hMediator complex (MED23,
CDK8, CCNC, MED7)
0.000 0.077 0.000
hMediator complex (MED23,
CDK8, CCNC)
0.000 0.058 0.000
CDK8-CyclinC-Mediator com-
plex
0.000 0.038 0.000
Mediator complex 1 0.000 0.096 0.000
Mediator complex 2 0.000 0.058 0.000
RET-Rai complex 0.008 0.000 0.000
SHC3-GAB1 complex 0.008 0.000 0.000
ARC92-Mediator complex 0.000 0.226 0.000
CRSP-Mediator 2 complex 0.000 0.170 0.000
CD8A-LCK complex 0.008 0.000 0.000
SNX complex (SNX1a, SNX2,
SNX4, LEPR)
0.004 0.000 0.000
SNX complex (SNX1a, SNX2,
SNX4, INSR)
0.004 0.000 0.000
SNX complex (SNX1a, SNX2,
SNX4, EGFR)
0.004 0.000 0.000
SNX complex (SNX1,1a,2,4,
PDGF receptor)
0.004 0.000 0.000
SMN complex 0.000 0.000 0.016
Integrator complex 0.000 0.032 0.000
DSS1 complex 0.000 0.016 0.000
Integrator-RNAPII complex 0.000 0.048 0.000
EGFR-containing signaling
complex
0.013 0.000 0.000
RNA pol II containing coactiva-
tor complex Tat-SF
0.000 0.018 0.000
Nrp1-PlexinD1 complex 0.004 0.000 0.000
IL4-IL4R complex 0.004 0.000 0.000
IL4-IL4R-IL2RG complex 0.008 0.000 0.000
IL6ST-PRKCD-STAT3 complex 0.004 0.000 0.000
p300-SMAD1-STAT3 complex 0.000 0.000 0.021
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G protein complex (BTK,
GNG1, GNG2)
0.004 0.000 0.000
FAK-beta5 integrin complex,
VEGF induced
0.004 0.000 0.000
ABL2-HRAS-RIN1 complex 0.004 0.000 0.000
IL2-IL2RA-IL2RB complex 0.013 0.000 0.000
SMN-PolII-RHA complex 0.000 0.016 0.000
SMN complex 0.000 0.000 0.018
CPSF6-ITCH-NUDT21-
POLR2A-UBAP2L complex
0.000 0.018 0.000
CPSF6-EWSR1-ITCH-
NUDT21-POLR2A-UBAP2L
complex
0.000 0.018 0.000
CPSF6-ITCH-NUDT21-
POLR2A complex
0.000 0.018 0.000
TGF-beta-receptor-SMAD7-
SMURF2 complex
0.000 0.000 0.042
TGF-beta receptor I-SMAD7-
SMURF1 complex
0.000 0.000 0.043
RNF11-SMURF2-STAMBP
complex
0.000 0.000 0.021
CIN85-CBL-SH3GL2 complex 0.008 0.000 0.000
SH3P2/OSTF1-CBL-SRC com-
plex
0.004 0.000 0.000
LEPR homodimer complex 0.004 0.000 0.000
AXL homodimer complex 0.004 0.000 0.000
STAT5B homodimer complex 0.004 0.000 0.000
STAT5A homodimer complex 0.004 0.000 0.000
JAK2-IL12RB2 complex 0.004 0.000 0.000
BRCA1-BARD1-POLR2A
complex
0.000 0.019 0.000
ITGA6-ITGB4-FYN complex 0.004 0.000 0.000
ITGB6-FYN-FN1 complex 0.004 0.000 0.000
ITGAV-ITGB3-PXN-PTK2b
complex
0.004 0.000 0.000
ITGAV-ITGB3-EGFR complex 0.004 0.000 0.000
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Multiprotein complex
(monoubiquitination)
0.013 0.000 0.000
CIN85-CBL-SH3GL2-EGFR
complex, EGF stimulated
0.013 0.000 0.000
CIN85-SH3GL2 complex 0.004 0.000 0.000
MET-CIN85-SH3GL3-CBL
complex, HGF stimulated
0.013 0.000 0.000
CIN85-SH3GL3 complex 0.004 0.000 0.000
p130Cas-ER-alpha-cSrc-kinase-
PI3-kinase p85-subunit complex
0.008 0.000 0.000
CRKL-PDGFRA-CRK-
RAPGEF1 complex
0.017 0.000 0.000
CIN85 complex (CIN85, CRK,
BCAR1, CBL, PIK3R1, GRB2,
SOS1)
0.029 0.000 0.000
GIPC1-NTRK1-RGS19 com-
plex
0.004 0.000 0.000
NCR3-CD247 complex 0.004 0.000 0.000
ArgBP2a-CBL-PTK2B complex 0.008 0.000 0.000
ZAP70-CRKL-WIPF1-WAS
complex
0.017 0.000 0.000
CRKL-WIPF1-WAS complex 0.013 0.000 0.000
CIN85-CBL complex 0.008 0.000 0.000
ERBB2-MEMO-SHC complex 0.008 0.000 0.000
LAT-PLC-gamma-1-p85-
GRB2-CBL-VAV-SLP-76
signaling complex, C305
activated
0.029 0.000 0.000
Cbl-SLP-76-Grb2 complex, Fc
receptor gamma-R1 stimulated
0.013 0.000 0.000
SLP-76-Cbl-Grb2-Shc complex,
Fc receptor gamma-R1 stimu-
lated
0.017 0.000 0.000
PLC-gamma-2-SLP-76-Lyn-
Grb2 complex
0.017 0.000 0.000
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PKC-alpha-PLD1-PLC-gamma-
2 signaling complex, lacritin
stimulated
0.004 0.000 0.000
BCR-ABL (p210 fusion
protein)-GRB2 complex
0.004 0.000 0.000
HGF-Met complex 0.004 0.000 0.000
EGFR-CBL-GRB2 complex 0.013 0.000 0.000
PLC-gamma-1-SLP-76-SOS1-
LAT complex
0.017 0.000 0.000
PDGFRA-PLC-gamma-1-
PI3K-SHP-2 complex, PDGF
stimulated
0.017 0.000 0.000
p56(LCK)-CAML complex 0.004 0.000 0.000
FGFR2-c-Cbl-Lyn-Fyn complex 0.013 0.000 0.000
p21(ras)GAP-Fyn-Lyn-Yes
complex, thrombin stimulated
0.017 0.000 0.000
CD20-LCK-LYN-FYN-p75/80
complex, (Raji human B cell
line)
0.013 0.000 0.000
CD19-Vav-PI 3-kinase (p85 sub-
unit) complex
0.013 0.000 0.000
Sam68-p85 P13K-IRS-1-IR sig-
naling complex
0.017 0.000 0.000
Sam68-p120GAP complex 0.008 0.000 0.000
RasGAP-AURKA/AURKB-
survivin complex
0.004 0.000 0.000
POLR2A-CCNT1-CDK9-NCL-
LEM6-CPSF2 complex
0.000 0.018 0.000
BRD4 complex 0.000 0.091 0.000
P-TEFb-BRD4-TRAP220 com-
plex
0.000 0.018 0.000
CDK8-MED6-PARP1 complex 0.000 0.038 0.000
CCNC-CDK8-MED1-MED6-
MED7 xcomplex
0.000 0.096 0.000
CCNC-CDK3 complex 0.000 0.019 0.000
HES1 promoter corepressor
complex
0.000 0.018 0.000
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HES1 promoter-Notch enhancer
complex
0.000 0.048 0.000
SMAD1-P300 complex 0.000 0.000 0.021
RNA polymerase II (RNAPII) 0.000 0.015 0.000
BRCA1-core RNA polymerase
II complex
0.000 0.016 0.000
PXN-ITGB5-PTK2 complex 0.004 0.000 0.000
FYB-CARMA1-BCL-10-
MALT1 complex
0.004 0.000 0.000
BRCA1-RNA polymerase II
complex
0.000 0.026 0.000
ING2 complex 0.000 0.000 0.018
CD20-LCK-FYN-p75/80 com-
plex
0.008 0.000 0.000
BCR-ABL (p185 fusion
protein)-GRB2 complex
0.004 0.000 0.000
BCR-ABL (p210 fusion
protein)-GRB2-SOS1 com-
plex
0.008 0.000 0.000
SHC-GRB2 complex 0.008 0.000 0.000
ITGA2b-ITGB3-CD47-FAK
complex
0.004 0.000 0.000
PLC-gamma-2-Syk-LAT-FcR-
gamma complex
0.017 0.000 0.000
PLC-gamma-2-Lyn-FcR-
gamma complex
0.013 0.000 0.000
PLC-gamma-2-SLP-76 complex 0.008 0.000 0.000
PLC-gamma-2-LAT complex 0.008 0.000 0.000
Grb2-Sos complex, Fc receptor
gamma-R1 stimulated
0.008 0.000 0.000
LAT-PLC-gamma-1-p85-
GRB2-SOS signaling complex,
C305 activated
0.021 0.000 0.000
Notch1-p56lck-PI3K complex 0.008 0.000 0.000
LCK-SLP76-PLC-gamma-1-
LAT complex, pervanadate-
activated
0.017 0.000 0.000
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PLC-gamma-1-LAT-c-CBL
complex, OKT3 stimulated
0.013 0.000 0.000
LAT-GRB2 complex, Fyn-
mLck(KA) or Syk kinase
activated
0.008 0.000 0.000
SMAD1-CBP complex 0.000 0.000 0.021
SMAD1-OAZ-HsN3 complex 0.000 0.000 0.021
SLP-76-PLC-gamma-1-ITK
complex, alpha-TCR stimulated
0.013 0.000 0.000
SLP-76-PLC-gamma-1-VAV
complex, alpha-TCR stimulated
0.013 0.000 0.000
CRK-BCAR1-DOCK1 complex 0.008 0.000 0.000
ITK-SLP-76 complex, anti-TCR
stimulated
0.008 0.000 0.000
ITGA9-ITGB1-VEGFA com-
plex
0.004 0.000 0.000
SMAD7-SMURF2 complex 0.000 0.000 0.043
SMAD7-SMURF1 complex 0.000 0.000 0.043
SMAD7-SMURF1-TGF-beta
receptor complex
0.000 0.000 0.042
RNA polymerase II complex
(RPB1, RAP74, CDK8, CYCC,
SRB7, BAF190, BAF47), chro-
matin structure modifying
0.000 0.071 0.000
RNA polymerase II complex
(CBP, PCAF, RPB1, BAF47,
CYCC, CDK8), chromatin
structure modifying
0.000 0.055 0.000
RNA polymerase II complex, in-
complete (CBP, RPBI, PCAF,
BAF47), chromatin structure
modifying
0.000 0.018 0.000
RNA polymerase II complex,
chromatin structure modifying
0.000 0.060 0.000
RNA polymerase II complex,
chromatin structure modifying
0.000 0.050 0.000
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RNA polymerase II complex,
chromatin structure modifying
0.000 0.066 0.000
RNA polymerase II complex,
incomplete (CDK8 complex),
chromatin structure modifying
0.000 0.053 0.000
ITGA6-ITGB4-SHC1-GRB2
complex
0.008 0.000 0.000
ITGB1-NRP1 complex 0.004 0.000 0.000
Phosphatidylinositol 3-kinase
(PIK3CA, PIK3R1)
0.008 0.000 0.000
MASH1 promoter-coactivator
complex
0.000 0.016 0.000
CAMK2-delta-MASH1
promoter-coactivator com-
plex
0.000 0.017 0.000
Sos1-Grb2 complex 0.008 0.000 0.000
Prolactin (PRL) - PRL receptor
(PRLR) complex
0.004 0.000 0.000
PRL receptor (PRLR) dimer
complex
0.004 0.000 0.000
CIN85 homotetramer complex 0.004 0.000 0.000
CIN85-BLNK complex 0.008 0.000 0.000
CIN85-c-CBL complex 0.008 0.000 0.000
PDGFRA-SHP-2 complex,
PDGF stimulated
0.008 0.000 0.000
GRB2-SHP-2 complex, PDGF
stimulated
0.008 0.000 0.000
Heterodimer complex (CDK9,
IL6ST)
0.004 0.000 0.000
SMN complex (GEMIN6,7,
UNRIP), SMN-independent
intermediate
0.000 0.000 0.021
RIN1-STAM2-EGFR complex,
EGF stimulated
0.004 0.000 0.000
SMURF2-SMAD2 complex,
TGF(beta)-dependent
0.000 0.000 0.021
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SMURF2-SMAD3 complex,
TGF(beta)-dependent
0.000 0.000 0.021
SMURF2-SMAD3-SnoN com-
plex, TGF(beta)-dependent
0.000 0.000 0.021
NRP1-VEGFR2-VEGF(165)
complex
0.013 0.000 0.000
SMAD6-HOXC8 complex 0.000 0.000 0.043
SMAD6-HOXA9 complex 0.000 0.000 0.021
ZO1-(beta)cadherin-
(VE)cadherin-VEGFR2 com-
plex
0.004 0.000 0.000
SH3KBP1-CBLB-EGFR com-
plex
0.013 0.000 0.000
Polycystin-1 multiprotein com-
plex (ACTN1, CDH1, SRC,
JUP, VCL, CTNNB1, PXN,
BCAR1, PKD1, PTK2, TLN1)
0.008 0.000 0.000
JAK2-PAFR-TYK2 complex 0.008 0.000 0.000
TIAM1-EFNB1-EPHA2 com-
plex
0.004 0.000 0.000
CAS-SRC-FAK complex 0.008 0.000 0.000
DDEF1-CTTN-PXN complex 0.004 0.000 0.000
ELMO1-DOCK1-CRKII com-
plex
0.004 0.000 0.000
NGF-TrkA complex 0.004 0.000 0.000
EPOR receptor complex 0.004 0.000 0.000
CRKII-C3G complex 0.008 0.000 0.000
EPO-EPOR complex 0.008 0.000 0.000
Mediator complex 0.000 0.436 0.000
MED18-MED20-MED29 medi-
ator subcomplex
0.000 0.058 0.000
LMO4-gp130 complex 0.017 0.000 0.000
CNTF-CNTFR-gp130-LIFR
complex
0.004 0.000 0.000
LIFR-LIF-gp130 complex 0.004 0.000 0.000
Emerin complex 32 0.000 0.014 0.000
PSD95-FYN-NR2A complex 0.004 0.000 0.000
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FARP2-NRP1-PlexinA1 com-
plex
0.004 0.000 0.000
FARP2-NRP1-PlexinA2 com-
plex
0.004 0.000 0.000
FARP2-NRP1-PlexinA3 com-
plex
0.004 0.000 0.000
FARP2-NRP1-PlexinA4 com-
plex
0.004 0.000 0.000
SEMA3C-PlexinD1-Nrp1 com-
plex
0.004 0.000 0.000
PlexinA1-Nrp1 complex 0.004 0.000 0.000
PlexinA3-Nrp1 complex 0.004 0.000 0.000
PlexinB1-Nrp1 complex 0.004 0.000 0.000
SEMA6D-PlexinA1-NRP1
complex
0.004 0.000 0.000
VEGFA(165)-KDR-NRP1 com-
plex
0.013 0.000 0.000
VEGFA(165)-KDR-NRP1 com-
plex
0.004 0.000 0.000
VEGFA(165)-VEGFR2-NRP1
complex
0.013 0.000 0.000
NRP1-VEGF(165/121) complex 0.008 0.000 0.000
CIN85-SH3GL3-CBL complex 0.008 0.000 0.000
NRP1-VEGFC complex, hep-
arin dependent
0.004 0.000 0.000
NRP1-VEGFD complex, hep-
arin dependent
0.004 0.000 0.000
Pre-initiation complex (PIC) 0.000 0.019 0.000
PlexinA1-NRP1 complex 0.004 0.000 0.000
PlexinA1-NRP1-SEMA3A
complex
0.004 0.000 0.000
PARK2-EPS15-EGFR 0.004 0.000 0.000
¯
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